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ABSTRACT OF THE THESIS
The obstructive sleep apnoea/hypopnoea syndrome (OSAHS) affects approximately
2 - 4% of the middle-aged population. OSAHS is characterised by obstruction of the
upper airway during sleep, resulting in repetitive breathing pauses accompanied by
both oxygen desaturations and arousals from sleep. OSAHS results in sleepiness and
daytime cognitive impairment and is an independent risk factor for hypertension. A
number of studies have shown that OSAHS runs in families and that this can occur
without obesity. Possible mechanisms for this familial predisposition include
craniofacial structure, differential deposition of adipose tissue, differential
susceptibility to sleepiness and g enetically determined differences in upper airway
control. This thesis examined possible candidate genes that might contribute towards
the development of OSAHS. The genes of interest included tumour necrosis factor -
alpha (potential associations with ageing, hypercytokinaemia in OSAHS, obesity and
sleepiness), Apolipoprotein E (associations with the development of cerebrovascular
disease), the serotonin receptor 2A (modulation of upper airway muscle tone and
response to selective serotonin re-uptake inhibitors), beta-2 adrenoreceptor (growth,
fat metabolism and blood pressure) and the growth hormone receptor (influence on
postnatal bone growth and height including the craniofacial complex). 557
consecutive subjects with a diagnosis of OSAHS were approached at the Scottish
Sleep Centre. 104 subjects (all Caucasian) were recruited together with 107 of their
siblings as well as an additional 17 unrelated subjects without OSAHS and
underwent overnight polysomnography and cephalometry. Blood was taken for DNA
analysis. Subjects were classified as having definite OSAHS (n=110), indeterminate
status (n=34) or not having OSAHS (n=83) based on their apnoea/hypopnoea
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frequency and sleepiness as measured by the Epworth Sleepiness Score. DNA was
extracted using standard techniques and polymorphisms in the candidate genes were
examined using allelic discrimination testing with TaqMan™. The Apolipoprotein
E4 polymorphisms were determined using polymerase chain reaction, restriction
fragment length polymorphism. DNA from 192 random, healthy UK blood donors
(assumed not to have OSAHS) was used as an additional control.
Differences between subjects with and without OSAHS were as expected: there were
over twice as many men in the OSAHS group compared to the non-OSAHS group
(p<0.0001) and systolic blood pressure was significantly higher (p = 0.002) in the
OSAHS group. Furthermore, the OSAHS group were more obese (p<0.0001) and
had a greater neck circumference (p<0.0001) than the non-OSAHS group.
Cephalometry revealed that both male and female apnoeics had significantly lower-
set hyoid bones than non-apnoeic snorers (p = 0.01 and p = 0.038 respectively). In
male subjects with OSAHS, a smaller mandible and lower-set hyoid were the most
important characteristics distinguishing siblings with from sibs without OSAHS,
independently of age and BMI. However, age, sex, BMI and edentulism were found
to influence craniofacial parameters in both groups.
For the genetic analyses, the Apo E e4 allele (examined in 73 subjects) was not
associated significantly with a diagnosis of OSAHS. The single nucleotide
polymorphisms examined i n e ach o f t he 4 o ther c andidate genes i n t his s tudy a re
summarised in the following table [the p-value is for the analysis comparing subjects
with OSAHS (n=l 10) to those without it (n=275)].
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Table: Genotype and Allele Frequencies for Single Nucleotide
Polymorphisms in 4 Candidate Genes for OSAHS
Gene Allele Distribution Minor Allele Carriage Minor Genotype
TNF-a (-308 A/G) A/G* A* A/A
GHR (+561 T/G) G/T* G G/G*
ADRB-2 (C+79G) G/C C C/C*
5-HT-2a (C/T) C/T C C/C
*
p < 0.02 after correction for multiple comparisons
In addition, the TNF-a -308 A allele showed significant association with the OSAHS
phenotype when comparing siblings discordant for carriage of this allele. The
increased prevalence of some of the minor polymorphisms in the study population
with OSAHS suggested there may be abnormalities in metabolism and the regulation
of growth, which may directly contribute to its aetiology.
These preliminary findings would require exploration in other populations, but are
compatible with OSAHS being a polygenic disorder. This thesis highlights that there
is much to be done in our search for relevant genetic factors that will lead to a greater
understanding of this complex, chronic and very common disease.
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CHAPTER 1
THE OBSTRUCTIVE SLEEP APNOEA/HYPOPNOEA SYNDROME -
AN OVERVIEW
Sleep apnoea had been recognised throughout human history, dating as far back as
the 4th Century BC. Numerous reports throughout the 19th Century and the early part
of the 20th Century g ave way to systematically conducted studies on patients with
OSAHS and related syndromes (Lavie 1984; Kryger 1983).
The obstructive sleep apnoea/hypopnoea syndrome (OSAHS) was first properly
documented in neurophysiological sleep laboratories using techniques developed for
the investigation of other conditions such as depression and narcolepsy. OSAHS was
first described as such in 1965 (Gastaut, Tasinari & Duron, 1965; Jung&Kuhlo 1965)
and since that time there has been an explosion in the facilities for its diagnosis and
treatment as well as a rapid advancement in our understanding of its far-reaching
consequences.
OSAHS is a common condition affecting approximately 0.3 - 4% of the middle-aged
population (Douglas 2002) and is defined on the basis of symptoms of daytime sleepiness and
objective measures of disordered breathing during sleep. Characteristic of OSAHS is
obstruction of the upper airway during sleep, resulting in repetitive breathing pauses
accompanied by oxygen desaturation and arousal from sleep. This results in diurnal sleepiness
leading to cognitive impairment. Furthermore, OSAHS has been recognised as an independent
risk factor for hypertension.
This chapter focuses on definitions of OSAHS, provides a general overview of its
epidemiology, aetiologies and treatment and concludes by defining the OSAHS phenotype
that will be used in this thesis.
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1.0 Definition of the Obstructive Sleep Apnoea/Hypopnoea Syndrome
OSAHS is the result of recurrent upper airways narrowing during sleep leading to
recurrent arousal from sleep with consequent sleep fragmentation and recurrent
transient hypertension among the important physiological effects.
The episodes of pharyngeal obstruction are termed apnoea if complete and associated
with no airflow and hypopnoea if partial. The term OSAHS is thus defined as a
combination of relevant symptoms with significant numbers of apnoeas and
hypopnoeas during sleep. The term apnoea is defined, in adults, as the cessation of
airflow for a minimum of 10 seconds. Apnoeas/hypopnoeas are often, but not
always, associated with an electroencephalographic arousal at their termination and
with a 2 - 4% drop in oxygen saturation (American Association of Sleep Medicine
Task Force 1999). Some controversy remains with respect to a standardised
definition of hypopnoea, but in our centre this is a 50% reduction in thoraco¬
abdominal movement for at least 10 seconds from the preceding stable baseline when
asleep, a definition since adopted by the American Academy of Sleep Medicine
(1999).
Brief consideration should also be given to the term upper airways resistance
syndrome (UARS) which is technically defined as the coexistence of daytime
sleepiness with increased respiratory effort during periods of increased upper airway
resistance but without accompanying hypopnoeas or apnoeas. It is increasingly
considered to be part of the spectrum on OSAHS rather than a separate condition in
its own right (Douglas 2000) and its frequency is highly dependent on the recording
techniques used to detect hypopnoeas.
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1.1 Epidemiology of OSAHS
Reporting of OSAHS was initially confined to case series, but more recently, large-
scale epidemiological studies have attempted to answer questions on the incidence
and prevalence of OSAHS. However, few of these have used ideal methods and it is
therefore difficult to draw firm conclusions from them.
Generally, the best-conducted studies in terms of method and rigor of technique
employed have found a prevalence ofOSAHS in the middle-aged male population of
0.3 - 4% (Stradling and Crosby 1991; Young et al 1993; Bearpark et al 1995;
Jennum and Sjol 1992). The study showing the lowest quoted prevalence may have
underestimated the occurrence of OSAHS in the population by using oximetry alone,
with > 5 4% dips in Sp02 per hour, as an initial screening measure (Stradling and
Crosby 1991), whilst those studies showing the highest prevalences may be
overestimating the prevalence by including central apnoeas and breath holds
occurring during wakefulness (Jennum and Sjol 1992) using inductance
plethysmography at home. Assessment of sleepiness differed between the studies on
account of using self-devised questionnaires specific to each study. Fewer studies
exist examining the prevalence of OSAHS in women, but it is probably half that of
men at 0.5 - 1% (Young et al 1993; Jennum and Sjol 1992).
OSAHS occurs throughout the entire lifespan - from neonates to the elderly. In
adults, the frequency of disordered breathing during sleep increases with age and is
poorly associated with an increased incidence of daytime sleepiness or other
symptoms of OSAHS (Ancoli-Israel et al 1985; Duran et al 2001; Bixler et al 1998).
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1.2 Pathophysiology of OSAHS
The p athogenesis o f o bstructive s leep apnoea (OSA) h as b een a matter of i ntense
investigation since the 1970's. Although, the precise mechanisms have not been
entirely elucidated, three fundamental features have been proven beyond doubt
(Kuna and Remmers 2000):
1. The pharynx is the site of upper airway obstruction during sleep
2. Patients with OSA commonly have anatomical abnormalities of the upper airway
when awake
3. During inspiration, the size of the pharyngeal lumen depends on the balance
between narrowing forces resulting from intrapharyngeal suction pressure and
dilating forces generated principally by pharyngeal muscles.
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The sites of upper airway narrowing can be broadly classified into three regions (Fig
1.): the retropalatal region; the retroglossal region and the hypopharyngeal region.
Fig1. Sites of Obstruction in the Upper Airway (denoted by shaded area)
The key pathophysiological feature in OSAHS is the occurrence of upper airway
obstruction during sleep which does not occur during wakefulness. Although the
precise pathogenetic mechanisms remain incompletely understood, they are thought
to be the result of the following:
1. Upper airway calibre is reduced and pharyngeal wall compliance increased as
a result of reduced tonic upper airway dilating muscle activity (Tangel et al
1991). The decrease in calibre results in an increase in upper airway
resistance of variable degree. This is not observed in the healthy non-snorers,
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rather it is a phenomenon observed in those who snore or have sleep apnoea
(Badr 1999). Increased pharyngeal wall compliance during sleep in snorers is
manifested by the occurrence of inspiratory flow limitation as flow plateaus
during inspiration, despite continuous generation of subatmospheric
intraluminal pressure. The combination of inspiratory flow limitation and
increased resistance leads to an increased work of breathing, hypoventilation
and frequent arousal from sleep.
2. Normally, the ventilatory controls system is able to compensate for added
loads and this is essential for the preservation of chemoreceptor homeostasis.
Immediate compensation is compromised during NREM sleep and thus,
resistive loading leads to a decrease in tidal volume and minute ventilation
and then alveolar hypoventilation with subsequent hypercapnia. The latter
restores ventilation towards normal levels. In awake humans, application of
negative pressure to the upper airway elicits reflex activation of the
genioglossus or the tensor palatini muscles leading to dilation of the upper
airway. This reflex is absent during NREM sleep (Wheatley et al 1993).
Thus, the failure of immediate load compensation results in hypoventilation
and a subsequent increase in respiratory muscle activity (Henke et al 1991).
3. The hypocapnic apnoeic threshold i s an iimportant determinant o f OSAHS.
When the wakefulness stimulus to breathe is lost during sleep, ventilation in
NREM sleep becomes critically dependent on chemoreceptor stimuli. When
PaC02 falls below a highly reproducible hypocapnic apnoeic threshold
(Skatrud et al 1983), central apnoea develops. Hypocapnia is thought to be
the most important inhibitory factor during NREM sleep. REM sleep differs
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in that peripheral atonia is accompanied by augmented inspiratory medullary
neuronal activity and the REM sleep EEG shares many features of the awake
EEG. It has as yet not been established whether hypocapnia inhibits
ventilation during REM sleep.
4. Central apnoea leads to pharyngeal narrowing or occlusion which adds and
obstructive component to central apnoea and requires a higher drive to
resume ventilation (Badr et al 1995). In order to resume rhythmic breathing,
an elevation of PaC02 above eupnoeic levels is necessary to overcome the
inertia of the ventilatory control system (Leevers et al 1993). Thus, the
combination of elevated PaC02 and upper airway obstruction leads to arousal
and hyperventilation which causes subsequent apnoea (Xie et al 2001).
5. Upper Airway Patency during s leep i s d etermined b y a n umber offactors.
There is evidence that the pharyngeal airway is smaller during wakefulness in
patients with OSAHS compared to those without it (Schwab et al 1993a & b;
1995). The airway in OSAHS narrows laterally in sleep compared to normals.
Pharyngeal patency during sleep is a function of transmural pressure across
the pharyngeal wall and the compliance of the pharyngeal wall. Negative
intraluminal pressure, generated by thoracic pump muscle activity, is thought
to cause UA obstruction in subjects with OSAHS (Morrell et al 1998). The
increase in air velocity resulting from inspiratory narrowing during sleep is
thought to cause decreased intraluminal pressure according to the Bernoulli
principle - intraluminal pressure becomes more negative and causes greater
collapse of the upper airway. This is the most widely accepted theory for
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apnoea generation but there is no direct evidence from sleeping human
studies.
Extraluminal pressures are also thought to influence upper airway patency
including passive g ravitational forces g enerated b y craniofacial structure or
adipose tissue surrounding the UA (Haponik et al 1983; Horner et al 1989 a&
b; Shelton et al 1993)
Intrinsic stiffness of the pharyngeal wall also determines its degree of
collapsibility during sleep and upper airway dilating m uscles a re presumed
critical to the regulation of this. However there is conflicting evidence
regarding the exact mechanism whereby upper airway muscles affect
pharyngeal compliance:
a. The pharyngeal airway is more collapsible in dead infants (Reed et al
1985) but not in paralysed dogs (Fouke et al 1986).
b. Patients with OSAHS have increased activity of the genioglossus
muscle during wakefulness and sleep (Mezzanotte et al 1992; Suratt et
al 1988).
c. Hypocapnic central apnoea results in greater upper airway narrowing in
subjects with OSAHS relative to normals (Badr et al 1995).
d. Compliance at the level of the retropalatal airway is decreased during
REM sleep relative to NREM sleep which may be due to increased
vascular perfusion of the pharynx during REM sleep (Rowley et al
1998).
Thoracic caudal traction may also play a role in UA patency during sleep. The UA is
connected to the thoracic cage and the mediastinum by several structures and
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increased lung volume during inspiration is associated with increased UA calibre in
awake human beings as a result of thoracic inspiratory activity providing caudal
traction on the UA (Van de Graaff 1988). This occurs independently ofUA dilation
muscle activity. This mechanism has been shown in sleeping subjects to reduce
upper airway resistance and increase retropalatal airway size when end-expiratory
lung volume was increased by passive inflation (Begle et al 1991).
Surface m ucosal factors are also thought to influence airway patency during sleep
(Olson et al 1988) and this may be an important pathogenetic mechanism in OSAHS
subjects with a lot of mucosal inflammation from repeated trauma. Jokic et al (1998)
showed that pharyngeal mucosal surface tension is associated with decreased AHI in
sleeping people but the relative contribution of this mechanism to the generation of
UA dysfunction in OSAHS is yet to be determined.
In summary, UA occlusion is the result of an interaction between multiple anatomic
and physiological abnormalities which involve a small, highly compliant pharynx,
central breathing instability leading to reduced ventilatory motor output to UA
dilators and collapsing transmural pressure. Although sub-atmospheric intraluminal
pressure contributes to the generation of a collapsing transmural pressure, it cannot
be construed of as the sole mechanism ofUA obstruction during sleep.
1.3 Risk factors for OSAHS
The pathophysiology of OSAHS cannot be seen in isolation as a dysfunction of
upper airway muscles alone, but as a number of interrelated pathologies and risk
factors. The strongest risk factors for OSAHS are obesity and ageing (Strohl and
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Redline 1996; Levinson et al 1993; Rajala et al 1991; Dealberto et al 1994; Grunstein
et al 1993; Katz et al 1990; Davies et al 1990).
Morbid obesity defined as a body mass index (BMI) of > 30kg/m2, is present in 60 -
90% of patients with OSAHS. Central obesity, characterised by a high waist:hip ratio
or increased neck circumference probably is probably better correlated with OSAHS.
OSAHS is more common in men and the risk of OSAHS is higher in females who
are obese and postmenopausal (Wilhoit and Suratt 1987; Guilleminault et al 1988;
Richman et al 1994; Dancey et al 2001).
OSAHS is also associated with craniofacial abnormalities such as retrognathia. Jaw
abnormalities are more important in thinner OSAHS patients (Lowe et al 1986, 1995,
1996; Ferguson et al 1995; Partinen et al 1988).
A familial component has been identified and this is further discussed in Chapter 2 of
this thesis. Additionally, race and certain congenital conditions such as Marfan's
syndrome, Down's syndrome and the Pierre-Robin syndrome predispose to the
development of OSAHS (Bassiri and Guilleminault 2000). Acquired conditions such
as acromegaly, hypothyroidism and menopause are also associated with OSAHS
(Bassiri and Guilleminault 2000).
OSAHS is exacerbated by alcohol ingestion - thought to reduce the activity of the
genioglossus muscle, thereby leading to upper airway collapse (Taasan et al 1981;
Krol etal 1984; Scrima et al 1982; Scanlan etal 2000). Further exacerbation can
occur as a result of sedative use, sleep deprivation, tobacco use and supine posture
(Wetter et al 1994; Bliwise et al 1988; Roth et al 1985). Reduced nasal patency, due
to congestion or anatomical defects as well as respiratory allergies can also
significantly contribute to OSAHS (Lavie et al 1983).
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1.4Clinical features of OSAHS
The symptoms of OSAHS can be conveniently divided into those manifesting during
sleep and those present whilst the patient is awake. The most common complaint of
patients with OSAHS is excessive daytime somnolence often associated with fatigue.
This may range from subtle to severe and impact on driving alertness, result in
intellectual impairment, personality changes and mood disturbances, and most
commonly, depression. Other symptoms suggestive of OSAHS include morning
headaches, decreased libido or impotence and decreased dexterity (Bassiri and
Guilleminault 2000; Douglas 2002). Nocturnal symptoms are sometimes apparent to
the patient but generally, are reported by a bed partner as most patients with OSAHS
will be oblivious to their behaviour whilst asleep. The most common symptoms
reported by bed partners include snoring, snorting, choking attacks terminating a
snore and witnessed apnoeas. Although an absence o f snoring does not exclude a
diagnosis of OSAHS or upper airway resistance, virtually all patients with this
condition snore. Apnoeic episodes are reported by about 75% of bed partners
(Hoffstein and Szalai 1993). During mild apnoeic episodes, there may be preserved
respiratory effort whilst in severe cases there may be a brief cessation of any
thoracoabdominal movement whatsoever. Gasps, chokes, snorts, vocalisations or
brief awakenings generally terminate apnoeic episodes. Bed partners will generally
report a sudden cessation of snoring followed by a loud snort and a resumption of
snoring. Some patients will awaken after such a sequence, however, most do not and
are unaware of their sleep disordered breathing (Bassiri and Guilleminault 2000;
Douglas 2000). Those who are aware of frequent events leading to awakening can try
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to delay and prevent themselves from falling asleep, thus presenting with a
'paradoxical' insomnia. Other symptoms commonly reported during sleep include
nocturia (Kales 1985), diaphoresis, gastro-oesophageal reflux and drooling (ASDA
1997; Kales 1985). Many patients awaken in the morning complaining of a dry
mouth. A number of clinical features are associated with OSAHS; however, the
predictive value of any single one is limited in confirming the diagnosis. It has been
shown that clinical impression alone has a sensitivity of 60% and specificity of 63%
(Hoffstein and Szalai 1993). The principal abnormalities include obesity (BMI > 28
kg/m) and enlarged neck circumference (>40 cm) (Kushida et al 1997). Dental
abnormalities identified include narrow mandible, narrow maxilla, dental overjet and
retrognathia, cross-bite and dental malocclusion (Class 2). Nasal problems include
enlarged nasal turbinates and deviated nasal septum. The vast majority of aberrations
occurs in the pharynx and includes high and narrow hard palate, elongated and low-
lying uvula, prominent tonsillar pillars, enlarged tonsils and adenoids and
macroglossia (Bassiri and Guilleminault 2000; Douglas 2002). An effective way of
clinically categorising abnormalities of the upper airway involves the use of the
Mallampati score (see Figure 2).
Fig 2. Classification of the Upper Airway after Mallampati (Can Anaesth SocJ
1983; 30: 316-317)
Class 1 Class 3 Class 4
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Nevertheless, history and clinical examination alone (including blood pressure and
BMI) can predict the presence of OSAHS in only 50% of patients attending a sleep
disorders clinic (Hoffstein and Szalai 1993). Definitive diagnosis requires overnight
investigation of breathing pattern.
1.5Morbidity and mortality associated with OSAHS
Untreated OSAHS can contribute to the development or progression of other
disorders. OSAHS has now been shown to be a cause for systemic hypertension
(Faccenda et al 2001; Pepperell et al 2002; Hla et al 2002; Sanner et al 2002; Becker
et al 2003; Lavie et al 2000) and there is accumulating evidence suggesting that it
can also cause pulmonary hypertension (Blankfield et al 2000; Sajkov et al 2002).
OSAHS is associated with ischaemic heart disease (Kiely and McNicholas 2000). A
recent study has shown that atrial pacing may ameliorate sleep apnoea present in
patients with significant cardiac rhythm disturbances (Garrigue et al 2002), but this
study has not been replicated.
Disordered breathing during sleep has been found to be a significant clinical feature
in a proportion of patients with cerebrovascular disease - stroke and transient
ischaemic attacks. However, studies are contradictory, with some showing no
increase in OSAHS in those with TIA (McArdle et al 2003), whilst others show a
high prevalence of OSAHS in those with stroke (see Neau et al 2003 for review).
Two studies have been published so far looking at the effectiveness of treating
OSAHS in stroke with a significant reduction in sleep-disordered breathing and
improvement in quality of life (Sandberg et al 2001; Wessendorf et al 2001). Patients
with OSAHS and moderate to severe co-existent lung disease such as COAD are
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more likely to develop type II respiratory failure that will improve with treatment of
the obstructive apnoeas (de Miguel et al 2002; Mansfield and Naughton 1999).
Likewise, nocturnal asthma may be worsened by sleep apnoea (Chan et al 1988;
Guilleminault et al 1988) and treatment may lead to improvement
OSAHS leads to neuropsychological impairment that includes deficits in attention,
concentration, vigilance, manual dexterity, visuomotor skills, memory, verbal
fluency and executive function (Engleman et al 2000). Perhaps the most important
complication of OSAHS, and the one which has the greatest impact from the public
health perspective, is driving accidents. Over a third of patients with OSAHS report
having had had an accident or near-miss accident on account of falling asleep whilst
driving (Engleman et al 1997). There is also objective evidence of 1.3 - 12 fold
increases in accident rates among those with sleep apnoea (Teran-Santos et al 1999;
Young et al 1997; Horstman et al 2000; Barbe et al 1998; Findley et al 1998; George
and Smiley 1999; Lloberes et al 2000) and accident rates in OSAHS patients have
been found to be 1.3-7 times higher than those in the general population (Barbe et al
1998; Findley et al 1998; George and Smiley 1999). Vigilance testing and driving
simulators in studies assessing driving performance in patients with OSAHS reveal
that performance is markedly reduced and the impairment is not just limited to
periods when patients actually fall asleep but also when they are awake due to
reduced vigilance. There is also evidence that OSAHS patients have a 50% increased
risk ofwork place accidents (Ulfberg et al 2000; Lindberg et al 2001).
There is no evidence related to mortality specifically as a result ofOSAHS. Only one
small, non-randomised study with 54% follow-up of patients has examined the
impact of CPAP therapy on survival of patients with OSAHS (He et al 1988). There
14
was a suggestion that survival was improved by CPAP but this must be viewed in the
context of the study's significant methodological limitations.
1.6Assessment of OSAHS
As stated in 1.5 above, definitive diagnosis of OSAHS requires objective recording
and measurement of sleep and breathing during the night in addition to a measure of
daytime sleepiness (objective or subjective) and other symptoms.
1.6.1 Sleep disordered breathing
An objective measure of sleep disordered breathing at night is generally required to
confirm the diagnosis of OSAHS. The method most widely used, and which is
considered by some to be the 'gold standard' for diagnosis despite limited evidence,
is o vemight p olysomnography (PSG). T he American A cademy o f Sleep M edicine
Task Force published indications for PSG in 1997 and measurement techniques and
syndrome definitions in 1999. Most PSG studies monitor the following routinely:
nasal and/or oral airflow; thoracoabdominal movement; snoring;
electroencephalogram (EEG); electro-oculogram (EOG); electro-myogram (EMG);
and oxygen saturation. Signal collection and interpretation is usually computerised,
but manual scoring of the trace should still be performed using guidelines for
interpretation of the EEG published in 1 968 b y Rechtschaffen and Kales, andthe
AASM criteria (1999) and Gould et al (1988) for scoring of respiratory and other
events.
Full night PSG is generally performed, but split-night studies are also used (Pepperell
et al 2002) in which the first half of the study night is used for diagnosis and the
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second half to monitor treatment response using continuous positive airway pressure
(see 1.7.2 below).
A more recent introduction to the assessment of sleep-disordered breathing has been
cardiorespiratory monitoring alone. This involves the measurement of airflow,
respiratory effort, oxygen saturation and heart rate, but no EEG. The great
advantages of these systems are price and portability and the ability of patients to
monitor themselves at home. Ferber et al (1994) reviewed seven studies on portable
ambulatory monitoring systems and reported a sensitivity of 78 - 100% and a
specificity of 67 - 100% in comparison to in-lab PSG, although this is of course not a
gold standard..
Overnight oximetry is sometimes used as a screening test for identifying patients
who are at risk of having significant OSAHS but should never be seen as a substitute
for i n-lab P SG o r h ome c ardiorespiratory monitoring. T here a re s evere limitations
inherent in this technique used in isolation including the inability to detect apnoeas or
hypopnoeas not associated with oxygen desaturation and the upper airway resistance
syndrome. Furthermore, nocturnal oxygen desaturation may be related to to sleep
hypoventilation without associated upper airways obstruction e.g. in COPD, severe
kyphoscoliosis, muscular dystrophy and morbid obesity and in the setting of periodic
breathing associated with severe heart failure.
1.6.2 Daytime Sleepiness
Sleepiness is difficult to define and is the subject of intense discussion (see Cluydts
et al 2002 for review). For the purposes of this thesis, sleepiness will be regarded as
'normal' sleepiness (result of the normal circadian rhythm) and 'pathological'
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sleepiness (result of altered sleep scheduling) (Moldofsky 1992). Pathological
sleepiness c an b e further s ubdivided into ' habitual' (e.g. as the r esult o f r ecurring
precipitants of sleepiness such as OSA) or 'occasional' (e.g. as the result of jet lag or
medication).
Three methods of classifying sleepiness can be utilised as proposed by Cluydts
(2002):
1. Inferring sleepiness from behavioural measures, e.g. observation of yawning
frequency, actigraphy, facial expression or performance tests such as the driving
simulator , psychomotor vigilance tests and reaction time tests
2. Self-evaluation of sleepiness by rating scales, e.g. the Stanford Sleepiness Scale
to measure sleepiness at a given instant, Epworth Sleepiness Score (ESS) to
measure sleepiness averaged over a month.
3. Direct electrophysiological measures e.g. multiple sleep latency test (Thorpy
1992) and multiple wakefulness test (Doghramji et al 1 997); pupillometry and
cerebral evoked potentials.
Probably the most widely used and best-validated scale assessing daytime sleepiness
is the Epworth Sleepiness Score (see Appendix 1) first devised in 1991 by Johns. Its
advantages include ease of administration and low cost. It assesses global level of
sleepiness and is independent of short-term variations in sleepiness with the time of
day and also inter-day variations (Johns 1994). The ESS aims at measuring the
general level of daytime sleepiness as a stable individual characteristic and has a
satisfactory test-retest reliability (Johns 1992). The ESS is also able to discriminate
between normal and pathological sleepiness (Johns 1991). The accuracy of the ESS
depends on the awareness of subjects falling asleep and this may not always be the
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case (Reyner and Home 1 998). Rating of the subject's sleepiness by a si gnificant
other may be more precise (Kingshott et al 1995). The ESS does not strongly
correlate with more objective measures of daytime sleepiness such as the MSLT or
MWT (Benbadis et al 1999; Johns 2000) but this is in keeping with the fact that
sleepiness is not a unitary concept. The ESS reproducibly reflects changes in
sleepiness with therapy in OSAHS (see Patel et al 2003 for review).Because of its
reliability and its ability to differentiate between abnormal and normal levels of
sleepiness as well as for its ease of administration, the ESS is the measure of
sleepiness used in this thesis.
1.7 Treatment of OSAHS
A number of modalities have been employed in the treatment of OSAHS, each with
inherent limitations. Some measures are more effective than others in reducing or
abolishing OSAHS and are not suited to all individuals. If the primary goal in
treatment is considered to be the reduction of the AHI to 5 events per hour or less,
then continuous positive airway pressure (CPAP) is the most effective form
(Lojander et al 1996; Wright and White 2000). However, it is obtrusive and often
poorly tolerated (see Engleman and Wild 2003 for review). Surgery of the upper
airway and face (e.g. uvulopalatopharyngoplasty, maxillo-mandibular advancement
osteotomy, hyoid myotomy with suspension, laser-assisted uvulopalatoplasty), can
improve OSAHS dramatically but is relevant in only a minority of patients. Results
are not often sustained in the long-term and use of other devices subsequently is
more difficult. Oral appliances are useful in many patients but are generally not
18
sufficiently effective in the moderate or severe c ategories of OSAHS (Wright and
White 2000). Pharmacotherapy has no major role (Smith et al 2002).
1.7.1 Conservative measures
These measures, generally addressing lifestyle modification, are probably the
simplest, cheapest and least effective method for the long-term treatment of OSAHS.
They are also the most frequently recommended in a clinical practice setting and
include advice re: weight loss; exercise; sleep hygiene; avoidance of smoking and
alcohol and soporific medications.
Weight loss is recommended on the basis that it should decompress the upper airway
and promote its patency, especially in the context of worsening of OSAHS with
weight gain. Uncontrolled studies have suggested that it may be effective (Lojander
1998; Noseda 1996; Smith 1985). Exercise is recommended as an adjunct to weight
loss and also to alter sleep structure.
Improvement in sleep hygiene includes measures to improve the sleep environment,
avoiding stimulants before bedtime, avoiding daytime naps etc. Few studies have
been conducted examining sleep hygiene and its effect on sleep apnoea (Redline et al
1998) but sleep deprivation has been shown to increase upper airway collapsibility
(Series 1994). Avoiding of excessive alcohol in the evenings has been shown to be
important (Issa 1982; Scrima 1982; Mitler et al 1988). Smokers have a four-to five¬
fold higher risk in having at least moderate OSA (Wetter et al 1994). Sleep position
has also been looked at in terms ofmodifying the degree of OSA experienced (Isono
et al 2002).
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However, t here are n o r andomised c ontrolled t rials 1 ooking at t he e ffects oft hese
lifestyle modifications in the context of OSAHS (Shneerson and Wright 2001) and
thereby a lack of evidence as to their true and sustained effectiveness. Nevertheless,
as they are non-invasive they can continue to be recommended.
1.7.2 Continuous positive airways pressure (CPAP)
Nasal CPAP therapy was first described in 1981 by Sullivan et al. and has since
become the 'gold standard' for the treatment of OSAHS. CPAP acts as a pneumatic
splint, preventing collapse of the pharyngeal airway. It acts by elevating the pressure
in the oropharyngeal airway and reversing the transmural pressure gradient across the
pharyngeal airway. One important factor, which determines the effectiveness of the
system, is that the apparatus providing the pressure at the nasal airway must have the
capacitance to maintain any given pressure during inspiration. Generally, CPAP is
commenced under supervision in a hospital-based setting. The optimal pressure
(cmH20) is titrated to reduce the AHI to less than five ideally. Once the correct
CPAP level is reached and the airway is open, sleep should no longer be fragmented
by repetitive arousals. It is well known that the response to CPAP therapy in patients
treated in this fashion is generally very good in terms of the amelioration of daytime
sleepiness and impaired daytime function - however, there are few controlled studies
that show this. A recent review of randomised placebo controlled trials included only
twelve such studies on the basis ofmethodological limitation in the others (White et
al 2002) but concluded nevertheless that CPAP (when compared to placebo) resulted
in significant improvements in objective and subjective sleepiness, measures of
oxygenation and mean arterial blood pressure as well as improvements in health
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status and the mental health role. A more extensive review by the NHMRC in
Australia (2000) came to the same conclusions.
CPAP is not without its problems and side-effects which include: nasal congestion,
nasal dryness, epistaxis, skin abrasions, conjunctivitis from air leak, chest
discomfort, aerophagy, sinus discomfort, noise levels, partner intolerance and
inconvenience. All these factors may affect compliance and usage - an issue
discussed in detail in the reviews by Engleman and Wild (2003), Douglas and
Engleman (1998), McArdle et al (2000) and Hoy et al (1999).
The newer forms of intelligent CPAP, which are also in use, are based on flow
limitation detection with a few in use that are based on the principles of the forced
oscillation technique for the measurement of complex resistances in the airway
(DuBois et al 1956). They enable treatment pressure to be adjusted to the actual
requirement to keep the upper airway patent. Two objectives are thus possible with
these devices: the determination of the pressure level for fixed CPAP home treatment
(autotitrating system) or the replacing fixed CPAP by automatically varying pressure
during the entire treatment period (autoadjusting system). The latter is hoped to
reduce pressure-associated side effects, which may compromise patient compliance.
A recent randomised crossover trial comparing APAP with CPAP showed that both
systems were equally effective in treating sleep apnoea (Randerath et al 2001).
1.7.3 Oral Appliances
There are two forms of oral appliance: those, which hold the tongue forward, and the
much commoner group which reposition the mandible and the tongue in a forward
position during sleep. Lowe (2000) has produced a full review of the types of oral
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appliances available on the market and their comparative effectiveness. In 1995, the
American Sleep disorders Association (ASDA) reviewed the available literature on
oral appliances and recommended that they be used in the treatment of simple
snoring or mild sleep apnoea, being reserved for the treatment of moderate or severe
sleep apnoea only in instances where CPAP therapy had failed or was declined by
the patient. Unfortunately, poor study design in a number of trials looking at the
effectiveness of oral appliances in comparison to CPAP or placebo alone has made
their role in day-to-day clinical practice difficult to evaluate. The first paper to be
published using the randomised, controlled crossover design of mandibular
advancement splint vs. p lacebo suggested that it is an e ffective treatment in some
patients with OSA, including those patients with moderate or severe OSA (Mehta et
al 2001). The results of further trials are currently awaited.
1.7.4 Surgery
Surgery for sleep apnoea is a complex and controversial field and encompasses
procedures carried out by surgeons attached to the subspecialties of Otolaryngology,
Maxillofacial surgery and specialised surgery of the gastrointestinal system (bariatric
surgery).There are no randomised controlled trials assessing the effectiveness in the
long-term of these methods and often they are best applied on a situational basis and
adapted to the patient's anatomy, e.g. if the patient has severe ankylosis of the
temperomandibular joint, has macroglossia or disabling prognathism. Some surgeons
hold the tracheostomy to be the 'gold standard' of treatment of OSAHS, as it
conveniently bypasses the upper respiratory tract where the problem resides.
However, this solution comes with its fair share of comorbidities, including loss of
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natural speech to start with! The details of the various surgical techniques will not be
discussed further in this thesis. The reader is referred to recent comprehensive
reviews on the subject by Sher (2002) and Riley et al (2000). Likewise, bariatric
surgery which may be extremely effective in the management ofmorbid obesity (and
OSAHS concurrently) (Sugerman 2001; Scheuller and Weider 2001). The techniques
involved have recently been reviewed by Gentileschi et al (2002) who conclude that
randomised controlled trials comparing the various laparoscopic operations are
strongly needed.
1.7.5 Pharmacotherapy
Drug therapy has been proposed as an alternative in the treatment of OSAHS. The
imputed mechanisms include: reduction in the proportion of rapid eye movement
sleep (REM), an increase in ventilatory drive and an increase in upper airway muscle
tone during sleep. There is little evidence currently for any of the drugs that have
been trialled in the management of OSAHS to be effective (Smith et al 2002). The
most commonly described potential drugs for OSAHS treatment have been
progestogens, shown to increase ventilatory drive (Cistulli et al 1994), acetazolamide
and theophylline, both known to increase ventilatory drive. Tricyclic antidepressants
and selective serotonin re-uptake inhibitors (SSRI's) reduce the proportion of REM
sleep and theoretically the RDI (sleep disordered breathing is more common during
REM). Clonidine has a similar action and has been proposed as a treatment for mild
to moderate sleep apnoea (Hudgel 1995). Pathways involving serotonin and
histamine have been shown to play an important role in modulating drive in the
innervation of the pharyngeal musculature (for detailed discussion see Veasey 2002).
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For this reason, ondansetron has also been trialled in the animal model of OSAHS,
the English bulldog (Veasey et al 1999; 2001).
Treatment of residual sleepiness with a central nervous system stimulant, modafinil,
in patients on CPAP has not shown to abolish sleepiness entirely (Kingshott et al
2001) and so this approach towards the management of this important component of
OSAHS is also fraught with difficulty at present.
1.8 The OSAHS phenotype
Despite the increasing and already established recognition of OSAHS as an
important syndrome with significant health implications for the individual as well as
society, a precise characterisation of a particular phenotype is difficult.
In view of the multiplicity of conditions in which OSAHS may be manifest, there is
no one specific human morphology that is typical such as is the case of
e.g.Duchenne's muscular dystrophy or Marfan's syndrome. OSAHS remains a
condition that must be classified on a physiological basis and on objective or
subjective evaluation of sleepiness manifest as a daytime symptom. In view of this,
the American Academy of Sleep Medicine Task Force (1999) recently defined
OSAHS in the following way:
1. Diagnostic criteria. The individual must fulfil criterion A or B, plus criterion C.
A. Excessive daytime sleepiness that is not better explained by other factors;
B. Two or more of the following that are not better explained by other factors:
choking or gasping during sleep,





C. Overnight monitoring demonstrated five or more obstructed breathing events per
hour during sleep. These events may include any combination of obstructive
apnoeas/hypopnoeas or respiratory effort related arousals, as defined below.
Obstructive apnoea/hypopnoea event
An event characterised by a transient reduction in, or complete cessation of,
breathing. The event must fulfil criterion 1 or 2, plus criterion 3 of the following:
1. A clear decrease (>50%) from baseline in the amplitude of a valid measure of
breathing during sleep. Baseline is defined as the mean amplitude of stable
breathing and oxygenation in the two minutes preceding onset of the event (in
individuals who have a stable breathing pattern during sleep) or the mean
amplitude of the three largest breaths in the two minutes preceding onset of the
event (in individuals without a stable breathing pattern).
2. A clear amplitude reduction of a validated measure of breathing during sleep that
does not reach the above criterion but is associated with either an oxygen
desaturation of>3% or an arousal.
3. The event lasts 10 seconds or longer.
Respiratory effort-related arousal (RERA) event
A sequence of breaths characterised by increasing respiratory effort leading to an
arousal from sleep, but which does not meet criteria for an apnoea or hypopnoea.
These events must fulfil both of the following criteria:
1. Pattern of progressively more negative oesophageal pressure, terminated by a
sudden change in pressure to a less negative level and an arousal.
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2. The event lasts 10 seconds or longer.
The American Academy of Sleep Medicine Task Force (1999) has also included
definitions of severity of OSAHS, which is based on two components: severity of
daytime sleepiness and of overnight monitoring of breathing. They suggest that the
severity for the syndrome be based on the most severe component, having rated
sleepiness and breathing events separately as below:
A. Sleepiness
1. Mild. Unwanted sleepiness or involuntary sleep episodes occur during activities
that require little attention.
2. Moderate. Unwanted sleepiness or involuntary sleep episodes occur during
activities that require some attention.
3. Severe. Unwanted sleepiness or involuntary sleep episodes occur during
activities that require more active attention.
B. Sleep related obstructive breathing events.
1. Mild: 5-15 events per hour
2. Moderate: 15 - 30 events per hour
3. Severe: greater that 30 events per hour.
Although this constitutes a good general working definition of the disorder and can
be applied satisfactorily in a research setting, it is pragmatic rather than soundly
evidence based and does not take into account age-related or gender-related changes
in sleepiness and sleep-disordered breathing. There are very few normative data for
either in the population and the results obtained are highly dependent on the
technology used to measure breathing during sleep or sleepiness. Table 1, 2, and 3
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summarise the age-and gender-related frequencies of apnoeas and hypopnoeas from
the most reliable and extensive studies available. The scoring definitions are listed
under each T able i n d etail and appear t o b e equivalent. The s tudy b y Bixler e t a 1
(1998) may slightly overestimate the number of sleep disordered breathing events as
they do not use arousals as part of their definition for a hypopnoea.
Table 1: Age and gender specific prevalence rates of the apnoea and
hypopnoea index based on polysomnographic results for a sample of 1,050
men and 1, 098 women from the Vitoria-Gasteiz region (Basque country,
Spain)
Percentage of Subjects (95% confidence interval)
AHI: ^5 ^10 ^15 ^20 >30
Men
(age/yr)
30-39 9.0(2- 16) 7.6 (0- 15) 2.7 (1-5) 2.1 (0-4) 2.1 (0-4)
40-49 25.6 (14-37) 18.2 (9-27) 15.5 (7-24) 10.1 (5-15) 7.0(3-11)
50-59 27.9(17-38) 24.1 (15-34) 19.4(11-27) 14.7(8-21) 11.4(6-17)
60-70 52.1 (33-71) 32.2 (17-48) 24.2(12-37) 15.0(8-22) 8.6 (4-14)
Women
(age/yr)
30-39 3.4(0-7) 1.7 (0-4) 0.9(0-2)
40-49 14.5 (3-25) 9.7 (0-19)
50-59 35.0(20-50) 16.2 (5-27) 8.6 (1-17) 8.3 (0-16) 4.3 (0-10)
60-70 46.9(31-63) 25.6 (13-38) 15.9 (6-26) 13.0(3-22) 5.9(0-13)
(Based on Table 2, pg. 687 in Duran et al., 2001)
Technique for data collection: Overnight use of the portable recording system MESAM IV
(Medizintechnik fur Artz und Patient, Munich, Germany). Polysomnography recorded using Alice 3
(Respironics Inc. Pittsburgh, OH).
Scoring: Manual scoring using conventional criteria. An abnormal breathing event was defined as
complete cessation of airflow for >10 sees (apnoea) or a discernible 50% reduction in respiratory
airflow accompanied by a decrease of> 4% in Sp02 and/or and EEG arousal (hypopnoea). Arousals
were defined according to ASDA criteria (1992).
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Table 2: Age and gender specific prevalence rates of the apnoea and
hypopnoea index based on polysomnographic results for a sample of 352
men and 250 women from Wisconsin (United States of America)
Percentage of Subjects (95% confidence interval)
AHI: ^5 ^10 >15
Men
(age/yr)
30-39 17.0 (9.6-25) 12.0 (5.4-19) 6.2(1.9-10)
40-49 25.0(18-32) 18.0(11-24) 11.0(6.7-16)
50-60 31.0(21-40) 14.0(7.5-20) 9.1 (5.1-13)
Women
(age/yr)
30-39 6.5 (1.4-11) 4.9 (0.6-9.8) 4.4(1.1-7.3)
40-49 8.7(4.2-13) 4.9(1.7-8.1) 3.7(1.0-6.5)
50-60 16.0(5.2-26) 5.9(0.0-12.0) 4.0(0.0-10)
(Based on Table 4., pg. 1230 in Young et al., 1993)
Technique for data collection: Overnight in-lab PSG recording in sound-attenuated, light-and
temperature-controlled rooms using standard set-up and a 16-channel polygraph (Model 78d; Grass
Instrument, Quincy, MA)
Scoring: Manual scoring using conventional criteria. An abnormal breathing event was defined as
complete cessation of airflow for >10 sees (apnoea) or a discernible 50% reduction in respiratory
airflow accompanied by a decrease of> 4% in Sp02.
Table 3: Prevalence rates of the apnoea and hypopnoea index by age based
on polysomnographic results for a sample of 741 men from two counties in
Southern Pennsylvania (United States ofAmerica)
Percentage of Subjects (95% confidence interval)
AHI: n >5 ^10 >20
AGE fvrl
20-44 236 7.9 (5.0-12.1) 3.2 (1.6-6.4) 1.7(0.6-4.4)
45-64 430 19.7 (16.2-23.7) 11.8 (9.1-15.3) 23.9 (15.7-34.9)
65-100 75 30.5 (21.1-41.7) 23.9(15.7-34.9) 13.3 (7.3-23)
(Based on Table 1., pg. 145 in Bixler et al., 1998)
Technique for data collection: Overnight in-lab PSG recording in sound-attenuated, light-and
temperature-controlled rooms using standard set-up and a 16-channel polygraph (Model 78d; Grass
Instrument, Quincy, MA)
Scoring: Manual scoring using conventional criteria. An abnormal breathing event was defined as
complete cessation of airflow for >10 sees (apnoea) or a discernible 50% reduction in respiratoty
airflow accompanied by a decrease of> 4% in Sp02.
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A similar dilemma exists with regard to measures of sleepiness (see 1.6.2 above).
Probably the most widely used and best-validated instrument clinically is the
Epworth Sleepiness Score designed by Johns in 1991 (see Appendix 1). This 8 point
scale has been found useful internationally in populations as diverse as the Chinese
(Chung 2000), the Spanish (Chiner et al 1999) and the Germans (Bloch et al 1999).
Normative data for a general population are sparse. Nevertheless, there is sufficient
evidence to suggest that an ESS in the range of 0 - 11 is within normal limits and an
ESS of > 11 generally indicative of abnormal levels of daytime sleepiness
irrespective of age (Parkes et al 1998; Manni et al 1999; Johns & Hocking 1997).
Table 4 and 5 summarise the extant data on the ESS looking at normal populations
by age group. The study by Carmelli et al (2001) looked at the heritability of the ESS
in 818 monozygotic and 742 dizygotic male twin pairs and estimated it to be 38%
(CI 95% 33 - 44%).
Table 4: Mean Epworth Sleepiness Score in a Normal or Control Population
according to Age and Region





30 75+6 6.93+3.54 Australia Crowley&Colrain 2000
30 20+3 7.23+2.96 Australia Crowley&Colrain 2000
188 49+16 4.5+3.3 U.K. Parkes et al 1998
70 47+13 10±5 Spain Chiner et al 1999
54 52±10 4.4+2.8 Italy Manni et al 1999
61 35+9 7.5±3 Hong Kong Chung 2000
1560 74+3 7.1±3.9 U.S.A. Carmelli et al 2001
72 22-59 4.6±2.8 Australia Johns & Hocking 1997
159 35+13 5.7+3 Switzerland Bloch et al 1999
29
Table 5: Mean Epworth Sleepiness Score in a Population of Drivers by Age






65 and over 905 6.2
* Number of drivers in whom ESS was recorded in general is ca 9% smaller than number quoted
(Based on Table 3., pg 457, Maycock 1997)
On the basis of the evidence presented above, the definitions for sleepiness, sleep-
disordered breathing and OSAHS which will be applied throughout this thesis and
which will define the sleep apnoea phenotype are as follows:
1. Sleepiness. This is defined as an ESS of>11.
2. Sleep-disordered breathing. This will be defined as the frequency of apnoeas and
hypopnoeas detected on overnight PSG in an age-specific context as follows:
Table 6: Classification of AHI according to Gender and Age




20-40 M< 10 F< 10
40-60 M <15 F< 10
>60 M < 20 F< 15
20-40 M 10-15 F 10-
40-60 M 15-20 F 10-
>60 M 20 - 30 F 15 -:
20-40 M> 15 F> 15
40-60 M >20 F> 15
>60 M > 30 F > 20
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3. OSAHS. The obstructive sleep apnoea/hypopnoea syndrome will be defined if
there is abnormal breathing during sleep and an abnormal level of daytime
sleepiness as defined above. Those falling into the indeterminate category in
respect to the AHI will also be classified as having OSAHS if they have an
abnormal level of daytime sleepiness.
The OSAHS phenotype in this thesis will thus be clearly demarcated on the basis of
criteria outlined above for the age-specific apnoea/hypopnoea index together with
abnormal daytime somnolence. Irregular breathing during sleep alone will be
defined on the basis of the AHI alone. Sleepiness alone will be defined on the basis
of an abnormal ESS alone. Although this is a conservative definition of OSAHS
overall, it allows for most individuals' data to be informative.
1.9 Concluding remarks
As outlined above, OSAHS is an important condition within our community with the
potential of being a significant health burden. OSAHS is associated with a number of
comorbidities and may contribute to the development of hypertension and other
cardiovascular and cerebrovascular diseases. It is also a condition, which is a public
health concern with respect to road safety and a small but important cause of further
morbidity and mortality in this context. OSAHS is easily diagnosed and readily,
although not always easily, treated.
The definitions for the phenotype of OSAHS to be used for further work presented in
this thesis have been discussed in detail in section 1.8.
In Chapter 2, the familial nature of OSAHS and the potential candidate genes to be
evaluated in this study will be described.
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CHAPTER 2
CANDIDATE GENES IN OSAHS
2.0 Introductory Remarks
A number of studies have shown that OSAHS runs in families (discussed below) and
that this can occur independently of obesity. Mechanisms contributing to the
aetiology of OSAHS include genetically and environmentally induced changes in
craniofacial dimensions, differential deposition of adipose tissue, abnormalities in
upper airway control and differential susceptibility to sleepiness. All of these
potential co-aetiologies have come under increasing scrutiny on a genetic level. With
the completion of the Human Genome Project and the establishment of a single
nucleotide polymorphism (SNP) gene map, enormous progress has been made in
clarifying the genetic causes ofphenotypic differences in the human population.
This chapter will focus on the hereditary aspects of OSAHS, discuss its polygenic
nature and consider candidate genes in relation to its various aetiologies. The aims of
this thesis are also outlined.
2.1 Is the Obstructive Sleep Apnoea/Hypopnoea Syndrome Hereditary?
Over a number of years, evidence has accumulated that there is a hereditary
component to OSAHS. Redline and Tishler (2001) in a review on the genetic aspects
of OSAHS have suggested that hereditary factors invoke 40% of the variance in the
occurrence ofOSAHS in the population, the rest attributable to obesity, upper airway
control dysfunction and craniofacial components.
Initially, case reports were suggestive of a familial link for OSAHS. Strohl et al
(1978) described 2 males and their father with severe hypersomnolence and
obstructive sleep apnoea. A third, asymptomatic son was shown to have increased
32
upper airway resistance during sleep. The electromyographic recordings of the
genioglossus muscle in this family showed loss of tonic activity when sleep apnoea
occurred. The asymptomatic son showed loss of tonic activity in REM-sleep only.
Two deaths were also present in the family, one in a four-month-old daughter of the
asymptomatic son presumed to be secondary to SIDS and a brother (2nd generation of
the family) who died aged 30 years in his sleep. The family members were
hypersomnolent. Other case reports of a similar nature were published by Rostand
(1978) who documented a man with OSAHS who had a son with OSAHS as well as
a brother and Manon-Espaillat et al (1988) who described a family of sleep apnoeics
who also suffered from anosmia, partial complex seizures and daltonism. This latter
disorder was termed the 'sleep apnoea plus' syndrome.
The above case reports are not representative of the population at large, where 2 -
4% of middle-aged people have OSAHS. Douglas et al (1993) performed a
prospective study of first-degree relatives of 20 consecutive non-obese patients with
OSAHS. In studying a total of 40 relatives, they found that 10 of them had more than
15 apnoeas and hypopnoeas per hour of sleep and 8 had more than five 4%
desaturations per hour. Teculescu et al (1994) suggested a familial basis for OSAHS.
A study by Mathur and Douglas (1995) looked at, among other factors, cephalometry
of relatives of patients with OSAHS compared to normal controls. The findings
suggested that the relatives had more backset maxillae and mandibles than age and
sex-matched controls.
Ferini-Strambi et al (1995) looked at snoring in 492 monozygotic and 284 dizygotic
twins and found there was greater concordance for snoring among the former with
obesity playing a more significant role in the latter.
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Guilleminault et al (1995) conducted a mail survey of first-degree relatives of 157
patients with OSAHS and their friends who were unrelated to the patients and
approximately the same age as the relatives. Despite limitation in method of this
study, there was a suggestion that the relatives and index cases were distinguishable
from their friends by snoring more and possessing slightly different craniofacial
characteristics (numbers were 22 relatives vs. 6 friends).
Familial aggregation and segregation analysis of snoring and symptoms of OSAHS
was performed by H olberg et a 1 (2000) w ho suggested that for their sleep apnoea
phenotype (applied to 584 pedigrees with 2019 cased enrolled in the Tucson
Epidemiologic Study of Obstructive Airways disease) demonstrated Mendelian
dominant or co-dominant transmission. However their analyses also suggested that a
non-genetic model would fit the data equally well. They concluded by stating that
their analysis showed that environmental factors contribute to the development of
OSAHS and that maternal components may be more important than paternal ones.
Ovchinsky et al (2002) who examined over 115 related caretakers of children with
OSAHS suggested too that there may be a familial basis to the syndrome.
The results of family studies are summarised in Table 7 below.
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Table 7: Prevalence of Sleep Disordered Breathing among First-degree
Relatives of Probands with OSAHS (After: Table 1, pg 238, Redline et at 2002)
Proband:Relative Controls
(n:n ratio) (n)






































Pillar et al 1995
Douglas et al 1995
20 Mathur &Douglas 1995
46 Guilleminault et al 1995
11
2 Redline et al 1995
Buxbaum et al (2002) performed a segregation analysis on a sample of 177
Caucasian families and 125 African American families. With the use of very
complex statistical techniques they demonstrated transmission of a putative candidate
gene for OSAHS (typified solely by AHI) that was variable depending on whether
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the mathematical model was age-or BMI-adjusted for the Caucasians and
independent ofBMI for the African Americans.
Unfortunately, this study is flawed on a number of counts. Not least are the lack of
proper phenotyping and the use of AHI alone to characterise subjects. The OSAHS is
a sy ndrome w hich t herefore r equires symptoms t o b e p resent. T hus, AHI a lone i s
inadequate as a definition of the syndrome per se. Furthermore, AHI is variable
within subjects on a nightly basis and subject to recording and scoring error and
therefore, is not an immutable characteristic that substitutes for phenotype. There
may be racial differences in the presentation of OSAHS. However, it is often taken
for granted that the human species is divided into homogeneous groups or races
among which biological differences are large (Barbujani et al 1997). Studies of allele
frequencies do not support this view, as differences between members of the same
population account for 85% of the total diversity. Differences among continents
represent roughly 1 /10 of human molecular diversity, which does not suggest that
racial subdivision of our species reflects any major discontinuity in our genome
(Barbujani et al 1997).
The postulated observation by Buxbaum et al (2001) is also not borne out by
previous studies showing that BMI is just as important in the aetiology of OSAHS in
African Americans as it is in American Caucasians (Redline et al 1997).
In summary, a number of studies over the last 25 years have suggested a familial
component to OSAHS, which may influence the diverse aetiopathologies associated
with its development including obesity, craniofacial structure and dysregulated upper




The craniofacial complex is probably one of the most important heritable
determinants of OSAHS development. The three components considered in this
context are bone size; head shape and facial profile.
Retroposed maxillae and mandibles predispose to OSAHS (Douglas &Mathur 1995;
Ferguson et al 1997). Such differences in jaw size can be inherited or acquired - for
example, following nasal occlusion in childhood (Trask et al 1987; Linder-Aronson
1970; Harvold 1979, 1981). There are also a number of syndromes such as the
Carpenter Syndrome and Apert's syndrome, which are associated with craniofacial
anomalies leading to OSAHS (Gaultier & Guilleminault 2001). Here the genetic
locus has been identified but the confounder remains the multitude of associated
anomalies, which characterise these syndromes (they will not be discussed further).
In order to discuss the genetic aspects of craniofacial characteristics, a brief overview
of development is undertaken in Section 2.2.1 below.
2.2.1 Craniofacial Development
The facial primordia in humans appear around the primitive mouth (stomodeum)
early in the fourth week of foetal development and are classified as follows:
1. The frontonasal prominence formed by the proliferation of mesenchyme
ventral to the forebrain, constitutes the cranial boundary of the stomodeum.
2. The paired maxillary prominences of the first branchial arch form the lateral
boundaries of the stomodeum.
3. The paired mandibular prominences of this arch form the caudal boundary of
the stomodeum.
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The mesoderm of the five facial primordia is continuous from one prominence to the
other. There are no internal divisions corresponding to the grooves demarcating the
prominences externally. Facial development occurs mainly between the fifth and
eighth weeks. The mandible is the first part to form and results from the merging of
the medial ends of the two mandibular prominences during the fourth week. Nasal
placodes, bilateral oval-shaped thickenings of the surface ectoderm, develop by the
end of the fourth week on each side of the lower part of the frontonasal prominence.
Mesenchyme proliferates at the margin of each placode, giving rise to the medial and
lateral nasal prominences. The nasal placodes come to lie in nasal pits.
The maxillary prominences enlarge and rapidly approximate each other as well as the
medial nasal prominences. The nasolacrimal groove separates each lateral nasal
prominence from its corresponding maxillary prominence. By the end of week five,
the eyes have come slightly forward on the face and the external ear has begun to
develop. Each maxillary prominence merges with the lateral nasal prominence by the
end of week five and continuity is established between the side of the nose formed by
the lateral nasal prominence and the upper cheek region formed by the maxillary
prominence.
During the sixth and seventh weeks, the medial nasal prominences merge with each
other and the maxillary prominences forming the intermaxillary segment which gives
rise to a. the philtrum of the upper lip, b. the premaxillary part of the maxilla and
associated gingiva and c. the primary palate.
The maxillary prominences merge with the mandibular prominences and form the
lateral parts of the upper lip, the majority of the maxilla and the secondary palate.
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The mandibular prominences give rise to the lower lip, the chin and lower cheek
region. The various bony structures are also formed from these prominences.
The frontonasal prominence forms the forehead and the dorsum and the apex of the
nose.
Development of the face is slow and results from changes in proportion and relative
position of the facial components. During early foetal life, the nose is flattened and
the mandible is underdeveloped. As the brain enlarges, creating a prominent
forehead, the eyes move medially and external ears rise. The face at birth is small on
account of rudimentary upper and lower jaws, unerupted teeth and the small size of
the nasal cavities and maxillary sinuses.
An integral part of facial development is palatal genesis. The primary palate develops
at the end of week five from the innermost part of the intermaxillary segment of the
maxilla which comprises mesoderm. The primary palate becomes the premaxillary
part of the maxilla, containing the incisor teeth. The secondary palate forms the hard
and soft palates extending from the incisive foramen posteriorly. It develops from
two horizontal mesodermal projections that extend from the internal aspects of the
maxillary prominences, the lateral palatine processes. These latter processes project
downward initially to flank the tongue on each side. With development of the jaws
and neck, the tongue moves downwards and the lateral palatine processed elongate
and move horizontally and superiorly to the tongue during the seventh week. The
lateral palatine processes fuse with each other in the midline and also with the
primary palate and the nasal septum commencing anteriorly in the 9th week with
completion by the 12l" week posteriorly in the region of the uvula. Bone develops in
the premaxillary part of the maxilla which carries the incisor teeth, then extending
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from the maxillae and palatine bones into the lateral palatine processes to form the
hard palate. The posterior portions of the lateral palatine processes extending beyond
the nasal septum remain as the soft palate and uvula.
Many genes are involved in the progressive development of the craniofacial
complex. A hierarchy of control genes is activated in sequence, which specifies how
the cells in a domain should develop. These controls are influenced by local feedback
and intercommunication mechanisms between cells and tissues. The effect of other
genes on contiguous tissue will also influence expression of the gene of interest with
resultant effects on each other. This is an epigenetic phenomenon and may account
for the variability seen in one particular tissue, which cannot be solely ascribed to a
single gene polymorphism as would otherwise be postulated.
Thus, the craniofacial complex is comprised of a number of components which are
interdependent in their growth patterns and which are so closely linked, that the
growth and shape of one component will influence the rest. Generally, size
influences shape and is probably the element that is most influenced by genes.
Genes identified through animal studies (mouse-mutants), human craniofacial
syndromes and expression studies of signalling molecules during facial development
have led to the identification of a variety of factors involved in the development of
the jaw. Fig.3 summarises the putative genes involved in facial development and
Table 8 summarises factors active in the developing face. For a more detailed
discussion of this information, see Francis-West et al (1998); Mina (2001) and
Thesleff (1998).
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Fig 3 : Processes involved in facial development (After: Fig.2, pg7, Francis-West et al 1998)
Process Genes involved Target genes
Head mesoderm induction




















Table 8: Signalling and transcription factors involved in the developing face
(not exhaustive) (After: Table 1, pg 6, Francis-West et al. 1998)
Signalling factor Homeobox gene Transcription Factors
Migrating neural crest Wnt-5a En protein AP-2*
Dlx-1*, 2* Gli-2*, 3*
Msx-l*f, 2 f twist *1
Otx-2*
Pax-3*f, 7*
Facial Primordia Activin Pa* Barx-1, 2 AP-2*
BMP-2,4*,5*,7* Dlx-1-6(1*,2*) Gli-1,2*, 3*
EGF En-2 Pax-1*
ET-1* GH-6 twist *{
FGF1,2,4,5,8,121 Gsc-1*
PDGF-cc MHOX*








* Mutation or loss of function by knockout studies in mice results in some facial
abnormalities.
t Human syndrome associated with mutation of this gene,
t Several craniofacial syndromes are associated with the FGF receptor mutation.
The precise role played by each gene, signalling factor and transcriptional factor is as
yet imperfectly understood. Known polymorphisms in genes regulating craniofacial
development are linked to syndromes and generally inherited on an autosomal
dominant basis and so are of little value in the context of the relatively mild
abnormalities observed in the sleep apnoea population.
Of possibly greater interest is the regulation of facial growth and postnatal
development of the maxilla and mandible as a potential future target for therapeutic
intervention.
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2.2.2 Postnatal Facial Growth
Growth of the craniofacial complex after delivery is dependent not only on genetic
factors, but is also subject to a wide variety of environmental influences which may
be related to the microenvironment of the face itself and its component structures but
also to more global influences such as malnutrition.
Bone forms in two basic modes, endochondral and intramembranous and its growth
is a mixture of two basic processes - deposition and resorption. Growth of the cranial
vault is paced largely by growth of the enclosed brain. Basicranial growth is effected
by a combination of synchondrosial elongation, sutural growth and cortical drift and
remodelling. Nasomaxillary growth involves the sutures, endosteal and periosteal
surfaces and alveolar processes. Alveolar remodelling influences height, width and
length increases that correlate with tooth eruption. Mandibular growth occurs
endochondrally with respect to length and also intramembranously with regard to
width. Important determinants of growth and shape change are the areas where
muscle and teeth are attached. The mandibular condyle is the chief determinant of
growth in this region. Mandibular growth coincides roughly with periods of stature
growth and may show coincident growth acceleration. There are important sexual
differences in overall craniofacial growth with boys growing more, over a longer
time and more likely to demonstrate growth spurts. Racial and ethnic differences in
craniofacial structure are also well documented, but little is known about growth
differences between groups of people of different descent.
The continued growth of the craniofacial skeleton through adulthood is an important
concept that was initially best demonstrated by B ehrents (1985). In performing an
extensive follow-up of 163 dentate subjects in the Bolton-Brush study who had
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ranged in age between 17 and 83 years he systematically documented the following
observations (among others):
1. Craniofacial growth continues throughout adult life into old age
2. Significant sexual dimorphism exists with men being larger at all ages with
more growth
3. Women demonstrated periods of increased growth beyond adolescence often
associated with pregnancy
4. Mandibular orientation and occlusal relations were subject to growth and
change throughout the life cycle.
Growth of the craniofacial complex can be affected by a number of environmental
mechanisms. These include: deleterious orofacial muscle habits such as thumb-
sucking and abnormal tongue posturing; nasopharyngeal disease and disturbed
respiratory function which may produce mouth-breathing; oral/gingival tumours;
dental caries with loss of teeth; loss of permanent teeth; malnutrition and
endocrinopathy.
As a consequence of postnatal growth, head shape and facial profde assume certain
characteristics that can be classified broadly as dolicephalic, mesocephalic and
bradycephalic with ethnic associations towards the extremes. For instance,
Caucasians are more likely to be dolicephalic and Asians more bradycephalic. There
are three types of facial profile: retrognathic, orthognathic and prognathic (see Fig.4).
The position of the cranial base (determined by the brain during embryogenesis) has
a significant impact on the position of the maxillo-mandibular complex. In a
dolicephalic head, the cranial base is flat. Consequently, the naso-maxillary complex
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Fig 4: Facial Profiles (from left to right): retrognathic (skeletal class II);
orthognathic (skeletal class I) and prognathic (skeletal class III)
is placed in a more protrusive position relative to the mandible and is lower than the
mandibular condyle. There is therefore a tendency towards retrognathia. By contrast,
in the bradycephalic head, the horizontal dimension of the middle cranial fossa is
decreased with posterior placement of the maxilla. There is shortening of the
horizontal length of the naso-maxillary complex and more forward placement of the
entire mandible. This results in a prognathic profile. Head shape and size are
determined genetically and it is likely that compensatory mechanisms that prevent
the two extremes are also at work such as drift ofmaxillary and mandibular teeth and
environmental factors including allergies, infections, otitis media, diet as discussed
above. A partial failure in these compensatory mechanisms may be responsible for
the observance of certain anatomic features noted more frequently in the OSAHS
population, most notably lower facial height and overbite (retrusion of the mandible)
(Pae and Ferguson 1999; Douglas and Mathur 1995) as well as bradycephaly
(Cakirer et al 2001).Mandibular size and position seem to play the greatest role in
determining facial alignment and predisposition to sleep related breathing disorders.
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In summary, morpho-spatial disharmony of the craniomaxillary and mandibular
complexes is dependent on genes that undergo gene-environmental interactions. The
craniofacial skeleton continues to grow and develop throughout adult life and
structural modifications can occur. Genes primarily involved in postnatal growth are
discussed below.
2.2.3 Determinants of Skeletal Growth
Genes controlling final adult height and stature may also influence craniofacial
growth. Studies using g enome-wide linkage analysis have so far failed t o confirm
with certainty the potential positions of candidate g enes for adult height. The first
study in this area by Hirschhorn et al (2001) examined 4 different populations: 408
individuals from 58 families in Botnia, Finland; 753 individuals from 183 families in
other parts of Finland; 746 individuals in 179 families in Southern Sweden and 420
individuals in 63 families from the Saguenay-Lac-St.-Jean region of Quebec.
Linkage to stature was found on chromosomes 6, 7 and 13 in three of these ethnic
groups, but not so convincingly in the Quebecois. These results were strengthened
further by the study of Perola et al (2001) who found evidence of linkage to
chromosome 7 and Wiltshire et al (2002) whose own data on a UK population
suggested a locus on chromosome 3 to be strongly associated with height in their
adult sample. These findings suggest that height is under the influence/control of
multiple genes.
Studies using genome-wide linkage to look at mandibular structure and size have so
far not been undertaken in humans. However, two groups have applied this technique
in mice. Klingenberg et al (2001) utilised the method of geometrical morphometries
to quantify shape and size of the mouse mandible and were able to identify 12QTLs
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(quantitative trait loci) for size, 25QTLs for shape and 5QTLs for left-right
asymmetry in the F2 mice resulting from an inter-cross of Large (LG/J) and Small
(SM/J) inbred mice from the Jackson Laboratory (Bar Harbor, ME). Using a
different strain of mouse, the SMXA recombinant inbred mouse, Dohmoto et al
(2002) found QTLs on chromosomes 10 and 11 influencing mandibular length.
Although genome-wide scans have the advantage of identifying genetic factors that
do not require a priori knowledge of the underlying biology of a condition or risk
alleles, there are significant drawbacks especially in the case of common diseases, or
complex traits (see Section 2.9 below for discussion). At present it is more profitable
to concentrate on SNPs in candidate genes identified as potentially important to the
development of the craniofacial complex (discussed below). An integration of the
two approaches would be ideal but is not feasible in terms of the current study.
Vitamin D Receptor
The vitamin D3 receptors (VDR) are intracellular polypeptides, 50 to 60 kD in size
that bind 1, 25 (OH) 2D3 and interact with target-cell nuclei to effect a variety of
biological actions. The human VDR gene is located on chromosome 12ql2-ql4,
contains 11 exons and spans approximately 75 kb. The 5-prime end of the VDR gene
is non-coding and includes exons 1A, IB and 1C, whilst its translated product is
encoded by exons 2-9. Polymorphisms in the VDR gene have been associated with
a number of conditions, largely related to metabolism of vitamin D, e.g. vitamin-D
resistant rickets, synthesis of osteocalcin, bone mineral density, osteoporosis,
osteoarthritis, primary hyperparathyroidism and psoriasis. The importance of
polymorphisms in VDR lies in its influence on the effectiveness of 1, 25 (OH) D3 in
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regulating the differentiation or proliferation of osteoblastic, osteoclastic and
chondrocyte lineage thereby affecting bone mineralization and linear bone growth.
The importance of the VDR gene in the development of the craniofacial complex can
be inferred from a small number of studies examining the effects of vitamin D on
mandibular condylar cartilage (Kyung et al 1992; Silberman et al 1987) and
craniofacial chondrocytes (Takano-Yamamoto et al 1992) where it was found
integral to the growth and differentiation process. In vitro effects of sex
hormones/receptors on VDR gene function or modulation of vitamin D have not
been investigated.
A number of studies have now looked at the influence ofVDR gene polymorphisms
on growth and height. Suarez et al (1997) studied the association between VDR
genotype and growth in 589 healthy infants who were homogeneous for age, diet and
vitamin D status. The Bsml polymorphism (825-bp in the intron separating exons 8
and 9) was significantly associated with differences in body size, which were found
to be sex-specific. In a subsequent study, Suarez et al (1998) showed that the
interaction between oestradiol receptor gene polymorphisms and the Bsml
polymorphism in the VDR gene lead to significant variation in body growth during
infancy, especially in boys.
A study by Lorentzon et al (2000) in 90 post-pubertal Caucasian males showed the
Bsml polymorphism to be significantly related to final height (homozygotes being
shorter) and to contribute to 8% of total variation in final height, taking
environmental and parental influences into account.
Minamitani et al (1998) examined a different polymorphism in the VDR gene (exon
2 A (T/C) G substitution affecting a putative translation initiation site) in 90 healthy
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female Japanese aged between 18 and 20 years, 159 Japanese 13 year olds and 24
children with constitutional short stature aged 6-10 years. The CC phenotype was
found to be significantly associated with shorter stature in this heterogeneous
population.
Beta-2-adrenergic receptor
The beta-2-adrenergic receptor (ADRB2) gene is located on chromosome 5q32-q34.
The receptor is comprised of 413 amino acid residues encoding a protein containing
7 clusters of hydrophobic amino acids suggestive of membrane-spanning domains.
The gene contains no introns in either the coding or untranslated sequences (Kobilka
et al 1987). There are nine different point mutations in the 02AR coding block. Four
of these variants changed and encoded amino acid (Reihsaus et al 1993; Liggett
1997). These latter four alter receptor function (Liggett 1997).
Apart from studies in asthma, the ADRB2 gene has been of interest in elucidating the
mechanism of energy expenditure regulation and more specifically its role in obesity.
In the context of growth, one study has been conducted examining the impact of
ADRB2 polymorphisms on changes in weight and height in children. Matsuoka et al
(2002) found that among 40 Japanese children of short stature treated with growth
hormone, those with the Glyl6Gly genotype remained shorter and more obese over a
period of 4 years. These findings remain to be reproduced in other populations, but
by inference would correspond to the observations in other studies looking at long-
term weight gain where BMI (requiring both height and weight for the calculation)




Growth hormone (GH) has a major role in the regulation of postnatal growth and it is
generally accepted that it is the most important hormone in this respect (Ohlsson et al
1998). GH is a protein that contains 191 amino acids with 2 disulfide bonds and 4 a-
helices. Its molecular mass is approximately 22,000 Da (Kopchick et al 2002). GH is
located on chromosome 17q22-24. Growth hormone insensitivity which when
complete is known as Laron dwarfism (Laron et al 1966) is characterised by small
overall stature, classical craniofacial symmetrical reduction in size, constriction of
the u pper a irway, o besity, e levated G H 1 evels a nd i nsulin r esistance. R ecently t he
first report of a patient with Laron syndrome and OSAHS was published (Dagan et al
2001). GH is important in the regulation of carbohydrate and lipid metabolism (Nam
and Marcus 2000) and is integral to the regulation of insulin at both a pre and post
receptor level (Dominici and Turyn 2002 for review). In the obese adult and
adolescent, GH levels are low (Attia et al) but growth continues, largely due to the
effects of IGF-1 and low IGFBP-1. Recently it has been shown that the direct effects
of leptin, sex hormones and insulin can directly activate the IGF system in growth
plates and at bone growth centres (Philip et al 2002) independently of GH although
GH can influence longitudinal bone growth directly without the mediation of IGF-1
(Ohlsson et al 1998). Current evidence available suggests that GH stimulates
longitudinal bone growth directly by stimulating prechondrocytes in the growth plate
followed by a clonal expansion caused both by the GH-induced local production of
IGF-1 and the GH-induced increase in circulating levels of IGF-1. GH appears thus
to be the major determinant for the stimulation of progenitor cells, although it is
possible that IGF-1 might stimulate progenitor cells to some extent (see Ohlsson et al
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1998 for detailed review). Thus, investigation into the other components of the
growth hormone system may be equally productive in examining direct influences on
bony development.
Insulin - like Growth Factor (IGF-1)
Growth p romoting factors i n s erum w ere first i dentified i n the 1 950's ( Salmon &
Daughaday 1957) and their purification, demonstration of their biological properties
and characterisation of their amino acid sequences revealed structural and functional
similarity to insulin. Hence the term insulin-like growth factor (IGF) was introduced.
The IGF system comprises two ligands (IGF-1 and IGF-II), two receptors (IGF1R
and IGF2R) and several IGF binding proteins. They have both paracrine and
autocrine modes of action. Single genes encode IGFs: 12q22-q24.1 for IGF-1 and
1 lpl5 for IGF-II. IGF-1 has 70 amino acid residues and 3 disulphide bridges and
was first synthesised in 1983 using the solid-phase method (Li et al 1983). IGF-1 is
continually synthesised and released as a single polypeptide chain primarily by the
liver, but also by many other organs and tissues. IGFs stimulate glucose transport and
metabolism as well as the differentiation of myoblasts, osteoblasts, neural cells,
fibroblasts etc. Woods et al (1996) noted that there is no direct evidence that IGF1
has a prominent role in human foetal growth. Nevertheless, on the basis of
experiments using IGF1 knockout mice, there is evidence that IGF1 is necessary for
axonal growth and myelination with a high neonatal mortality in the knockouts.
IGF level and function is not only determined by the particular gene polymorphism,
but also by GH level (major regulator), nutrition, adequate insulin secretion and
thyroid function (Froesch et al 1985; Le Roith et al 1999). IGF gene expression is
for the most part independent of GH in the foetus, but after birth, GH increasingly
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begins to regulate expression and release of IGF-1 and is the primary regulator in the
adult (Baker et al 1993; Ohlsson et al 1998).
Gene targeting strategies, which involve the alteration or knockout of critical regions
of any gene, have been used to explore the contribution of single genes to the
development of the entire organism. Two studies have looked in detail at the
consequences of introducing mutations at the IGF-1 locus in mouse germ lines and
constructing chimaeric animals.
Baker et al (1993) showed that IGF-1 (-/-) mutants grew at a slower rate and weighed
30% of the normal adult weight of their wild-type littermates. The IGF-1 null mutant
mice w ere d ^proportionately and s ignificantly sm aller with a small head size and
blunt nose. A more recent study byMcAlarney& Rizos et al (2001) showed that
IGF-1 null mutant mice had a 43 - 64% decrease in craniofacial size compared to
wild-type and a non-allometric change of shape with significant changes in the facial
and cranial areas. The mandible, although shorter, did not exhibit any shape changes.
Further, Powell-Braxton et al (1993) showed that heterozygous IGF-1 null mutant
mice were 10-20% smaller than wild-type litter mates - with a decrease in organ,
muscle and bone mass.
Other evidence of IGF-1 influencing the growth of the mandibular condyle has come
from the work of Maor et al (1993) in mice. Using immunoflourescence, they
showed that the distribution of IGF-1 receptors in the chondroprogenitor and
chondroblast cell layers of the mandibular condyle was parallel to that of IGF-1
production. They also showed intense staining with antibodies to IGF-1 in the
mandibular condyle of 2-day-old mice. Immuno-inhibition of IGF-1 resulted in an
almost complete inhibition of thymidine incorporation into DNA and marked
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degenerative changes in the morphological appearance of the condyle. This
supported the role of paracrine activity of endogenous GH-independent IGF-1 in
early postnatal mandibular development. The importance of IGF-1 and its receptor in
mandibular growth has also been demonstrated in experiments looking at the role of
sex steroids on growth, e.g. testosterone (Maor et al 1999) which has been shown to
promote growth t hrough t he m ediation o f IGF-1. T he i nterdependence o f GH a nd
IGF-1 in stimulating chondrocyte growth has also been demonstrated many times
e.g. by Smith et al (1989) who showed that GH alone had no effect on chondrocyte
DNA and proteoglycan synthesis compared to IGF-1 alone and the two in
combination resulted in the highest levels of adult chondrocyte extracellular matrix
synthesis (see discussion above).
In summary, IGF-1 has been shown to be an important and independent regulator of
maxillofacial and mandibular growth postnatally (see also MCarthy & Centrella
2001 for detailed discussion re: local IGF-1 expression and bone formation).
Deficiencies in IGF-1 may arise as a result of GH receptor/postreceptor
abnormalities, IGF-1 receptor abnormalities or secondary to GH deficiency. Primary
IGF-1 deficiency due to partial IGF-1 gene deletion is rare in humans and results in a
syndrome characterised by short stature, sensorineural deafness and mental
retardation (Woods et al 1996 and 2000; Camacho-Huebner et al 1999). Investigation
into polymorphisms in the IGF-1 gene has been unhelpful in linking them to the
phenotype of short stature, such as that of African pygmies (Bowcock and Sartorelli
1990) vs non-Pygmy black Africans. Direct sequencing of PCR-amplified DNA
failed to demonstrate an alteration in the region upstream of the IGF-1 start site in
Pygmies. A further study by Rasmussen et al (2000) considered the IGF-1 and IGF-
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1R genes as candidates for low birth weight, insulin resistance and type II diabetes in
a Danish population. They found no mutations predicting changes in the amino acid
sequences of the IGF-1 or IGF-1R genes. Thus, at present it may be speculative to
search for a particular gene polymorphism of IGF-1, which may be specifically
linked to mandibular growth and maxillo-facial size. Since the effects of IGF-1 and
GH are mediated by their receptors, it is integral to their understanding to examine
these components involved in the growth pathway.
Insulin-like Growth Factor Receptor
The gene for IGF-1R is located at 15q25-q26. The complete primary structure of the
receptor was first determined in 1986 by Ullrich et al and Abbott et al (1992)
determined that the IGF-1R gene contains 21 exons and spans about lOOkb. The gene
sequence predicts a 1, 367 amino acid receptor precursor with a 30-residue signal
peptide, which is removed during translocation of the nascent polypeptide chain
resulting in alpha and beta subunits. There is further cleavage after the removal of the
signal peptide to generate the two subunits of the IGF-1R.
Gene function studies have demonstrated that mutation in the IGF-1R gene interferes
with suppression of GH in cultured rat pituitary cells (Prageret al 1992). IGF-1R
plays a pivotal role in transformation events in malignant tissues where it appears to
function as an anti-apoptotic agent, thus enhancing cell survival (Kaaks and
Lukanova 2001; Werner and Le Roith 1996; Maor et al 2000). Monozygosity for the
IGF-1R results in severe abnormalities associated with intrauterine growth
retardation, microcephaly, micrognathia, renal anomalies, lung hypoplasia and
delayed growth and development Roback et al (1991). The study by Rasmussen et al
(2000) looking at polymorphisms in the IGF1R gene has been discussed above.
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One study so far has looked at hormonal control of condylar cartilage (Visnapuu et al
2001). In this study, the distribution of GH and IGF-1 receptors in the
temperomandibular joint was investigated. GH receptors were detected in various
components of the temperomandibular joint but not the fibrous articular surface or in
the cartilage layers of the condyle where the IGF-1R was found. They concluded that
early post-natal growth and development of the mandibular condylar cartilage seems
to be IGF-1-dependent and not directly dependent on GH. Apart from this
experimental evidence, no associations have been found for the remaining
polymorphisms for the IGF-1R gene.
Growth Hormone Receptor (GHR)
GH binds the transmembrane receptor GHR that subsequently dimerizes and
activates an intracellular signal transduction pathway leading to synthesis and
secretion of IGF-1. After IGF-1 binds to the soluble IGF-1R in plasma, the resultant
complex activates signal -transduction pathways resulting in the mitogenic and
anabolic responses leading to growth. The gene for GHR is located on chromosome
5pl3-pl2. The gene has 9 exons encoding the receptor and several additional exons
in the 5-prime untranslated region. The coding exons span at least 87kb (Godowski
et al 1989). The molecular genetics of GHR has been chiefly concerned with
mutations resulting in Laron dwarfism and idiopathic short stature (see Gastier et al
2000 and Woods et al 1997 for detailed discussion).
The functional role of GHR in the growth of the craniofacial unit has been discussed
above in the context of IGF-1R. The function of all GHR variations is not
characterised. A recent study by Yamaguchi et al (2001) aimed to quantitatively
evaluate the relationship between craniofacial morphology and the Pro561Thr
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(P56IT) variant in the GHR gene in a normal Japanese population. They showed that
subjects without P56IT had a significantly greater mandibular ramus length as
measured cephalometrically compared to those with P56IT. They postulated that the
GHR gene P56IT variant may be associated with mandibular height growth and may
be a genetic marker for it.
2.2.4 Summary of Craniofacial Factors
In summary, development of the craniofacial structures is complex and regulated by
a large number of genes. Postnatal growth is also influenced by a large number of
genetic and environmental processes which include regulation by the hormones GH,
IGF-1 and their respective receptors. As yet, no specific variants in the genes of these
hormones and their receptors have been linked to the development of the craniofacial
unit in isolation from other somatic growth. However, a putative association of the
P56IT GHR variant with mandibular size has been identified and deserves replication
to establish the strength of the association in other populations.
2.3 Obesity
Obesity is the most commonly identified risk factor for OSAHS (Kushida et al 1997;
Hoffstein & Szalai 1 993). The mechanism whereby obesity may contribute to the
development or expression of OSAHS appears to be due to reduction in
nasopharyngeal calibre secondary to fat deposition or as a result of hypoventilation
due to a decrease in chest wall compliance. Twin studies have shown that up to 70%
of the variance in obesity within a population may be attributable to genetic factors
(Stunkard et al 1990; Bodurtha et al 1990). Adoption studies, by contrast have
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generated the lowest heritability estimates in the order of 30% with family studies
showing a level of heritability intermediate between the latter and twin studies
(Ravussin &Bouchard 2000). Bouchard et al (1997) included all series of relatives in
the same analysis and concluded that the heritability estimate for BMI in large
sample sizes was between 25% and 40%.
The susceptibility to becoming obese therefore seems likely to be determined
significantly by genetic factors, but a favourable 'obesogenic' environment is
necessary for phenotypic expression (Ravussin and Bouchard, 2000).
Obesity is defined in Table 9 below. Increasingly, it is becoming a global epidemic
and is associated with a large number of comorbidities as well as having a strong
negative impact on quality of life for the individual (Ravussin and Bouchard, 2000).
Table 9: WHO classification of weight in adults according to BMI (WHO 1997)
Classification BMI (kg/m2) Risk of comorbidities*
Underweight <18.5 Low - risk of other problems
Normal 18.5-24.9 Average
Overweight 25 - 29.9 Increased
Obese class I 30.0 - 34.9 Moderate
Obese class II 35.0 - 39.9 Severe
Obese class III > 40,0 Very severe
*Increased risk ofmetabolic complications at waist circumference > 94cm in men and > 80 cm in
women. Substantially increased risk at waist circumference >102 cm in men and > 88 cm in
women (see National Institutes ofHealth guidelines 1998).
The regulation of energy expenditure comprises an extremely complex system with a
large number of redundant pathways biased towards weight gain. Energy
homeostasis is not only a function of lifestyle and environmental influences but has
an important genetic component. Obesity develops when energy intake exceeds
energy expenditure over time and there are a large number of short and long-term
regulators of appetite and energy intake. The system is extremely complex and
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outside the scope of this thesis. However, the major factors influencing energy
balance are summarised in Fig 5 below and the chief neurotransmitters involved in
energy expenditure are listed in Table 10.
Table 10: Neurotransmitters that influence energy expenditure and appetite
(after Wilding 2002; Diabetic Medicine 19:621)
Neurotransmitters that increase intake Neurotransmitters that decrease intake
Agouti-related peptide a- melanocyte-stimulating hormone
Neuropeptide Y Bombesin/gastrin-releasing peptide








Fig 5 : Short and long-term factors influencing energy homeostasis
(after Wilding 2002; Diabetic Medicine 19:621)
INPUT CNS OUTPUT
GIT = gastrointestinal tract
The search for obesity susceptibility genes has snowballed since the 1990s with
numerous study designs being employed to identify genes of interest such as family
linkage studies and association studies in affected vs. non-affected individuals
(Chagnon et al 2000; Barsh et al 2000).
The information accumulated so far is so extensive, that it is currently published in
updated form on an annual basis as The Human Obesity Gene Map (see Chagnon et
al 2003 for most recent version) and is now available as a website
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('http://obesitygene.pbrc.edu). This most current update (the ninth so far),
incorporates published results on single-gene mutation obesity cases, Mendelian
disorders exhibiting obesity as a feature, quantitative trait loci (QTLs) from human
genome-wide scans and animal crossbreeding experiments as well as association and
linkage studies with candidate genes and other markers. Transgenic and knockout
murine models exhibiting obesity as a phenotype are included (n= 38 studies). Since
October 2002, 33 Mendelian syndromes relevant to human obesity have been
mapped to a genomic region and the causal or strong candidate genes have been
identified for 23 syndromes. QTLS reported from animal models are 168 in number
and there are 68 human QTLS for obesity candidate genes in targeted studies.
Linkage peaks with candidate genes have been identified in targeted studies with
seven genomic regions harbouring QTLS replicated in 2 to 5 studies. There are over
222 studies reporting positive associations with 71 candidate genes with 15 such
replicated in at least 5 studies. Putative loci for obesity genes are present on all
chromosomes except Y. In total, more than 300 genes, markers and chromosomal
regions have been associated or linked with human obesity phenotypes.
Thus, candidate genes for obesity are numerous, but so far only a few single gene
mutations causally related to obesity have been convincingly detected in a small
number of people, often with other related conditions. These include the leptin
receptor gene (Clement et al 1998), the leptin gene (Montague et al 1997; Strobel et
al 1998), the pro-opiomelanocortin gene (Krude et al 1998), the prohomone
convertase 1 gene (Jackson et al 1997) and the melanocortin MC4 receptor gene
(Cone 2000; Hinney et al 1999; Vaisse et al 1998; Yeo et al 1998). A recent meta-
analytic review of the linkage association of the 3 leptin receptor gene
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polymorphisms in a total of 3,263 individuals (> 74% Caucasian) showed no
statistically significant association with waist circumference or body mass index at
the p = 0.05 level (Heo et al 2002).
Other genes that have been sequenced and screened in the search for what
predisposes to obesity include the agouti gene, the uncoupling proteins (UCP1 - 3),
all the melanocortin receptor genes, the neuropeptide Y receptor 1 and 5 genes, TNF-
a, peroxisome proliferation-activated receptor-gamma (PPAR-y) and the (T -
adrenoceptor genes among many others. As stated above, Mendelian disorders and a
large number of linkage studies have also been conducted to date and are presented
in the Human Obesity Gene Map (Chagnon 2003). It is important to note that none of
the genetic associations reported so far has been proven to be the consequence of a
mutation affecting the function or amount of a gene product. Many of the studies
reporting single gene polymorphisms associations also need to be supported by
cellular work identifying the functional consequences of the reported polymorphisms
and it would be of greater clinical relevance if the environmental circumstances
necessary for the full phenotypic consequence of these g enes and their expression
were identified.
In OSAHS, obesity constitutes a problem as it has been shown to contribute to the
expression of the disease and to disease severity. From a purely clinical perspective,
useful information when dealing with OSAHS patients would be knowledge
regarding their propensity to lose or gain weight. This may affect the severity of
OSAHS and determine choice of treatment modality. The question arises as to which
patient will do well with calorie restriction, behaviour modification or potentially
pharmacotherapy and which one won't?
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There are far fewer studies on candidate genes associated with weight loss or weight
gain in certain populations and they are summarised in Table 11 below. At present
only a few of these studies have followed up the population under study for
prolonged periods of time, but some of the work appears encouraging in terms of
replication status in other studies. No work in this area has so far been carried out in
the OSAHS population.
From the evidence available, the beta2-adrenoceptor gene (ADBR2) appears most
promising. Catecholamines play a central role in energy expenditure both as
hormones and as neurotransmitters. This regulation is in part effected by stimulating
lipid mobilisation through lipolysis in adipocytes. ADBR2 is a major lipolytic
receptor in human fat cells. As described in section 2.2.3 above, the gene for ADBR2
is found on chromosome 5q32-q34. ADRB2 has 6 different polymorphic forms
comprising amino acid substitutions, the most common being glyl6arg and gln27glu
(Reihsaus et al 1993). All are in linkage disequilibrium. The most convincing animal
study to date showing that the sympathetic nervous system is indeed the efferent arm
of diet-induced thermogenesis is by Bachman et al (2002) who created mice that
lacked ADBR1, 2 and 3. Beta-less mice fed a chow diet showed reduced metabolic
rate and were slightly obese. On a high-fat diet, in contrast to wild-type mice, they
became massively obese. Thus, beta-adrenergic receptors play a critical role in the
body's defence against diet-induced obesity. Translating these results to humans,
Corbalan et al (2002) showed that Spanish women with the glu27 ADRB2
polymorphism did not benefit equally from physical activity compared to noncarriers
of the glu27 allele. They concluded that this could result from a blunting of the
sympathetic nervous system activity response to exercise and thereby constitute a
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Table 11: Positive association studies of candidate genes for weight loss or
weight gain in humans
Candidate gene Allele Population Association Reference




Lindi et al 2002




5-HT1B receptor G861C 98 Caucasian women
with bulimia nervosa
G/G - high BMI over
lifetime






Val/Val - 2 x risk of
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310 German women Decreased weight
loss with Trp64Arg
& Gly972Arg
Benecke et al 2000




UCP# 1 & 2 163 French Weight loss with 2/2 Fumeron et al 1996




Sakane et al 1997
5-HTR2C -759 T/C 32 schizophrenic
Chinese Han men
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Higher leptin &
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Van Rossum et al
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* Catechol-O-methyltransJerase;** Insulin receptor substrate 1;# Uncoupling protein;A NIDDM =
Type IIdiabetes mellitus;AA Leptin receptor;*** Angiotensin-converting enzyme
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physical activity-dependent factor for obesity risk. Studies along these lines have
also shown similar results for ADBR2 gly27glu polymorphisms in men and women
in other Caucasian populations (see Meirhaeghe et al 1999; Ukkola et al 2002;
Macho-Azcarate et al 2002 a&b).
2.4 Sleepiness
Epidemiological studies have shown that sleepiness does not necessarily correlate
with the severity of sleep apnoea and that there is a differential susceptibility to
somnolence between individuals (Cluydts 2002; Moldofsky 1992). Therefore,
mechanisms involved in sleep promotion need to be considered as part of the process
aimed at elucidating the reasons for the observed differences and as a predisposition
to the syndrome of OSAHS.
2.4.1 The Role of Cytokines
Sleep is regulated by neuronal and humoral mechanisms that are interdependent
(Krueger et al 1999). Fig 6 below illustrates a multitude of factors that are currently
thought integral to promoting sleep. To be considered a sleep regulatory substance, a
substance must fulfil certain criteria (see Krueger et al 1999). For NREM sleep,
sleep-regulating substances include IL-1, TNF-a, GHRH, PGD2, adenosine and
uridine (Kreuger and Obal 1997; Borbely and Tobler 1989). In REM sleep, the
substances include prolactin and vasoactive intestinal peptide (Roky et al 1995).
Although cytokines are pleiotropic and there is a great deal of redundancy within the
cytokine network, much evidence has been accumulated about their integral role in
the generation and promotion of sleep (Opp 2003).
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Fig 6 : Factors involved in sleep promotion and regulation (After Krueger et al
1999; pg 57)
The mediation of a large number of neurohumoral factors by IL-1 and TNF-a
appears to be central to the sleep activation pathway and will be discussed in detail.
Interleukin-1 b belongs to the gene family that also includes IL-1 a and IL-1 receptor
antagonist. All three bind to two IL-1 receptors, the IL-1 type I and type II receptors.
The IL-1 type I receptor complexes with an accessory protein to form the unit for
signal transduction, whereas the second type has no signalling role (Opp 2003). The
genes for IL-1 a and for IL-lb are found on chromosome 2ql4. II-la is generally cell-
associated. whilst IL-lb is found in tissue fluids and plasma. Although IL-1 a
promotes sleep, most investigations into sleep regulation have used IL-lb. IL-lb
induces SWS in every species examined so far, including rabbits, rats, cats, monkeys
(Opp 2002) and anecdotally, humans (Dinarello 1991), whether administered
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intravenously, intraperitoneally or intracranially. IL-1 receptors are located in CNS
sleep pathways (Ban et al 1 993; Cunningham et a 1 1 993; Takoa et a 1 1 990), IL-1
containing neurones are found in the hypothalamus (Breder et al 1988) and IL-1
mRNA may be detected in many brain regions (Van Dam et al 1992; Schobitz et al
1994). IL-1 mRNA expression increases during sleep deprivation (Markiewicz et al
1996) and IL-1 is detected more frequently in plasma samples taken from humans
during sleep than during wakefulness (Gudewill et al 1992). Plasma levels of IL-1 (3
peak in humans at sleep onset (Moldofsky et al 1986) and leukocyte cultures taken
from blood samples during sleep produce more IL-1 than those taken during
wakefulness (Hohagen et al 1993). Direct evidence for the involvement of IL-1 in
sleep regulation comes from studies inhibiting binding of IL-1 to its receptor. This
has been achieved either through IL-1 RA administration, IL-1 antibodies or a
soluble IL-1 receptor fragment resulting in the reduction of spontaneous SWS in
otherwise normal animals (Opp et al 1991; Opp et al 1992; Takahashi et al 1996).
When experimental animals are pre-treated with anti-IL-1 or with an IL-1 receptor
fragment, sleep deprivation-induced enhancement of SWS is either attenuated or
blocked (Opp et al 1994; Opp et al 1994; Takahashi et al 1997).
TNF is also a pleiotropic cytokine that is expressed in normal brain. It exists in two
forms - TNF-a, which is primarily produced by macrophages, and TNF-P, which is a
product of lymphocytes. The genes for TNF- a and TNF- P map to the 6p23-ql2
segment. Both proteins share about 30% amino acid sequence homology and have
similar, though not identical modes of biological function (Opp 2002). TNF-P has
been shown to promote sleep (Kapas et al 1992), but most sleep studies have used
TNF-a In the brain, TNF- a is produced by astrocytes, and TNF- a immunoreactive
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neurones are located throughout the CNS (Breder et al 1993). There are two cell
surface TNF receptors - TNF receptor 1 which maps to chromosome 12pl3.2 and
TNF receptor 2 whose gene is located on chromosomelp36.3 - p36.2. Both mediate
distinct actions (Schutze et al 1994), with TNF receptor 1 responsible for mediating
the somnogenic effects of TNF- a (Fang et al 1997). The biological actions of IL-1
and TNF- a overlap and they induce each other's synthesis (Dinarello et al 1986;
Philip and Epstein 1986). TNF- a induced SWS response is attenuated in animals
pre-treated with a soluble IL-1 receptor and TNF antagonists inhibit somnogenic
responses to IL-1 (Takahashi 1996). TNF- a induces SWS in a number of animal
species (Opp 2002). TNF- a mRNA (Bredow et al 1997) and protein in brain and
plasma fluctuate with circadian rhythm (Gudewill et al 1992; Darko et al 1995). In
otherwise normal animals, the use of TNF- a antibodies (Takahashi 1995), binding
proteins or soluble receptors or receptor fragments (Takahashi et al 1995) reduces
SWS. Mice that lack TNF- a receptor 1 sleep less than wildtype mice do (Fang et al
1997) and pre-treatment of experimental animals with TNF- a antagonists attenuates
SWS following periods of sleep deprivation (Takahashi et al 1996) or increases in
ambient temperature (Takahashi et al 1997). TNF- a has also been associated with
human obesity, although association studies are conflicting in their results (Romeo et
al 2001; Herrmann et al 1998; Walston et al 1999; Pausova et al 2000). Other
cytokines thought to induce sleep include IL-10, IL-6, interferon; 11-2, IL-4, GM-
CSF and FGF (see Opp 2002). Interleukin-6 also has an increasingly important role
in the genesis of somnolence (Opp 2002; Kreuger et al 1999; Spath-Schwalbe et al
1998; Redwine et al 2000).
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Cytokine profiles that deviate from the normal circadian pattern may alter the normal
expression of sleep-wake behaviour and it is possible that levels of sleep-inducing
cytokines are increased during the daytime when they should be low in patients with
OSAHS and thus may contribute to excessive daytime sleepiness. Two studies have
addressed this hypothesis (Entzian et al 1996; Vgontzas et al 1997) and both suggest
levels of these cytokines may be different in OSAHS compared to normal subjects.
Entzian et al (1996) studied 10 patients with OSAHS compared to 10 normal
controls. The patients with OSAHS were obese with an AHI of 48+13/hr. Blood
samples were collected every 4 hours during the day (08:00 - 20:00) and 2-hourly
whilst patients were asleep. Cytokine release was determined from whole blood
cultures stimulated with LPS. Supernatant from the cultures was assayed for IL-ip,
IL-6, TNF-a and IFN-y in addition to melatonin and Cortisol. Circadian rhythmicity
was evident in the production of all the substances. Concentrations and circadian
profiles for IL-ip, IL-6, IFN-y, melatonin and Cortisol were not statistically
significantly different between cases and controls. The circadian rhythm of TNF- a
production however, was markedly altered in sleep apnoea patients with peak
concentrations in the afternoon - the time period during which concentrations in
normal controls were at a minimum. Absolute IL-1 P concentrations were twice those
obtained from controls although not statistically significantly different. The OSAHS
group was then treated with CPAP for three months and the cytokine profiles re¬
examined. However, they were not normalised despite normalisation of sleep
fragmentation, oxygen desaturation and arousal frequency. These findings were
suggestive of a biological basis to excessive daytime somnolence not completely
accounted for by sleep fragmentation.
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Vgontzas et al (1997) measured morning plasma levels of TNF-a, IL-1 (3 and IL-6 in
12 patients with OSAHS, 11 patients with narcolepsy, 8 patients with idiopathic
hypersomnia and 10 normal controls. Single blood samples were drawn between
0600 and 0700 hrs in the morning after completion of the overnight PSG. The
cytokines were measured by ELISA. I n the OSAHS patients, the TNF-a and IL-6
concentrations were significantly elevated compared to controls and TNF-a was
significantly elevated in the narcoleptics compared to controls.
Both these studies are correlational and do not provide an explanation for why the
cytokine profiles should be abnormal in OSAHS. Furthermore, cytokine
concentrations were measured in the periphery rather than in the CNS and may not
reflect the cytokine concentrations in the brain. However, the CNS does respond to
peripheral events and there are many mechanisms whereby the brain may be
signalled with subsequent effects on sleep (Dantzer 1994).
Differences among patients with OSAHS in terms of excessive daytime somnolence
may in part be accounted for by differences in cytokine production, which in turn
may be mediated by genetic polymorphisms. In narcolepsy, an examination for TNF-
a polymorphisms in the promoter region of the gene has given conflicting results.
Some investigators failed to show an association with narcolepsy in a Japanese
population (Kato et al 1999) whilst others have demonstrated one (Hohjoh 1999,
2000, 2001). No studies looking at cytokine gene polymorphisms have been
conducted thus far in patients with OSAHS.
2.4.2 Hypocretin (Orexin)
Animal studies and most recently human studies have identified that the
neuropeptide hypocretin is integral to sleep pathways (see Mignot 2001 for
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discussion). Most patients with narcolepsy have undetectable levels of hypocretin in
the cerebrospinal fluid (Nishino et al 2000) and a marked decrease in hypocretin
imrnunoreactivity and transcript levels in the perifornical hypothalamus (Peyron et al
2000; Thannickal et al 2000). A rare polymorphisms in the prepro-orexin gene has
been associated with narcolepsy (Gencik et al 2001) but further population based
studies comparing narcoleptic subjects with controls have shown no association of
polymorphisms in the hypocretin gene nor in genes coding for its two receptors -
hcrtrl and hcrtr2 (Olafsdottir et al 2001; Hungs et al 2001). On the basis of these
findings, the hypothesis has now been evolved that narcolepsy may be an
autoimmune disorder associated with peripubertal destruction of hypocretin-
containing cells (Mignot 2001).
The same pathways that cause sleepiness in narcolepsy may potentially be implicated
in the induction of sleepiness in the normal population as well as in OSAHS.
However, the pathogenesis and clinical expression of the two disorders is so different
that it is unlikely that a gene polymorphism in the hypocretin system is involved.
Furthermore, hypocretin is involved also in the pathogenesis of cataplexy which does
not occur in OSAHS.
2.5 The Upper Airway in OSAHS
2.5.1 Regulation of Upper Airway Tone
As discussed in Chapter 1, section 1.2, sleep-related reductions in pharyngeal muscle
activity are thought integral to the pathogenesis of sleep-related breathing disorders.
A decrement in pharyngeal muscle activity leads to snoring and upper airway
obstruction, which in turn leads to arousal from asleep. These arousals in turn
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activate the pharyngeal muscles thereby restoring airway patency and more effective
breathing.
Pharyngeal motor neurones share a number of common pre-motor inputs.
Anatomical and electrophysiological evidence shows that some these pre-motor
inputs exhibit sleep-state dependent activity and may be involved in the suppression
of pharyngeal activity during sleep (Horner2000). Implicated are both inhibitory and
disfacilitatory mechanisms (reduced excitation).
Most work in this area has been done studying the genioglossus muscle as it is
considered to be the major upper airway dilator. The genioglossus is innervated by
the hypoglossal nerve. The loss of activity of the genioglossus especially during
REM-sleep (Sauerland and Harper 1976) is thought to contribute to the onset of
airway narrowing and occlusion (Remmers et al 1978) but some controversy remains
(Horner 2000).
Hypoglossal nerve output is subject to tonic or phasic pre-motor influences, which
effect either slow time-varying or fast transient changes.
Respiratory pre-motor neurones also have important influences on hypoglossal motor
neurones and these in turn may be subjected to the influence of sleep mechanisms
(Orem 1994).
Reduced excitation of the hypoglossal nerve leading to sleep-related suppression of
genioglossus activity has been demonstrated in a number of animal models (Woch et
al 200; Yamuy et al 1999), especially in the instance of REM-sleep. The models used
have involved the use of carbachol which itself is controversial (Horner 2000; Ursin
2002), but valuable insights have nevertheless been gained.
















Fig 7: Diagram representing the neuronal circuitry thought to be involved in
the pontine regulation of REM sleep and generation of postural motor atonia.
(-ve = inhibition; +ve = excitation; M muscarinic)
Most evidence at present supports the hypothesis that non-REM sleep and especially
REM sleep are associated with the withdrawal of tonic excitation of the hypoglossal
motor neurones via reduced firing of predominantly serotonergic medullar raphe
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neurons and less so by noradrenergic locus coeruleus neurones (Foote et al 1 983;
Parkis et al 1995).
However, depending on the animal model used, contradictory effects are seen when
serotonin receptor antagonists are used.
One study using the normally respiring adult rat (Richmonds et al 1996) has shown
that use of ritanserin (a 5HT2a, 2c and 7 receptor antagonist) results in increased
phrenic and hypoglossal activity whilst administration of the same drug in the
English bulldog model of OSAHS causes decreased activity of upper airway dilator
muscles with concurrent oxyhaemoglobin desaturation and collapse of the upper
airway (Veasey et al 1996).
This may not be entirely a species-specific effect.
In a recent study, Nakano et al (2001) found that ritanserin did not alter ventilation in
adult lean Zucker rat but did so in the obese Zucker rats in addition to reducing upper
airway dilator activity, increasing collapsibility of the upper airway and increasing
oxygen consumption at rest. These findings are similar to those found in the English
bulldog model (Veasey et al 1996). This supports one hypothesis regarding serotonin
receptor antagonists and their effect on the upper airway being state dependent.
Upper airway collapse can occur in models where there is pre-existing compromise,
which in turn may reflect 5-HT involvement in the neuronal adaptation mechanisms
for narrowed upper airway. For example, long-term facilitation of respiratory motor
output after exposure to intermittent hypoxia is 5-HT dependent (Bach et al 1996).
Cervical dorsal rhizotomy may further augment the response to 5-HT antagonism
(Kinkead et al 1998).
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The pharmacology of 5-HT receptors is complex and at least 14 5-HT receptor
subtypes are molecularly and pharmacologically distinguishable among mammals.
The 5-HT3-receptor antagonist, ondansetron, produces very different effects in
animal models of OSAHS in comparison to ritanserin. In the English bulldog,
ondansetron reduces REM sleep disordered breathing events (Veasey et al) and in the
normal rat increases respiratory drive by increasing hypoglossal activity and also
reduces central sleep apnoeic events during REM sleep (Fenik et al 2000). This
effect in turn is thought to be secondary to peripheral stimulation at the nodose
ganglion, rather than directly originating in the nucleus of the hypoglossal nerve
(Carley and Radulovacki 1999).
Molecular dissection techniques have most recently shown the 5HT2A receptor to be
the predominant receptor subtype in hypoglossal motor neurones (Fonseca et al
2001; Zhan et al 2002). Pharmacologic trials of 5-F1T receptor agonists and
antagonists support this receptor subtype as well as 5-HT2c (found in much smaller
quantities) as the predominant post-synaptic facilitator of hypoglossal motor
neurones (McAll & Aghajanian 1980; Berger et al 1992; Kubin et al 1992; Al-
Zubaidy et al 1996; Douse and White 1996; Bayliss et al 1997; Inoue et al 1999). A
further study on the pharmacological activity of the serotonergic receptors in the
hypoglossal nucleus (Fenik and Veasey 2003) showed that the receptor 2A
antagonist MDL - 100, 907 dropped intrinsic hypoglossal nerve respiratory activity
by 61% and significantly suppressed serotonin excitation of hypoglossal nerve
activity in contrast to the 2C receptor.
Attempts have been made to alleviate obstructive apnoeas by neurochemical means
in humans (Sunderram et al 1998; Slamowitz et al 1998) using selective serotonin
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reuptake inhibitors (Hanzel et al 1 991; Kraiczi et al 1 999). The results have been
mixed, with incomplete responses to the SSRIs despite demonstration of increased
genioglossal activity as measured by EMG in the awake state. Part of this may reside
in our currently incomplete knowledge of the exact mechanisms regulating
pharyngeal motor control during sleep and the role of other upper airway muscle
stabilizers and dilators (e.g. geniohyoid and myohyoid).
Nevertheless, i n 1 ight o f t he c urrent r esearch i n t his area, i t w ould b e o f p otential
therapeutic and scientific value to explore whether gene polymorphisms in the 5-
HT2A receptor may play a role in the modulation of serotonin metabolism
potentially affecting upper airway responsiveness.
5HTR2A was first cloned and sequenced by Sparkes et al (1991) who showed it to be
located on human chromosome 13ql4-q21. Four polymorphisms have been
identified - a silent T/C polymorphism at nucleotide 102; a Thr25Asn
polymorphism; a -143861A polymorphism and the His452Tyr polymorphism. This
latter SNP has functional consequences with the Tyr-allele being associated with
smaller peak amplitude in intracellular calcium ion mobilization and different time
course of calcium response (Erdmann et al 1996; Ozaki et al 1997). All
polymorphisms are in linkage disequilibrium (Erdmann et al 1996). Because
serotonin has been implicated in a large range of human disease including
depression, obsessive-compulsive disorder, appetite control and schizophrenia, the
vast majority of studies examining polymorphisms in the 5HTR2A gene have
concentrated on its association with personality and mental illness. For example,
Williams et al (1997) reported a meta-analysis of the association between 102T-C
polymorphism of the 5HTR2A gene and schizophrenia backed up by Lohmueller et
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al (2003). They concluded that the C allele is significantly associated with the
disease (first reported by Inayama et al 1996).
No studies to date have examined the role of 5HTR2A polymorphisms in serotonin
metabolism in the central nervous system with respect to motor function.
Another very important consideration with the 5HTR2A is the phenomenon of
genomic imprinting. Genomic imprinting is an epigenetic process that causes non¬
allelic gene expression by silencing or activating one of the alleles of an autosomal
gene, depending on the parent of origin (Tycko & Ashkenas 2000). Initially, the
5HTR2A gene was thought to be paternally imprinted and transcribed from the
maternal allele only (Kato et al 1996). However, a study by Bunzel et al (1998)
examined brain tissue in 18 patients and found that 4 samples showed mono-allelic
expression, whilst the remaining 14 were bi-allelic for 5HTR2A expression. Thus,
5HTR2A demonstrates polymorphic functional imprinting. This is an important
consideration in the context of disease-specific associations and pharmacogenetics.
In conclusion, there is some value in examining polymorphisms in the 5HTR2A
receptor. It is important to bear in mind that other neurotransmitters are involved in
the regulation of upper airway tone, so focussing on serotonin may lead to only a
partial elucidation of the problem - however, it is the first step in considering
pharmacological treatments for OSAHS.
2.5.2 Neuropathy in the Upper Airway - its role in OSAHS
OSAHS can progress in its severity and snoring can progress to OSAHS
independently of weight gain (Pendlebury et al 1997; Lindberg et al 1999; Svanborg
and Larsson 1993; Larsson et al 1991). This observation has led to the hypothesis
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that a pharyngeal nerve lesion caused by the trauma of snoring (vibration and stretch)
exists and is worsened by the hypoxia caused by hypopnoeas and apnoeas. (This has
been demonstrated in peripheral nerves of hypoxaemic OSAHS patients by Mayer et
al 1999). According to Friberg (1999), a pharyngeal afferent neuropathy may impair
the reflex to the muscles for upper airway dilation and an efferent neuropathy may
impair muscle strength. Table 12 summarises the major findings of studies that have
demonstrated the pathophysiology and histology of this process.
Table 12: Pharyngeal nerve lesions in snorers and patients with OSAHS









4 4 4 A + E Histology Uvula Muscle atrophy Woodson et al
Deg. Axons 1991
7 8 E Histology Palato - Muscle atrophy Edstrom et al
pharygeus 1992
15 15 A Temperature Soft palate High threshold Larsson et al
thresholds for warmth 1992
11 11 10 A Immunohisto- Soft palate Abnormal Friberg et al
chemistry nerve endings 1997
13 11 24 A Laser doppler Soft palate Abnormal Friberg et al
flowmetry vascular 1998
reactions
10 11 10 E Histology Palato - Progressive Friberg et al
pharyngeus neuropathy 1998
15 12 38 A Sensation Soft palate Reduced Kimoff et al
Vibration sensation 2001
Vibration
7 34 ? Histology Soft palate Inflammation Berger et al
Fibrosis 2002
5 11 A+E Histology Palato- Denervation Lindman &
pharygeus Degeneration Stal 2002
Uvula Increased connective
tissue
E = efferent nerves; A = afferent nerves; Deg. = degenerating
Neuropathy of afferent nerves is characterised by axonal degeneration or segmental
demyelination. Reinervation generally occurs within 1-2 weeks with regrowth of
neurofilament immunoreactive nerve fibres in close connection with blood vessels
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(Hermansson et al 1987). Degeneration of efferent (motor) nerves leads to lack of
electro-mechanical activity in muscle fibres. Denervated muscle fibres can be
reinervated from the destroyed axon or from sprouting from nearby intact axons.
This process may result in 'type grouping' with blocks of muscle fibres of a single
histochemical type. Within this block there will be atrophied as well as hypertrophied
muscle fibres. This may explain the histological findings on tissues taken from the
oropharynx of patients with heavy snoring or OSAHS.
The success of peripheral nerve regeneration is highly dependent on its
microenvironment. Axotomy or crush injury leads to degeneration of the distal nerve
stump referred to as Wallerian degeneration (WD). Schwann cells respond to this
axonal loss by extrusion of their myelin sheaths, down-regulation of myelin genes,
dedifferentiation and proliferation. Molecular changes in the distal stump include up-
regulation of neurotrophins, neural cell adhesion molecules, cytokines and other
soluble factors and their receptors (Stoll and Muller 1999; Kury et al 2001). One of
the more important factors involved in neural regeneration is brain derived
neurotrophic factor (BDNF) (Zhang et al 2000) and nitric oxide has also been shown
to be a key player in successful regeneration (Zochodne 2000; Levy et al 2001).
Studies simulating deprivation ofBDNF during regeneration have shown impairment
in myelination of regenerating axons (Zhang et al 2000). The BDNF gene is located
on chromosome lip 13. Although initially regarded to be responsible for neurone
proliferation, differentiation and survival through its uptake at nerve terminals and
retrograde transport to the cell body, it has now been shown that it is also transported
anterogradely and released upon neurone depolarisation. BDNF has been shown to
potentiate intracellular signals and action potentials in central neurones and recently
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has been considered important in the regulation of dopamine. For this reason, a
number of studies have examined gene polymorphisms in BDNF in Parkinson's
disease (Momose et al 2002), bipolar disorder (Sklar et al 2002), addictive behaviour
(Uhl et al 2001), schizophrenia (Virgos et al 2001; Krebs et al 2000; Wassink et al
1999) and Alzheimer disease (Kunugi et al 2001). Only one study has examined
BDNF gene polymorphisms in peripheral neuropathy (Davar et al 1996). This study
focussed on kindred with hereditary sensory neuropathy II (an autosomal recessive
disorder characterised by loss of peripheral sensory modalities) but found no
segregation of polymorphic alleles at loci for p75NGFR, TRKA, TRKB or BDNF.
A further consideration in snoring is the trauma of vibration. This has long been
recognised as a cause of vibration white finger in those who work in heavy industry
necessitating the long-term use of low-frequency (< 500Hz) hand-held vibrating
tools (Liapina 2002; Noel 2000). The result is a decrease in sensitivity to vibration
and temperature. The histological lesion comprises muscle hypertrophy,
demyelinating neuropathy and axonal regeneration without myelin sheaths (Takeuchi
et al 1986). The vascular disorder has now been classified as digital organic
microangiopathy; a digital vasospastic phenomenon and arterial thrombosis (Noel
2000). The vasospastic phenomenon has been recognised since 1990 as the
consequence of an imbalance between endothelin-1 and calcitonin-gene-related
peptide (CRGP) (Noel 2000). A further important observation has been the
deficiency of immunoreactive CGRP nerve fibres in the cutaneous microvasculature
of patients with primary and secondary white finger with the distribution and
quantity of other types of nerve fibres not significantly altered (Goldsmith et al
1994). The study by Kimoff et al (2001) alluded to in Table 12 not only
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demonstrated a selective reduction in the detection ofmechanical stimuli in the upper
airway of snorers and patients with OSAHS, but also showed a significant, but not
complete reversal of this neuropathy on use of CPAP. The fact that the deficiencies
were only partially reversible is suggestive of either permanent neuronal injury
secondary to snoring (i.e. an epiphenomenon) or may be due to increased
susceptibility to damage due to underlying genetic factors governing sensory
function. In the latter instance, it may be of interest to examine polymorphisms in
BDNF and other neurotrophic factors as well as CRGP in a population with OSAHS.
At present however, it remains unresolved as to whether the neuropathy of OSAHS
and snoring is a by-product or a primary aetiological factor in disease expression.
2.5.3 Disorders of Connective Tissue
Connective tissue can have a role in OSAHS pathogenesis through increased upper
airway collapsibility. Marfan's syndrome (classically a defect in the fibrillin gene) is
the best characterised of the disorders showing marked increases in upper airway
collapsibility (Cistulli & Sullivan 1995). One study has also suggested that sleep
disordered breathing is increased in patients with Ehlers-Danlos syndrome, although
the frequency of other sleep-related disorders was also high, e.g. periodic limb
movements (Verbraecken et al 2001).
Both disorders are well characterised at a molecular level and will not be discussed
further as they represent only a tiny minority of patients with OSAHS.
Polymorphisms in the elastin and collagen (specifically collagen type 1, alphal and
2) genes have been investigated in the context of disorders such as cutis laxa, Ehlers-
Danlos syndrome, atypical Marfan's syndrome, supravalvular aortic stenosis, the
Williams-Beuren syndrome, osteogenesis imperfecta and osteoporosis. One study so
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far has examined the Ser422Gly elastin gene polymorphism in human carotid arteries
in respect of aging and distensibility (Hanon et al 2001). It is at present unknown,
whether this work can be extended to examine soft tissue structures, which likewise
are affected by the ageing process. There is also limited information regarding
polymorphisms in collagen and elastin genes in the general population, which might
go towards explaining the spectrum of upper airway elasticity contributing to a
'floppier' upper airway.
2.6 Control of Ventilation
The existence of genetic diseases such as the congenital central hypoventilation
syndrome (Shea 1997; Gozal 1998) points to specific genetic mechanisms involved
in the control of breathing. Genetic influences m ay play a role in determining the
wide variability in the magnitude of response to hypoxia and hypercapnia in the adult
human (Hirshman et al 1975; Kawakami et al 1985 and 1984; Collins et al 1978;
Lahiri et al 1976). Studies in adult monozygotic twins have shown concordance in
responses to hypoxia, but not consistently to hypercapnia (Kobayashi et al 1993;
Arkinstall et al 1974). Thomas et al (1993) showed a high degree of heritability of
peripheral chemoreceptor response to hypoxia and hyperoxia in monozygotic twins
during infancy compared with dizygotic twins exposed to similar environmental
conditions.
Familial studies examining ventilatory responses have suggested that healthy family
members (Kawakami et al 1982, 1985; Mountain et al 1978) share reduction in
ventilatory response to hypoxia with the index case. Examination of the ventilatory
drive in OSAHS patients and their healthy relatives as well as healthy unrelated
81
controls has been undertaken by a number of investigators with conflicting results. A
summary of these studies is presented in Table 13 below.
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Patients with SDB are normocapnoeic unless otherwise indicated; **Hypercapnoeic patients; * Normocapnoeic patients; J Children (mean age I
years)
Based on the information in Table 13, it is difficult to conclude that there is one
single abnormality i n v entilation i n S DB. This makes s earch for a c andidate gene
currently untenable. Knowledge with regard to neural control of breathing in
vertebrates is still in its infancy - see Fortin et al (2000) - and strategies defined in
invertebrates are being applied in the investigation of the vertebrate brainstem. Table
14 summarises gene deletion models and their effects on ventilatory responses in
transgenic mice. These potentially play their most important role during early
embryonic development and for a brief and transient period only, e.g. Hox and Krox-
20 (Lumsden and Krumlauf 1996).
82
Table 14: Gene deletion models in transgenic mice and effects on ventilatory
response to chemical challenges (After Table l,pg 283, Gaultier and Guilleminault 2001)
Genes -/- +/- Baseline breathing pattern HVR
Annoeas Respiratory Rate
HCVR
Krox-20 + + Low NS
Tst-1 /Oct-6/SCIP + Low NS NS
Rnx + + High
Ret + NS D
Ret + NS D
Mash-1 + D D
Mash -1 (adults) + NS NS
ET-1 + D D
Et-1 (adults) + D D
ETA + D D
ECE-1 + D NS
ECE-1 (adults) + NS NS
BDNF + + Low D NS
PDGF-b (adults) + It
NEP (adults) + I
NOS (adults) + I NS
Lectin (adults) D
-/- = homozygous; +/- = heterozygous; NS = not significantly different to wildtype animals; D =
decreased; I = increased; all mice new-bom unless otherwise stated; $ increased in late phase ofHVR
A number of studies have shown that gene expression in the cardiorespiratory sites of
the brainstem during development and in later life may be modified by responses to
hypoxia in the context of environmental constraints (Larnicol et al 1994; Belegu et al
1999; Dumas et al 1996; Bianchi et al 1995). Hypoxia inducible factors (HIF) such
as HIF-la (Wang et al 1995; Gassman and Wenger 1997) is upregulated in the
mammalian brainstem in response to a hypoxic stress compatible with normal
respiratory physiology (Pascual et al 2001). The role ofHIF in control of respiratory
rhythms is currently under investigation. The role of neurotrophins during
development of the brainstem has also been found integral to establishment of
functional respiratory control (Fortin et al 2000). The best studied of these is BDNF.
BDNF, acting through the Trkfi receptor tyrosine kinase has been implicated in the
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chemoafferent control of breathing. In BDNF -/- mice, ventilatory responses to
hyperoxia and hypoxia are depressed but sensitivity to hypercapnia is intact
(Erickson et al 1996). Respiratory frequency and tidal ventilation per body mass are
smaller than normal and lead to chronic hypoventilation and death within 3 weeks of
birth (Erickson et al 1996). There is a hypoplasia of cranial sensory ganglia with an
intact brainstem anatomy (Conover et al 1995). Neuronal growth factors are thought
to regulate survival by m odulating g enetically programmed c ell death and thereby
quantitatively match neuronal populations to the size of their target field (Oppenheim
1991). A sub-population of dopaminergic chemo-afferent neurones that controls the
respiratory network is selectively reduced by 50% in mice lacking BDNF (Erickson
et al 1996). Balkowiec and Katz (1998) have also shown that BDNF is integral to the
normal development of the central respiratory rhythm, including its stabilisation by
modifying the size of specific neuronal populations within the respiratory network
(Balkowiecz and Katz 1997) in these transgenic mice. The molecular biology of
BDNF is discussed in 2.5 above.
The other major issue is whether respiratory control is implicated in the pathogenesis
of OSAHS. Although there are abnormalities of respiratory control in OSAHS
(Ayappa et al 2002; Garcia-Rio et al 2002; Asyali et al 2002) , these reverse with
CPAP (Moura et al 2001; Lin et al 1994; Verbraecken et al 1995; Verbraecken et al
2000). Thus the changes may be secondary rather than causative. This makes
searching for a gene cause of OSAHS relating to respiratory control likely to be low
yield.
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2.7 Apolipoprotein E - a role in OSAHS?
A recent study by Kadotani et al (2001) looked at APOE e4 allele frequencies in a
population with sleep disordered breathing. The hypothesis was that complex
interactions among sleep disordered breathing, brain pathology (such as early onset
Alzheimer's disease) and cardiovascular disorders may occur with increased
frequency in subjects heterozygous or homozygous for APOE e4.
Apolipoprotein E (APOE = gene; ApoE = protein) occurs in all lipoproteins and its
major role is thought to be the conversion of LDL proteins to IDLs (Davignon et al
1988). It is a 299 amino-acid polypeptide residue found at position ql3.2 on
chromosome 19. The 3 major isoforms of human apo E (apoE2; apoE3 and apoE4)
are coded for by 3 alleles (epsilon 2, 3, 4). The difference among the isoforms is
found at two sites - residue 112 (site A) and residue 158 (site B). At site A/B apoE2
contains cysteine/cysteine; apoE3 contains cysteine/arginine and apoE4 contains
arginine/arginine (Weisgraber et al 1981; Rail et al 1982). ApoE3 is the most
commonly occurring isoform (wildtype) in human populations. Four different
mutations giving a band at the E2 position with isoelectric focusing have been
described: E2 (argl58-to-cys), E2 (lysl46-to-gln), E2 (argl45-to-cys) and E2-
Christchurch (argl36-to-ser). E2 (argl58-to-cys) is the most common of the four.
There is now a large body of data on the APOE allelic variants and their gene
frequencies i n v arious p opulations. C orbo and S cacchi ( 1999), Gerdes et al (1992
and 1996), Schiele et al (2000) and Roychoudhury and Nei (1988) have most
extensively documented these. As stated above, the APOE3 allele is the most
frequent in human populations the world over and especially so in populations with a
long-established agricultural economy such as those in the Mediterranean basin
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where the frequency of the allele is 0.849 - 0.898. The APOE4 allele frequency
remains higher in populations such as the Pygmies (0,407), Aborigines of Malaysia
(0.240) and Australia (0.260), Papuans (0.368), some Native Americans (0,280) and
Lapps (0.310). The current theory links the occurrence of this allele with a
population where foraging still exists or where food supplies tend to be scarce and
sporadically available within traditional lifestyles. The APOE2 frequency fluctuates
with no apparent trend (0.145 - 0.02) and is absent in Native Americans. Corbo and
Scacchi (1999) have suggested on the basis of these observations that APOE4 may
be a 'thrifty allele' and that the exposure of the allele to the environmental conditions
of a Western diet and longer lifespan may have rendered it a susceptibility allele for
atherosclerosis and Alzheimer disease. The absence of the association of APOE4
with either disorder in sub-Saharan Africans and presence of the association in
African Americans is viewed as supportive of this hypothesis. Table 15 below shows
frequencies for the 3 allelic variants in a European population.
Table 15: Distribution of APO E allelic frequencies among a European
population (After: Table I, pg 303, Corbo and Scacchi 1999)
Population n APOE2 APOE3 APOE4
Lapps 70 0.050 0.640 0.310
Swedes 279 0.119 0.675 0.206
Danes 466 0.085 0.741 0.174
Finns 2245 0.044 0.748 0.208
Dutch 2318 0.085 0.752 0.163
Belgians 760 0.072 0.765 0.163
Icelanders 185 0.068 0.767 0.165
UK 734 0.089 0.767 0.144
French 1228 0.108 0.771 0.121
Germans 2031 0.077 0.778 0.145
Norwegians 395 0.087 0.781 0.132
Tyroleans 469 0.090 0.789 0.117
Hungarians 202 0.064 0.807 0.129
Swiss 173 0.072 0.821 0.107
Poles 137 0.055 0.839 0.106
Italians 2000 0.060 0.849 0.091
Spaniards 1286 0.052 0.856 0.091
Turks 8453 0.061 0.860 0.079
Greeks 551 0.054 0.878 0.068
Sardinians 280 0.050 0.898 0.052
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In disorders of lipid metabolism and cardiovascular disease, the E2 isoform appears
to play the greatest role as it has been shown to bind remnants to hepatic lipoprotein
receptors defectively (Schneider et al 1981; Rail et al 1982) and to delay their
clearance from plasma (Gregg et al 1981). Expression of the defect is however
modulated by other factors such as obesity; diabetes and age (see Hazzard et al 1981
and Goldstein 1 983 for more detailed discussion). There is some suggestion from
epidemiological studies that ApoE4 is associated with greater risk of atherosclerosis
(Bockxmeer amd Mamotte 1992; Stengard et al 1995; Stengard et al 1996; Lehtimaki
et al 1990; Tiret et al 1994; Luc et al 1994), but this has not been a consistent finding
(Payne et al 1992; O'Malley and Illingworth 1992; De Knijff et al 1992) and some
authors postulate that environmental influences have a major impact on expression of
coronary artery disease in conjunction with the APOE4 allele (Corbo et al 1999).
ApoE4 has also been associated with Alzheimer disease as well as a number of
neurological disorders, including Creutzfeldt-Jakob disease, Down's syndrome,
schizophrenia and vascular dementia. The reason for the intense research in this area
is based on the observation that ApoE is found in senile plaques, congophilic
angiopathy and neurofibrillary tangles of Alzheimer's disease (AD). When
Strittmatter et al (1993) compared the binding of synthetic amyloid beta peptide to
purified ApoE4 and ApoE3, both bound to it in the oxidised form. However, binding
to ApoE4 was observed in minutes whereas binding to ApoE3 occurred within hours.
The conclusion drawn was that isoform-specific differences in ApoE binding or
oxidation might be involved in the pathogenesis of the lesions of AD. Further to the
numerous studies linking ApoE4 with the presence of AD, early onset AD and
preferential development of AD in postmenopausal women, are studies suggesting
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that the E2 allele may confer protection against AD (Talbot et a 1994; Corder et al
1994). In these latter studies, although 65% of AD is attributable to the presence of
E4 alleles, risk of AD is lowest in subjects with the E2/E3 genotype with an
additional 23% of AD attributable to the absence of an E2 allele. A large study by
Myers et al (1996) which examined the association of apolipoprotein E4 with AD
and other dementias in 1,030 elderly individuals in the Framingham cohort study did
find an increased risk of these conditions in patients either homozygous or
heterozygous for E4. However, most apoE4 carriers did not develop dementia and
about half of the patients with AD did not have the E4 allele. Bennett et al (1995)
examined APOE genotypes in families with a positive history and those with a
negative history ofAD and found that the allele distribution of at-risk but unaffected
sibs for E 4 was i n excess a nd t his d id n ot d iffer from t hat o f affected s ibs. T hey
found no evidence for linkage between the APOE4 locus and AD and speculated that
it may modify preclinical progression at most.
As outlined above, E4 is neither necessary nor sufficient for the expression of AD
which is also affected by environmental or other genetic factors.
With respect to sleep disordered breathing, 3 studies have been published, with a
fourth paper looking at APOE4 in relation to chronic daytime somnolence.
The first by Saareleinen et al (1998) examined allelic variants in APOE on the basis
of its role as an 'injury-response' macromolecule in peripheral nerves and
neuromuscular junctions (Akaaboune et al 1994). The primary hypothesis was to
examine the importance of APOE genotype in OSA in relation to pharyngeal dilator
muscle patency and also increased risk of cardiovascular disease. 291 patients with
OSA (AHI> 5 events/hour) with no neurological or cerebrovascular disease were
88
examined in association with 728 controls from a random sample of the Finnish
population used in previous studies without any polysomnography. The cases and
controls were age matched (mean ages 53.3 and 53.7 years respectively). The mean
AHI was 38 (5 - 106) in cases. There was no significant difference in distribution of
either APOE alleles or genotypes between cases and controls as shown in Table 16
below.
Table 16: Distribution of APOE genotypes and alleles in OSA and Controls
(After Table 1, pg 148, Saareleinen et al 1998)
OSA (n=291) Controls (n=728) p-value
Genotype
E2/E2 0 (0%) 0 (0%)
E2/E3 25 (8.6%) 70(9.6%) NS
E2/E4 4(1.4%) 18(2.5%) NS
E3/E3 166(57%) 408 (56%) NS
E4/E3 79 (27.1%) 206 (28.3%) NS
E4/E4 17(5.8%) 26(3.6%) NS
Allele frequency
E2 5% 6% NS
E3 74.9% 75% NS
E4 20,1% 19.0% NS
The major criticism of this study resides in the absence of data regarding sleep
disordered breathing in the control group and the absence of stratification of the
cases by degree of SDB.
The second study to be published in this area by Kadotani et al (2001) looked
exclusively at the presence or absence of apolipoprotein E4 alleles in a group of
patients who had all undergone polysomnography (up to three times per patient) and
were classified by the authors as all having sleep apnoea according to their criteria
(AHI > 5). No control group was used and subjects were grouped as either APOE4
positive (n=222) or APOE4 negative (n=569). The two groups did not differ
significantly i n t erms o fm ean a ge (49 years), p ercentage o fm ales i n e ach group,
ethnicity, BMI or presence of hypertension. Sleep architecture was likewise not
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significantly different between the two groups. There was a significantly higher
mean AHI in the E4 positive group (6.5SE0.6 vs. 4.8SE0.3) and there was a higher
percentage of patients with AHI >15 in the E4 positive group (12% vs. 7%).
However, the distribution of the AHI in the groups was non-parametric and the
median values between groups were not significantly different - 1.3 (0 - 121) in the
E4 negative group vs. 2 (0 - 81) in the E4 positive group. Additionally, rather than
averaging the AHI for an individual who had had more than one sleep study, results
for all sleep studies ever undertaken in both groups were reported as if for individual
patients, i.e. 960 in the E4 negative group (n=569) vs. 384 (n=222). The authors went
on to suggest that increased SDB in E4 positive patients might be responsible for the
observed association of recalling napping behaviour and subsequent development of
AD (Asada et al 2000). However, they may have simply demonstrated a statistical
association.
The third study to report findings in this area by Foley et al (2001) looked at 718
Japanese-American men in Hawaii aged between 79 to 97 years. Only 18% of the
sample had the E4 allele. Moderate to severe SDB (AHI >15) was present in 42% of
this sample of men and adjustment for age, BMI, smoking and use of
antihypertensive medication did not reveal an association between E4 and an AHI>
15. The authors postulated that the difference between their results compared to those
of Kadotani et al (2001) may have been attributable to the high false-positive rate of
a genetic association study, the differences in the populations in terms of age, sex,
ethnicity and BMI as well as SDB and the fact that risk factors for chronic disease
often have weaker relationships in older persons. This latter bias may stem from
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selective survival, misclassification and changes in biological relationships
associated with increased age.
The most recently published study has examined APOE4 homozygosity in the
context of memory and chronic daytime somnolence (Caselli et al 2002). In this
study, 42 patients homozygous for E4 were matched to 42 patients heterozygous for
E4 and 42 non-carriers of the E4 allele. None of the patients underwent a sleep study.
The mean ESS was not high in any of the t hree groups - 6.4 (sd 3 .8) in the E 4
homozygotes, 8.2 (sd 3.8) in the heterozygotes and 6.8 (sd 4.5) in the nonE4 carriers
(p= 0.85, one-way ANOVA). All groups were matched in terms of age (mean age
55years), gender, BMI and obesity. However, analyses were confined to E4
homozygotes vs. nonE4 carriers and no comparison was made in a 3-way test across
the groups for the multitude of neuropsychological tests that were carried out.
Although the authors concluded that chronic daytime somnolence was associated
with a decline in verbal memory in cognitively normal APOE E4 homozygotes in
comparison to non-carriers of E4, the study displayed a large number of flaws in
method, definitions and statistical analysis for any definitive conclusions to be
drawn.
In summary, Apo E is associated with the presence of atherosclerosis and
Alzheimer's disease and potentially neuropathy. The association with sleep apnoea is
potentially even more complex. No controls without SDB have been examined in the
positive studies. Secondly, OSAHS is associated with a number of comorbidities that
have independently been shown to associate with increased frequency of the E4
allele, such as atherosclerosis, and coronary artery disease irrespective of the
presence of SDB. Thirdly, even if the E4 allele were found with increased frequency
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in an OSAHS population, this would not constitute causation and indeed, there
appears to be no biologically plausible mechanism currently under consideration that
would allow for a hypothesis to be generated in this regard.
2.8 Hypertension in OSAHS
As discussed in Chapter 1, section 1.5, OSAHS is an independent risk factor for
diurnal hypertension (Stradling et al 2000, Faccenda et al 2000; Pepperell et al 2002)
and has now been implicated as a risk factor for first stroke, recurrent stroke and
post-stroke mortality (Dyken et al 1996). The Wisconsin Sleep Cohort Study
(Peppard et al 2000), which prospectively investigated the association between OSA
and the development of hypertension at four y ears of follow-up showed that sleep
disordered breathing present at initial evaluation was accompanied by a substantially
increased risk of future hypertension. Subjects with an apnoea/hypopnoea index
(AHI) of > 15 events per hour had a risk ratio for developing new hypertension over
a 4 year period that was threefold compared to those without any apnoea.
There are a number of potential mechanisms that may mediate the vasculopathy that
contributes to the development of hypertension. In OSA, repetitive episodes of
airway occlusion resulting in hypoxaemia, hypercapnia and changes in intrathoracic
pressure elicit chemoreflex activation with consequent increases in sympathetic
vasoconstrictor traffic to peripheral blood vessels (Somers et al 1995). This results in
increases in blood pressure and elevated levels of circulating catecholamines. Whilst
sympathetic activation is one mechanism contributing to diurnal hypertension, the
pressor effect of vasoactive peptides such as endothelin may sustain the elevated
blood pressure (Faller 1999). Lastly, endothelial dysfunction may contribute to
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vasculopathy in OSA and is a characteristic of hypertension (Panza et al 1990) and
atherosclerosis (Celermajer et al 1992). Theoretically, it may result from the
repetitive hypoxaemia and pressor surges evident in patients with OSA.
The treatment of OSA w ith continuous positive airway p ressure (CPAP) has been
shown to attenuate the above effects (Narkiewicz et al 1999) and to result in the
reduction of blood pressure in both hypertensive (Stradling et al 2000, Faccenda et al
2000) and normotensive patients with OSA (Faccenda et al 2000; Pepperell et al
2002). This effect has been most marked in those with a high number of oxygen
desaturations during sleep associated with apnoeas and hypopnoeas.
Recent studies have shown abnormal vascular responses in patients with OSAHS
which are present even in the absence of overt cardiovascular disease, and are similar
to those in patients with essential hypertension (Kraiczi et al 2001; Kraizci et al
2000). OSAF1S may be associated with increased vasoconstrictor sensitivity (Kraiczi
et al 2000), impaired endothelium dependent vasodilatation to acetylcholine (Kraizci
et al 2000) and bradykinin (Kato et al 2000; Duchna et al 2000), and decreased
alpha- and beta 2-adrenergic vascular responses (Grote et al 2000). Nocturnal
hypoxaemia was associated with decreased endothelium-dependent vasodilatation in
a recent correlational study (Kraizci et al 2001). Methods employed in these studies
have differed between groups and so it is difficult to compare results between patient
populations and to determine reliably the reproducibility of the reported findings.
The endothelium plays a vital role in the control of blood flow, coagulation,
fibrinolysis and inflammation. Consequently, the maintenance and regulation of
tissue perfusion critically depends upon the integrity of endothelial function and the
release of potent endothelium-derived factors. In a small study, Kato and colleagues
93
(2000) demonstrated impaired endothelium-dependent vasodilatation to
acetylcholine but unchanged responses to sodium nitroprusside and verapamil in the
forearm circulation of 8 patients with OSAHS. This suggests that OSAHS is an
endothelial dysfunctional state.
Endothelium-dependent vasomotion may not be representative of other aspects of
endothelial function. The e ffects o f i ntermittent nocturnal h ypoxaemia r esulting i n
hypertension are thought to at least partly involve the release of vasoactive peptides.
These determine the response of the vascular endothelial and/or smooth muscle cells
to the hypoxic stimulus resulting in remodelling, fibrosis and angiogenesis. The key
peptides involved include vascular endothelial growth factor (VEGF), endothelin-1
(ET-1), platelet-derived growth factor (PDGF) and insulin-like growth factor-1 (IGF-
1) (Faller 1999). Levels of expression and activity of these factors may be
determined by genotype.
VEGF levels have been found to be elevated in patients with OSAHS (Imagawa et al
2001, Schulz et al 2002, Gozal et al 2002) and the levels decrease with t reatment
with CPAP (Lavie et al 2002).
The result of studies examining circulating levels of ET-1 in patients with OSAHS
with and without hypertension have been contradictory (Grimpen et al 2000; Phillips
et al 1996; Saareleinen et al 1997; Kanagy et al 2001; Phillips and Somers 2000) and
each study has displayed limitations in method which may have affected results. No
studies are available to date looking at the gene polymorphisms of vasoactive
peptides in the context of OSAHS. One study examining angiotensin converting
enzyme inhibitor (ACE-I) gene polymorphisms has been reported in the literature in
subjects with and without OSA and hypertension (Zhang et al 2000).
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The importance of looking at gene polymorphisms in OSAHS with respect to
hypertension is largely related to the reversibility of abnormal vascular responses
with treatment. The distribution of polymorphisms potentiating hypertension may or
may not be similar to that in patients with essential hypertension as they share much
comorbidity. However, it is of secondary importance to this work, which is focussed
largely on the causes of OSAHS rather than its consequences.
2.9 Methods of Genetic Studies
Genetic polymorphisms occur throughout the human genome approximately once
every 500-1000 base pairs (bp). A genetic polymorphism is defined as a variation in
the DNA sequence that occurs at least once in every 100 copies (Vogel & Motulsky
1996). Apart from the genes on the sex chromosomes, each individual will have two
copies of every gene so the variation needs to occur at least once in every 50
individuals to be classified as a polymorphism. Rarer sequence variants are usually
referred to as isolated mutations. The normal DNA sequence for a particular gene is
called the wild-type allele and the rarer sequence the variant allele. Different
polymorphisms that occur close together are often linked and within a single
chromosome, this arrangement is known as a haplotype. When haplotypes are found
together more frequently than would be expected by chance, they are said to be in
linkage disequilibrium. The most common type of genetic polymorphism is the
single nucleotide polymorphism where one base is replaced by another. Sometimes
insertions of additional sequences or deletions can occur. SNPs can be silent or
functional. SNPs are useful markers in the investigation of susceptibility in polygenic
diseases. The Human Genome Project has made possible a SNP map which is a high-
95
density map of 200,000 - 300, 000 SNPs and a database that contains 1.8 million
SNPs accessible via the internet (http://snp. cshl.org/).
Two general approaches in study design have been used in linking human disease
with a genetic component (Table 17).
Table 17: Study designs for the identification of disease genes
(after Daly & Day 2001; Br J Clin Pharmacol 52: 490)
Linkage Studies
1. Used mainly in the study of single gene disorders
2. Utilize genetic markers situated throughout the genome which are not
necessarily functionally significant in terms of phenotypic effect
3. Use extended families (rarely in study cases and controls)
4. Linkage of genotype for a genetic marker to disease may be unique to the
particular family
Association Studies
1. Used to identify genes involved in polygenic disorders.
2. Determine genotype for polymorphism (may be functionally significant) in
candidate gene ofbiological relevance to disease
3. Use cases and appropriately matched controls (unrelated usually)
4. Association of a genotype or phenotype with disease is a statistical finding
not necessarily reflecting genetic linkage
In the last 20 years, genes implicated in Mendelian diseases have been identified by
using genetic linkage and positional cloning methods. These methods have allowed
for the identification of relative risk genes but have not been so successful in
identifying genes involved in polygenic disorders. The failure of these methods
(linkage studies) in complex diseases arises from three main features inherent to
them:
1. Complex diseases vary in severity of symptoms and are generally of late
onset which means parents of the index case are not usually available for
family studies and often makes definition of an appropriate phenotype
difficult. Furthermore, a number of epigenetic phenomena, such as parental
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imprinting, disease fluctuation and sex- effects (see Petronis 2001) can also
alter phenotype.
2. Complex diseases may vary in their aetiological mechanisms which might
involve various biological pathways.
3. Complex diseases are more likely to be polygenic with each gene having a
small overall contribution and relative risk for disease expression.
Therefore, association studies using candidate-gene approaches are more likely to
be more effective tools than linkage studies in the investigation of complex traits.
By utilizing the case-control method of study design, a candidate-gene study has
the advantage ofboth the increased statistical efficiency of association analysis of
a complex disease (Risch & Merikangas 1996; Tabor et al 2002) and the
biological u nderstanding o f t he p henotype, t issues, genes a nd p roteins t hat a re
likely to be involved. Association studies may provide adequate power to detect
relative risks as low as 1.5 which is generally not possible in family studies
(Risch 2000) and by looking at functionally significant polymorphisms, concerns
about linkage disequilibrium and adequacy of SNP markers to detect association
are not relevant (Weiss & Terwilliger 2000). Segregation and linkage analysis
studies have difficulties with non-Mendelian disorders. Segregation analysis is
very sensitive to biases and linkage analysis requires the specification of a
precise genetic model which includes disease gene frequency and information on
the penetrance of each genotype (Gambaro et al 2000).
However, in order to be effective, a number of relevant issues in the design of
case-control studies must be addressed including choice of candidate g ene and
SNP; recruitment methods; control matching and number of study subjects
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(especially with respect to power) - see Little et al (2002) for exhaustive
discussion on design adequacy and checklist on gene-disease association studies
and Daly & Day (2000). It is also important to consider the confounding factors
inherent in case-control studies using the candidate-gene approach which include:
1. Population stratification - this can be minimised by using internal family
control subjects (Hassan et al 2001; Silverman & Palmer 2000)
2. Phenotypic heterogeneity
3. Linkage disequilibrium of the SNP under study with other causal SNPs
4. No biological role for the gene/protein studied; SNP studied has no functional
effect even though the protein is involved
5. Degree of generalisability to other populations
6. Lack of replication of results in subsequent studies or studies undertaken in
different populations (due to false-positive, false-negative studies or true
variability among different populations).
Largely r elated to questions regarding causality (does the c andidate g ene cause or
contribute to the disease process?), these issues are less of a concern if there is
biological plausibility in the association and the association is strong. Furthermore,
Lohmueller et al (2003) and Tabor et al (2002) have argued that consistent
replication in different populations is strong evidence of causality b ut that lack of
replication does not necessarily imply lack of causality. A large number of SNPs
studied may have real but modest effects on common disease risk but the studies are
underpowered leading to false-negative reports (Lohmueller 2003).
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Despite these limitations, the association study remains the most cost-effective,
practical and reliable method of examining for candidate genes in complex diseases
such as OSAHS.
2.10 AIMS OF THE THESIS
The aims of this thesis were to conduct a case-control study examining the
association of 5 SNPs in 5 candidate genes with OSAHS. On the basis of evidence
presented above, OSAHS is considered to be a complex disease.
The genes of interest included:
1. Tumour necrosis factor -a (SNP: - 308 A/G). The most widely studied
polymorphism within the TNF-a gene involves the G/A substitution at position -308
(relative to transcription start site of (+1)) in the promoter region. It was first
described by Wilson et al in 1992. Guanine at position -308 is considered to be the
wildtype variant (TNF1) whilst the adenine at this position is considered the minor
allele (TNF2). The functional relevance of the TNF2 polymorphism in vivo remains
in contention. The postulated functional effect would appear to be an effect on
transcription of the TNF- a gene. Two approaches have been used to investigate the
effects of the TNF2 polymorphisms: 1. investigation of the influence of
polymorphism on transcriptional activity of reporter genes expressed in various cell
lines; 2. investigation of the expression of TNF2 by cells derived from individuals
with varying TNF- a promoter genotypes.
Each approach has its advantages and disadvantages (see Allen 1999 for detailed
discussion). In Table 18 and Table 19 below, the results of studies on the TNF- a
G/A polymorphisms are summarised according to the investigative approach used.
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Table 18: Findings from studies of the relationship between -308 genotype
and TNF-a production by stimulated peripheral blood mononuclear cells
(afterAllen 1999, pg 1022)
Authors N for G/A: G:G Ratio G/A: G:G* P-
value
Cell stimulant used
Bouma et al 1996 13: 26 1.3 x <0.05 l|i/ml each anti-CD3 &
anti-CD28
Danis et al 1994 6: 29 1.4 x NS 5 r|g/ml IFN-y
Huizinga et al 1997 6: 67 1.2 x NS 10 or 1000 ng/ml LPS
Pociot et al 1993 ? 1.2.x 0.08 250pg/ml LPS
Louis et al 1998 16:41 ~ 1.8 x <0.05 1 or 100 rig/ml LPS
Mycko et al 1998 ? 0.95 x NS 10 pg/ml LPS
* Genotype at position -308. Ratio of TNF- a production from cells of heterozygotes compared to
cells of liomozygotes
Table 19: Study results using reporter gene constructs to investigate the
transcriptional effects of the -308 G/A polymorphism (after Allen 1999, pg
1023)
Author 5' segment 3'UTR Cell line Origin of Effect of
used segment line SNP
Braun et al -627 to+164 Nil BHK Hamster Positive
1996 A>G
Kroeger & -993 to+110 Nil Jurkat Human Negative
Abraham U937
1996
Kroeger & -993 to+110 +1957 to + Jurkat Human Positive
Abraham 2792 U937 A>G
1996
Wilson et -585 to+106 Nil Raji Human Positive
al 1997 A>G
Brinkman -619 to +108 +1951 to Raji, Human Negative
et al 1996 +3013 Jurkat
Stuber et -1173 to+130 Nil ANA-1 Murine Negative
al 1996
Uglialoro -977 to +93 Nil A20, Ar-5 Murine Negative
et al 1998
The conflicting results clearly arise largely from problems with statistical power in
the studies looking at TNF- a production in cells from individuals with different
genotypes (Table 18). A further confounder may lie in the possibility that TNF- a is
in linkage disequilibrium with the MFIC and that the -308 allele is specifically in
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linkage disequilibrium w ith HLA-DR3 (Wilson et al 1993). This latter a ssociation
results in a relatively high TNF- a production (Jacob et al 1990). However, Bouma et
al (1996) showed that secretion of TNF- a was elevated in -308G/A individuals
irrespective of whether they were DR3+ or DR3-. The high TNF- a production
associated with the HLA-DR3 allele may be due to its close association with the -308
A TNF- a promoter allele.
Studies using the reporter gene approach also show conflicting results (Table 19).
The one variable that may be contributing to this may be the segment of the promoter
used. A sequence as short as 6 - 8 bp could b ind a transcription factor and have
repressor or activator activity which could be significant (whereby DNA structure is
modified). Despite the variation in results, studies that do report a difference report
the same type of difference. Taken together, the two approaches to studying the
effects of an SNP on gene function, suggest that there may be a small but significant
effect of the -308 A allele increasing the levels of TNF- a transcription. As Allen
(1999) points out, the degree to which an increase or decrease in transcriptional
activity is required to be biologically relevant is still unknown. It is possible that
even a 5% difference in levels of locally produced TNF- a could alter the kinetics of
an ongoing immune response at a crucial time. Kaijzel et al (1998) showed that TNF-
a increases its own production by a positive feedback mechanism (Amiot et al 1997;
Philip and Epstein 1986). Thus, a small initial increase in TNF- a production may be
magnified during an in vivo immune response and therefore have a significant effect
on the outcome of that response. In this respect, promoter polymorphisms may not
need to exert a large effect on transcription in order to influence the immune
response.
101
The TNF-a -308 A polymorphism has been associated with an increased risk of
cerebral malaria (McGuire et al 1994), obesity (Hermann et al 1998) and a diverse
range of inflammatory conditions including asthma (Moffat & Cookson 1997), usual
interstitial pneumonia (Whyte et al 2000; Pantelidis et al 2001; Riha et al 2004) and
chronic lymphocytic leukaemia (Demeter et al 1997). The number of conditions with
which the -308 SNP is associated or in which it has been tested is so diverse and so
numerous, that it has prompted the establishment of a website that regularly updates
the information and which can be found at:
http://www.bris.ac.uk/Depts/PathAndMicro/services/GAI/cytokine4.htm
It is also important to bear in mind that the TNF-a gene is located within the highly
polymorphic major histocompatibility complex (MHC) region on chromosome
6p21.3. The TNF gene cluster contains many polymorphisms including
microsatellites and single nucleotide polymorphisms. Many of these polymorphisms,
including TNF-a -308 have been found to be in linkage disequilibrium w ith HLA
class I and II alleles, including lymphotoxin-a (TNF-b - one of five microsatellites
within the TNF locus). The association of TNF-a SNPs with various conditions may
therefore be due to the direct influence of the SNP in question and/or due to linkage
disequilibrium with other polymorphisms within the TNF-a gene or the HLA system.
The reasons that the TNF-a gene may be important in the pathogenesis of OSAHS
are as follows:
1. TNF-a levels are raised in OSAHS. To date, four studies have demonstrated this in
subjects with OSAHS (Vgontzas et al (1997; 2000), Entzian et al (1996) and Liu et al
(2000)) and can be summarised as follows:
a. TNF-a is elevated in OSAHS independently of obesity
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b. TNF-a may play a role in daytime sleepiness experienced by the obese even
in the absence of OSAHS.
2. TNF-a may promote sleepiness. This is discussed in Section 2.4.1.
3. TNF-a may be associated with hypertension (Pausova et al 2000).
4. TNF-a may be associated with obesity. A number of studies have shown an
increased association of the TNF-a -308 A allele with obesity in various ethnic
populations including Pima Indians (Norman et al 1995), French and Northern Irish
(Hermann et al 1998), French Canadians with differential body fat deposition in line
with gender differences (Pausova et al 2000) and Germans (Brand et al 2001). See
also Das (2001) for detailed discussion.
5. TNF-a is implicated in bone growth and remodelling. Gerstenfeld et al (2001)
have shown that TNF-a plays a crucial role in promoting postnatal bone repair
through the induction of osteoprogenitor cell recruitment or osteogenic cell
activation in the context of intramembranous bone formation. Suda et al (2001) have
demonstrated that TNF-a plays an important role in pathological bone resorption due
to inflammation and Cheng et al (2003) showed TNF-a to be integral to
osteoclastogenesis.
Thus, TNF-a may play a significant role in the pathogenesis and expression of
OSAHS.
2. Apolipoprotein E (Alleles: E2, E3, E4). As discussed in section 2.7
above, the APOE gene products are intimately associated with the regulation and
binding of lipoprotein receptors. The product of the 3 APOE alleles differs in such
properties as its affinity for binding to apoE (protein) and low density lipoprotein
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(LDL) receptors and its affinity for lipoprotein particles (Davignon et al 1988). In
vitro observations have associated APOE4 (gene) with higher levels of total and
LDL cholesterol and apoB, thereby acting as a risk factor for atherogenesis. APOE 4
(gene) carriers show lower apoE levels (protein) compared to the other alleles
(Davignon et al 1988). The largest amount of APOE mRNA is found in the liver with
the second largest concentration in the brain. Brain apoE is synthesized locally (as
shown in liver transplant recipients) and is the major apolipoprotein in the
cerebrospinal fluid. It has been implicated in lipid transport and cholesterol
redistribution following peripheral and CNS injury and it is possible that it acts as a
neurotrophic factor, antioxidant and mediator of immune responses. ApoE4 is found
in senile plaques, congophilic angiopathy and neurofibrillary tangles ofAlzheimer's
disease. When Strittmatter et al (1993) compared the binding of synthetic amyloid
beta peptide to purified ApoE4 and ApoE3, both bound to it in the oxidised form.
Elowever, binding to ApoE4 was observed in minutes whereas binding to ApoE3
occurred within hours. It appears that the ApoE4 allele gives rise to structural
changes that affect binding kinetics and transport. In the case ofOSAHS, these
observations may be of relevance in respect of changes in the brain related to chronic
intermittent hypoxaemia (e.g. study by Davies et al 2001 which showed a higher
number ofwhite matter lesions of unknown significance using MRI in patients with
OSAHS compared to perfectly matched controls) or the development of atherogenic
complications. Two studies have suggested that the APOE4 allele may be more
frequently associated with OSAHS than expected by chance alone (section 2.7).
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3. Serotonin receptor 2A (SNP: T102C).
The 5HT2A receptor was one of the first serotonin receptors to be cloned (Saltzman
et al 1991; Chen et al 1992; Stam et al 1992). 5HTR2A is a member of the G-protein
linked receptor superfamily and thereby shares a common mechanism for signal
transduction with other HT2 receptors which when activated stimulate
phosphoinositide (Pi) hydrolysis. A number of SNPs have now been identified in the
coding and regulatory regions (see Table 20).





Region of Gene Function?
Thr25Asn +74 C —>■ A Coding (N-terminus) Unknown
102T/C +102 T->C Coding Silent
516C/T +516 C —> T Coding Silent
His452Tyr +1354 C —» T Coding (C-terminus) Ca++ mobilization
-1438 G/A -1438 G —» A Promoter Promoter activity
Inayama et al (1994) were the first to report an association with the silent mutation in
the coding region T102C with schizophrenia. The mutation does not alter the
expression or structure of the protein and this suggests that a functional receptor
variant of 5HTR2Amay be in linkage disequilibrium with T102C. This prompted
Erdmann et al (1996) and Ozaki et al (1996) to search for two other relatively
abundant amino acid substitutions in the 5HTR2A receptor which were also located
in the coding region. These were identified as C+74A (Thr25Asn) and C+1354T
(His452Tyr) and were found to be located close to the N-and C-terminals
respectively of the 5HTR2A molecule. At that stage no functional role for the protein
could be assigned, but further studies using radioligand binding in human platelets
demonstrated an effect on Ca++ mobilization.
Ozaki et al (1997) looked at the influence of the His452Tyr SNP on cellular 5HT
functions using 5HT2A binding and 5HT-stimulated Ca++ response in platelets
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derived from clinically matched subjects (patients with seasonal affective disorder
and normal controls). The His452Tyr heterozygotes showed significantly smaller
amplitude of intracellular Ca++ mobilization after stimulation with two different
doses of 5HT compared to the His452His homozygotes. There was also no apparent
effect of increasing concentrations of serotonin to augment calcium mobilization in
the heterozygotes compared to a clear dose-response relationship seen in the His452
His homozygotes. However, the T102C SNP was not found to be in linkage
disequilibrium with these two potentially functional SNPs discussed above and
continued to independently associate with the schizoaffective disease state (Erdmann
et al 1996; Spurlock et al 1998). Spurlock et al (1998) and Nothen and Propping
(1998 - unpublished) identified an A-G polymorphism at -1438 in the promoter
region of the 5HTR2A which was in complete linkage disequilibrium with the silent
T102C SNP, also confirmed by Ohara et al (1999) and Basile et al (2001). Two
clinical studies examining the 5HTR2A -1438G/A promoter polymorphism showed
an association with increased food and alcohol intake in those with the G allele
(Aubert et al 2000) and a higher BMI, waist to hip ratio and abdominal sagittal
diameter in homozygotes for the G allele compared to homozygotes for the A allele
(Rosmond et al 2002).
Functional analysis of A-1438G using luciferase assay demonstrated significant basal
promoter activity in serotonin expressing HeLa cells by both the A and G variants.
Comparison of the A and G variants however, showed no significant differences in
basal activity or when promoter activity was induced by cAMP and protein kinase C-
dependent mechanisms (Spurlock et al 1998). Though these are disappointing
findings, the 5HTR2A gene is greater than 20kbp in length and thus, it is possible
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that other areas that affect expression of the gene may vary and have not as yet been
identified.
The T102C SNP in the 5HTR2A gene, despite being silent, has been chosen in the
context of OSAHS to examine for associations in relation to obesity, hypertension
and potential responsiveness to selective serotonin re-uptake inhibitors. The
serotonin 2A receptor has been identified as the primary receptor on motor neurones
involved in the function of the hypoglossal nerve and is thereby instrumental to the
regulation of upper airway tone.
The s ize o f t he 5 HTR2A gene w hich continues t o b e s equenced s uggests t hat t he
silent SNP T102C studied is in linkage disequilibrium not only with the A-1438G
SNP but potentially with other, as yet unidentified polymorphisms which may affect
function of the gene.
4. Beta-2 adrenoceptor (SNP: C+79G).
The structure of ADBR2 is similar to other G protein coupled receptors. The amino
terminal end is localized extracellularly, has seven transmembrane spanning domains
and an intracellular carboxyl-terminus.
The C+79G SNP is one of nine polymorphisms in the coding block of ADBR2.
C+79G is one of four SNPs that change and encode amino acid and is found in the
amino terminus of the receptor. The change is designated Gln27 —> Glu. Initial
studies have focussed on the association o f the various SNPs in the ADBR2 with
asthma and response to [Vagonist treatment.
The consequences of the alterations in receptor function have been assessed by using
recombinant expression systems where each SNP is mimicked using oligonucleotide-
directed site-specific mutagenesis of the wild-type ADBR2 cDNA. These constructs
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are inserted into mammalian expression vectors and transfected into Chinese hamster
fibroblasts that normally do not express ADBR2. Permanent cell lines are then
established and receptor function is studied (Green et al 1993; Green et al 1994).
Findings for the Glu27 variant showed that agonist binding and coupling to adenylyl
cyclase remained intact, but that agonist downregulation was absent.
Studies by Green et al (1993 & 1994) in human bronchial smooth muscle cells
obtained by rapid autopsy in disease-free individuals showed about 25%
downregulation in receptor expression in the Glu27 variant cells. This was much less
however, than for some of the other SNPs, e.g. the Argl6 - Gly SNP. Liggett (1997)
summarises at length the associations of the various SNPs with asthma in a number
of populations. The results of these studies have not been consistent in their findings
(Martinez et al 1997; Tan et al 1997; Israel 2000). It has now been demonstrated that
haplotype for a total of 13 SNPs in the upstream and coding sequences of the
ADRB2 appear to be a better predictor of agonist response with 5 different
haplotypes relatively common among Caucasians (Drysdale 2000). This is an
example of how determination of haplotype may be more useful than a single SNP in
predicting treatment responses in a diseased population.
All the SNPs located in the ADBR2 are in tight linkage disequilibrium. It should also
be noted that the ADBR2 gene is localized to chromosome 5q32-34 very close to
several cytokine genes. It is thus possible that the individual SNPs of the ADBR2
may be markers for the action of cytokines in various pathological processes.
As discussed above in sections 2.2.2 and 2.3, ADBR2 mediates response to
catecholamines, is therefore involved in the energy pathways of the body especially
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in regard to lipolysis and has also been implicated in the growth process and the
development of hypertension.
In this thesis it was postulated that in OSAHS, the ADBR2 SNP Glu27Gln may
show an association with obesity (as a result of poor energy expenditure) and
possibly independently associate with hypertension. Knowledge of a differential
response to exercise according to genotype may help predict those who respond to
certain lifestyle and behavioural modifications, thereby enhancing their clinical
management.
5. Growth Hormone Receptor (SNP: + 561 T/G).
As discussed previously in section 2.2.2, the GHR gene consists of 9 coding exons,
spanning at least 87kb of chromosome 5. Exon 2 encodes the signal peptide; exons 3
- 7 the extracellular domain, exon 8 the transmembrane domain and exon 9 and part
of exon 10 the intracellular domain (Godowski et al 1989). The majority of
mutations in the GHR gene are located in the portion involving exons 3-7 which
also codifies for the GH binding protein (GHBP) generated by limited proteolysis of
the GHR (Leung et al 1987). This accounts for the majority of patients with growth
hormone insensitivity having lower levels of GHBP (Daughaday & Trivedi 1987).
Over 30 different missense, nonsense, frameshift and splice mutations of the GHR
gene have been reported, which also include the P561T polymorphism which occurs
in exon 1 0. This SNP results in an amino acid substitutionPro561 —> Thr but its
functionality in vitro has not been assessed. Goddard et al 1997 reported this SNP to
occur at a frequency of 2% in 102 control subjects in their large study of GHR
polymorphisms. Chujo et al (1996) identified the SNP in a Japanese child with
Noonan syndrome who showed a b lunted IGF-1 response to an acute injection of
109
growth hormone. Forty-one men and 55 women aged 20 - 80 years were recruited
from the population and tested for presence of the SNP. Fourteen of the 96 (15%)
were heterozygous for the P561T mutation but it was not associated with any
differences in body height. Yamaguchi et al (2001) aimed to quantitatively evaluate
the relationship between craniofacial morphology and the Pro561Thr (P56IT) variant
in the GFIR gene in 80 subjects taken from the Japanese population. They showed
that subjects without the P56IT allele had a significantly greater mandibular ramus
length as measured cephalometrically compared to those with P56IT. They
postulated that the GHR gene P56IT variant may be associated with mandibular
height growth and may be a genetic marker for it.
There have been no further functional studies in the area of GHR SNPs in terms of
examining binding or signalling properties in vitro. Only 3 larger studies have
examined the prevalence of various mutations in the GHR in terms of in vivo
responses to GH and GHBP levels (see Sjoberg et al 2001; Goddard et al 1997;
Sanchez et al 1998).
The +561G/T SNP in the GHR has been chosen to act as a marker for possible
disease associations as it may be in linkage disequilibrium with potentially more
functional polymorphisms. GHR SNPs have been associated with postnatal bone and
soft tissue growth and with obesity. The GHR P561T polymorphism (within lOkb of
the +561 T/G SNP in this study) has recently and uniquely been associated with
mandibular size in a group of Japanese subjects (Yamaguchi 2001).
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2.11 Summary
In this chapter, the hereditary aspects of OSAHS have been discussed. It is a
complex, polygenic disease with a number of aetiologies interacting to produce a
single p henotype. T he aims o f t he t hesis a re t o i nvestigate t he p ossible r oles o f 5
candidate genes in the aetiology of OSAHS. The methods used in this study are




This chapter outlines the rationale, tests and techniques used in this thesis to examine
the variables of sleepiness and sleep disordered breathing, the craniofacial complex,
and the presence of genetic polymorphisms in the study population. The statistical
methods employed in the subsequent analyses of the results are also discussed.
3.0 Introduction
A case-control study based on the recruitment of sib-pairs commenced in January
1997 with completion in December 2002 and data analysis in February 2003.
In order to augment the recruited numbers, data from another study conducted at the
Scottish Sleep Centre were included in the final analysis (Vennelle et al 2003) as were
192 random anonymous UK blood donors to act as additional controls
(http://www.ecacc.org.uk).
The study was approved by the Lothian Research Ethics Committee, the Wellcome
Trust Clinical Research Facility Scientific Advisory Committee and had Research and
Development approval from the Lothian University Hospitals NHS Trust. All
participants in the study signed a written informed consent (copies Appendix 2 & 3).
Copies of the consent form and an information letter were also sent to each
participating subject's general practitioner (Appendix 3). All subjects with abnormal
sleep study results were notified by letter, as was their general practitioner.
3.1.1 Recruitment of subjects
Between 1997 and 2000, 296 consecutive patients attending the sleep laboratory were
chosen as they had symptoms of OSAHS, a body mass index less than 30kg/m2 and
an AHI >15. Recruitment was undertaken directly in the Sleep Centre by approaching
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patients and by a mail-out based on a register of all patients attending for studies
previously and who fulfilled criteria. Index cases in the mail-out lived within a 50-
mile radius of Edinburgh. Each index patient was sent a letter requesting participation
in the study (Appendix 2). The letter requested that the index cases contact their
siblings. As we sought a sleep apnoea enriched relative group, siblings who were
willing to participate were asked to complete and return a short questionnaire about
their sleep, sleepiness and snoring (Appendix 2). The siblings who were sleepiest or
snored were then asked to attend the Scottish Sleep Centre for polysomnography,
cephalometry and to have blood taken. If the index case had only one other sibling,
he/she was requested to participate regardless of their sleepiness or snoring status.
Response rates for this phase of the study were:
165 index cases agreed to participate in the study (165/296)
97 index cases had siblings who were willing to participate
21 siblings defaulted despite originally agreeing to participate in the study
76 sib-pairs completed the study
8 pairs had inadequate or missing blood samples.
This left a total of 68 complete sib-pairs.
The second phase of recruitment for the study commenced in 2001 and was
completed in 2002. The inclusion criteria for the index cases were changed to a BMI
> 30kg/m2with an AHI >15 and symptoms of OSAEIS. The reason for the shift in
recruitment criteria was to augment the number of obese cases with OSAHS. Index
cases were taken from the register of patients on CPAP at the Scottish Sleep Centre
who lived within a 50-mile radius of Edinburgh. Potential index cases were also
approached during sleep clinics and at two annual meetings of the Scottish
Association for Sleep Apnoea.
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An invitation to participate in the study was given or mailed out (Appendix 4 for
study protocol and letters) and followed up by a telephone call. A second letter was
sent to participants who did not respond. 261 index cases were approached of whom
147 could be reached by telephone or responded to the letter.
58 of 147 index patients participated (4 had died, 10 declined outright, the remainder
because they had no sibs or their siblings were unavailable; 7 index patients defaulted
after originally agreeing to participate).
38 siblings participated (3 index cases had 2 siblings each participating)
35 sib-pairs completed the study.
The overall participation rates for the study were thus:
162 of 557 index subjects contacted had siblings and were willing to participate in the
study (29% response rate); 103 sib-pairs (209 subjects in total) completed the study
with blood samples available (18%). The 557 subjects approached represent 0.01% of
the total Scottish population (~ 5 million).
The lowish participation rate overall is largely attributable to the availability of
siblings who could travel easily to the Scottish Sleep Centre in Edinburgh. There has
been widespread migration from Scotland in the last 50 years, which is reflected in
the Census data over that period (General Register Office for Scotland 2002).
Younger subjects with few or no sibs reflected the societal trend for smaller families
in the last 30 years and in the older patient groups (now in their 50s and 60s) where
larger families were more common, siblings had passed away, emigrated or were




All subjects had height; weight and neck circumferences measured and were asked to
fill out a standard sleep questionnaire that has been extensively validated in the
Scottish Sleep Centre (see Appendix 5 for copy of questionnaire).
Height was measured without shoes and socks in centimetres using a stadiometer.
Weight was measured in light clothing without shoes on an electronic scale in
kilograms. Neck circumference was measured with the subject seated with a soft
dressmaker's tape measure at the level of the thyroid cartilage (in centimetres).
All siblings had overnight polysomnography (see section 3.3 below). Index patients
had either overnight PSG or a home study (see section 3.3 below). All subjects
participating in the study had cephalometry (see section 3.2 below) and 20 mis of
blood collected (see section 3.4.1 below). Blood pressure was measured on one
occasion using a mercury sphygmanometer.
All data were recorded manually and then transferred onto an electronic spreadsheet.
Where required, travelling expenses for participating siblings were paid.
3.1.3 Additional Subjects without a diagnosis of OSAHS
In order to augment the number of subjects without a diagnosis of OSAHS, we
utilised bloods obtained from a previously conducted study at the Scottish National
Sleep Centre (Vennelle et al 2003) aimed at examining the polysomnography and
cephalometric parameters in parents of SIDS victims. Although a number of papers
have been published suggesting that there is a possible increase in the prevalence of
OSAHS in families of SIDS victims (Oren et al 1987; Tishler et al 1996; Mathur and
Douglas 1994; Pinholster 1995), there is no proof of causality, or indeed anything
more than a tenuous link between OSAHS and SIDS despite the use of sophisticated
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statistical analysis or conducting a population-based study (Gislason et al 2002). Use
of DNA and sleep study data obtained in this study, represents a valid study group
from the same Scottish population. .The method of case selection was as follows:
SIDS victims were identified by the Departments of Paediatric Pathology in the Royal
Hospital for Sick Children in Edinburgh and Yorkhill Hospital, Glasgow. In all cases,
expert medical and legal staff, following a combination of inquiry and a detailed post¬
mortem examination, had excluded known causes of sudden infant death syndromes.
The parents of 265 consecutive SIDS cases were then contacted and invited to take
part in this study, all approaches being made through the family practitioner on whose
list the SIDS victim had been at the time of death. The parents of 57 of the SIDS
victims could not be traced by the family practitioner and the family practitioners
indicated that the parents of 12 victims should not be contacted for emotional reasons.
The parent(s) of 171 of the 196 SIDS cases were located. 119 pairs of parents declined
to participate in the study and 18 pairs agreed to take part but did not attend for their
sleep studies. 55 parents of 34 SIDS victims participated. Control subjects for this
study were obtained from family practice registers and were matched with the parents
studied on a one to one basis for gender, age within 5 years, height to within 5 cm and
weight to within 5 kg. Each was approached by an independent research guardian and
asked to participate in an unspecified medical research study. 132 possible subjects
were approached before 55 suitable controls agreed to participate. The Local Medical
Ethical Advisory Committees approved the study and all parents and controls gave
written informed consent (see appendix for copy of consent form and information
sheet). Consent included the collection of 20mls of venous blood for future DNA
analysis.
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All participants in the study completed the standard clinical sleep symptoms
questionnaire (Appendix 5) and underwent overnight polysomnography in the Sleep
Centre as discussed below (section 3.3). Prior to the sleep study, all subjects had their
height and weight measured as detailed above and all were asked to have lateral
cephalometry performed to determine upper airway dimension and facial bone
structure (section 3.2).
Of the subjects recruited, 34 complete data sets (blood, cephalometry and sleep study)
were available for inclusion in this study - comprising 24 SIDS parents and 10
controls.
3.1.4 Phenotyping
Phenotype for OSAHS was defined using Table 6 in Chapter 1. Each subject's AHI
was first scored as either definitely abnormal (1), indeterminate (2) or definitely
normal (0) on the basis of gender and age. Each subject's ESS was then scored as
either sleepy = 1 (ESS >11) or not sleepy (ESS < 11) = 0.
OSAHS was then classified as being definitely present, indeterminate or definitely
absent as represented in Table 21 below.
Table 21: Presence or absence of OSAHS phenotype using scores derived
for SDB and sleepiness





2 0 NO OSAHS
0 1 NO OSAHS
0 0 NO OSAHS
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3.1.5 Blood donors
As a second set of controls, DNA from UK Caucasian human random control DNA
panels (Product No. HRC-1 96 array and No. HRC-2 96 array) produced by ECACC
® (European Collection of Cell Cultures; http://www.ecacc.org.uk) and distributed by
Sigma ® w as u sed. T he 9 6 a rray p anels a re i ntended asanaidtod etermining t he
characteristics ofDNA from apparently normal, randomly selected subjects as a basis
for comparison with DNA from subjects that have been selected for particular
phenotypic characteristics. The arrays can be used directly in automated gene analysis
systems.
Human random control (HRC) DNA is extracted from lymphoblastoid cell lines
derived by Epstein Barr Virus (EBV) transformation of peripheral blood lymphocytes
from fresh, single donor blood samples. The donors selected for this study were all
UK Caucasian and were characterised (incompletely) by gender and age at
venesection. All donors had given written informed consent for their blood to be used
for research purposes.
3.2 Cephalometry
3.2.1 Technique of cephalometry
Hofrath in Germany and Broadbent in the USA first introduced radiographic
cephalometry in 1934 (Moyers 1988). The original purpose of cephalometry was for
research on growth patterns in the craniofacial complex. Apart from its utility in
following treatment progress in the sphere of orthodontics, cephalometry is useful in
the evaluation of dentofacial proportions and in the clarification of the anatomic basis
for malocclusion. The goal of cephalometry is therefore to establish the horizontal and
vertical relationships between the functional components of the face - the cranium
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and cranial base, the skeletal maxilla (the portions of the maxilla that would remain if
there were no teeth or alveolar processes), the skeletal mandible (similarly defined),
the maxillary dentition and alveolar process, and the mandibular dentition and
alveolar process.
There are two basic approaches in cephalometry. The first approach pioneered by
Down (seeMoyers 1988) and followed by most workers in this field is the use of
selected linear and angular measurements to establish appropriate comparisons
between the functional components of the face. The other approach is to express the
normative data graphically rather than as a series ofmeasurements and to compare the
patients' dentofacial form directly with the graphic reference (template). Any
differences can be observed without making measurements.
In our study, we recorded the measurements and angles on each subject's radiograph
and focussed on the bony components of the craniofacial complex rather than on the
dentition in an effort to establish craniofacial characteristics that might be associated
with OSAHS. Because 50% of the sample was on CPAP, soft tissue measurements
were not analysed in this study (Mortimore et al 1996; Schwab et al 1996). Neck
angles were also not analysed.
3.2.2 Method of measurement and recording of results
Radiology
Cephalometric roentgenograms were carried out in the Department of Radiology at
the Royal Infirmary Edinburgh using the Orthoceph ® 10 (Type No.: D 3198;
Siemans AG, UB Med). Subjects were seated and facing at 90° to the X-ray beam
(see Fig 8), 152.4cm (60 inches) from the target of the x-ray tube with their left side
toward the film. The ear olives were placed into the external auditory meati and the
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nasal root supported and aligned with the nose support to prevent lateral head tilt or
rotation. The distance of the median plane to the film was 18cm. The subjects were
directed to face forward holding their heads in a natural position. They were asked to
close their mouths with their normal resting occlusion and their lips together to allow
the tongue to relax onto the floor of the mouth and not to swallow during the
exposure. The peak kilo voltage was adjusted to optimise the contrast of both hard
and soft tissues. Generally, for an average built subject, the voltage and exposure
times were kV 71, mAS 15, 0.3 seconds and for those more obese - kV 77, mAS14,
0.4 seconds. Magnification was 1:1.1 for all films. Radiographs were taken with the
subject exhaling slowly from a deep breath by radiographers familiar with the
procedure. The films were taken using a 24X30 fast speed cassette with Agfa© Ortho
H film and Curix® Standard screens (Agfa Ltd).
60" 1 $ nm
Mid sagittal
Plane'
X ray Source Patient in
Head Positioning Device
Fig 8: Technique of performing cephalometry
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Measurement
In this study the reference work for all points and planes used was by Rakosi (1982).
All radiographs were secured with tape on a light box. Acetate tracing paper was
placed on the radiograph and the points, lines and angles traced by hand using a fine
tip permanent pen (0.5mm) and measured using a ruler (millimetre markings) and
protractor. All measurements taken were recorded manually on a data collection sheet
separately for each subject and converted to life size.
Cephalometric landmarks are represented in Fig 9 and planes in Fig 10. Table 22
shows the measurement abbreviations with their definitions.
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Fig 9 Cephalometric Points of Reference
(1 =Na; 2 =ANS; 3 =point A; 4 =point B; 5 = Gn; 6 - RtGn ;7 = H;8 = C3;9 = Post. Phar.
wall; 10 = Ba ; 11 = Ar; 12 = PNS; 13 = Sella; 14 = tip of tongue; P = porion)
Fig 10 Cephalometric Planes and Angles
(1 = Go-Gn; 2 = H-RtGn; 3 = H-MP; 4 = C3-H; 5 = Go-Ar; 6 = PNS-Ba; 7 = Int max length; 8 =
Go; 9 = ANS-PNS; 10 = SN-Ba; 11 = SNA; 12 = SNB; P = Porion)
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Table 22: Abbreviation of Cephalometric Distances and Angles
ABBREVIATION DEFINITION
Go-Gn Distance from gonion to gnathion
Go-Ar Distance from gonion to articulare - the
intersection of a line along the posterior border of
the mandibular process and the temporal bone
ANS-PNS Distance between anterior nasal spine and
posterior nasal spine
PNS-Ba Horizontal distance from posterior nasal spine to
basion
H-MP Distance from the anterior-superior point of the
body of the hyoid bone perpendicular to
mandibular plane (a plane constructed from
gnathion to gonion)
C3-H The distance between the inferior and anterior tip
of the C3 vertebra and hyoid
H-Rtgn Distance from hyoid to retrognathion (most
infero-posterior point of the mandibular
symphysis)
ANSFOP Anterior maxillary length, vertical line between
functional occlusal plane and anterior nasal spine
GnFOP Anterior mandibular length, vertical line between
gnathion and functional occlusal plane
Int max length Internal maxillary length - linear distance
measured along the facial occlusive plane from
the intersection with tongue tip anteriorly to
where it intersects posterior pharyngeal wall
Post max height Post maxillary height - perpendicular distance
between ANS-PNS plane to Gn-Go plane which
passes through the point where functional
occlusal plane intersects the posterior pharyngeal
wall
SNA Angle between lines from sella to nasion and
nasion to point A (subspinale)
SNB Angle between lines from sella to nasion and
nasion to B (submentale)
NS-Ba Angles between lines from nasion to sella and
sella to basion, cranial base angle or cranial base
flexure
ANB Angle difference between SNA and SNB which
indicates skeletal class (1 - orthognathic; 2 -
retrognathic; 3 - prognathic
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3.2.3 Reproducibility
All studies were scored blind to index/control status and sleep study result and a
research assistant performed the blinding.
Two measurers scored all studies (MV, RR) and had 3 calibration sessions together
prior to performing their number ofmeasurements independently.
No facilities were available for digitisation.
Although cephalometric measurements are made in accordance with strict criteria,
there is a subjective element in performing and measuring radiographic tracings. This
is due to variability in the quality of the radiographs in terms of exposure (film
density and sharpness), rotation in the cephalostat, imprecise anatomic definitions of
landmarks, degree of osteoporosis in the subject, presence or absence of teeth and
oedema in soft tissue in the upper airway as well as in the experience of the measurer.
Therefore, inter-rater and intra-rater reliability was evaluated by reanalysing a
randomly selected number of studies as follows: 10 radiographs originally traced by
Operator 1 (MV) retraced by Operator 2 (RR); 10 radiographs originally traced by
Operator 2 (RR) retraced by RR. Operator 1 (MV) also retraced 10 cephalograms that
she had originally scored. All reassessments were done blinded to previous outcome
and at least 2 weeks apart.
Results for inter- and intra-rater reproducibility for four measurements and 3 angles:
is shown in Table 23. The correlation coefficient (using Spearman's rank correlation)
for both inter- and intra-rater scores was high. Additionally, the mean differences
between the initial (measurement 1) and subsequent measurements (measurement 2)
demonstrate high reproducibility.
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Inter-rater Reliability (n = 20)
GoGn 81+5 80+3 ±2.6 0.8 0.004
GoAr 60±6 58+7 ±2.5 0.95 <0.0001
ANSFOP 32+3 32+4 ±1.9 0.8 0.006
GNFOP 47+3 47+4 ±3.5 0.95 < 0.0001
SNA 81+4 79+3 ±2 0.8 0.005
SNB 78+4 78+4 ±2 0.93 < 0.0001
NSBA 132+6 131+5 ±2.5 0.8 0.004
Intra-rater Reliability (MV) (n = 10)
GoGn 81+5 80+3 ±1.6 0.8 0.004
GoAr 60.4+6 58+7 ±2.3 0.95 < 0.0001
ANSFOP 32.5+3 32+4 ±1.5 0.8 <0.0001
GNFOP 47+3 47+3 ±0.8 0.95 <0.0001
SNA 81+4 79+3 ±2 0.8 0.005
SNB 78+4 78+4 ±1 0.94 <0.0001
NSBA 132+6 131+5 ±3 0.82 0.004
Intra-rater Reliability (RR) (n = 10)
GoGn 80+4 82+7 ±2.3 0.93 < 0.0001
GoAr 59+8 59+9 ±1.7 0.93 <0.0001
ANSFOP 33+3 33+3 ±1.1 0.87 0.001
GNFOP 43+3 44+2 ±1.5 0.75 0.012
SNA 83±6 82+5 ±1 0.97 <0.0001
SNB 80+4 79+4 ±1 0.9 0.001
NSBA 126+7 127+7 ±0.8 0.93 <0.0001
All measurements in mm exceptfor SNA, SNB andNSBa measured in degrees
The cephalograms for the subjects included from the SIDS study were all scored by
one operator (MV) who was blinded to case status.
Random method error in the series of radiographs was assessed using Dahlberg's
method (Dahlberg 1940) and ranged from 0.46 to 1.6 mm and 0.035 - 0.64 degrees.
Systematic error, which is revealed when applying a t-test at the 10% level (Houston,
1983), was also assessed. Houston's coefficient of reliability was calculated for all




3.3.1 Technique of measurement and measurement parameters recorded
Home - based Sleep Studies
Home-based sleep study monitoring was used to obtain a diagnosis of OSAHS in 7%
(n=l 6/228) of the cases.
This was performed using the limited sleep study system Edentrace (EdenTec Model
3711 Digital Recorder, Nellcor, Eden Prairie, Minnesota, USA) that has been
extensively validated against polysomnography (Parra et al 1997; Whittle et al 1997).
This device records oronasal airflow using a thermocouple, chest wall movement by
electrical impedance, heart rate using an electrocardiogram, and finger pulse
oximetry. There is no EEG recorded.
Patients are instructed in the application of the system by the sleep technician on the
afternoon of their study and then sleep overnight at home. The equipment is returned
the next morning. Patients are requested to keep a note of the time they retire in the
evening and the time at which they rise. This time in bed is then assumed to represent
roughly the total sleep time.
All information recorded during the night is stored electronically. This is subsequently
downloaded, printed out as a trace on paper and scored manually with frequencies of
respiratory events calculated per hour of recording.
Apnoea is defined as the cessation of airflow for > 10 seconds and hypopnoea as a
reduction of > 50% in chest wall movement for > 10 seconds. An apnoea-hypopnoea
index thus obtained is considered significant for sleep disordered breathing if it
measures greater than 30 events per hour.
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In-lab Polysomnography
Two h undred and n ine subjects ( 92%) underwent i n-lab p olysomnography. Studies
were performed in soundproofed and electrically screened bedrooms at the Edinburgh
Sleep Centre (hospital-based). (The three remaining subjects are discussed below).
Sleep was recorded using electroencephalography (EEG), electro-oculography (EOG)
and electromyography (EMG) using bipolar signals from silver chloride surface
electrodes. EEG was recorded using the 10/20-electrode placement system (Cooper et
al 1980) from 2 scalp sites - Cz/Pz. Frontal EEG was also recorded using 'mixed'
channels comprising EEG/EOG signals (Cz/Fpl, Cz/Fp2). The EOG was recorded
from electrodes placed at sites on the outer canthus of the eye and Fpl and Fp2. This
allows both horizontal and lateral eye movements to be monitored. Submental EMG
was recorded using 2 electrodes placed on the belly of the genioglossus. A grounding
electrode was placed at Fpz. Electrodes placed on the right and left anterior tibialis
recorded leg EMG. All signals were fdtered using a high and low bandpass in order to
reduce artefact in addition to 50Hz notch filtering. The aim was to achieve electrode
impedances of less than 5 kOhms.
3.3.2 Sleep staging and scoring of respiratory events
With the exception of oxygen saturation, all sleep studies were scored manually using
standard in-lab definitions (Gould et al 1988; Cheshire et al 1992).
Sleep was staged in 30-second epochs using the criteria developed by Rechtschaffen
and Kales (1968). Sleep stages were classified from 1 - 4, REM sleep, awake and
movement time and are defined below.
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Awake (Fig. 11): the EEG comprises alpha activity (8 - 11 Hz (cycles per second))
and / or low voltage, mixed frequency activity (beta waves greater than 1 6 Hz) for






Fig 11: Example of Awake EEG
Stage 1: This is a transient sleep stage comprising relatively low voltage, mixed
frequency EEG. More than 50% of the epoch should consist of theta EEG frequencies
(4 - 7Hz). There is an absolute absence of clearly defined K complexes and sleep
spindles. Slow eye movements may be present (approximately 7 seconds in
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duration) - rapid eye movements are absent. Tonic EMG levels are below those of
relaxed wakefulness.
Stage 2 (Figl2): is defined by the presence of sleep spindles and/or K complexes and
the absence of sufficient high amplitude, slow activity to define the presence of
stages 3 and 4. 50% of the epoch must comprise EEG frequencies in the theta range
(4-7Hz). Sleep spindles must be minimum 0.5 seconds (up to 2 seconds) duration and
comprise sigma frequencies (12 - 15 Hz). K complexes are EEG waveforms with a
well-delineated negative sharp wave, which is immediately followed by a positive




Fig 12: Example of Stage 2 Sleep
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Stage 3: At least 20% but not more than 50% of the sleep epoch consists of delta
waves (0 - 3Hz) not less than 75 uV in amplitude. Sleep spindles may or may not be
present.
Stage 4 (Fig 13): The EEG record shows more than 50% of the epoch comprising
waves of 0 - 3 Hz which have amplitudes greater than 75 uV. Sleep spindles may or





Fig 13: Example of Stage 4 Sleep
Stage REM (Fig 14): This stage is defined by the appearance, concomitantly, of
relatively low voltage, mixed frequency EEG activity and episodic rapid eye
movements. The EEG pattern resembles that of Stage 1. However, the vertex sharp
waves are not prominent. Distinct 'saw-tooth' waves are often present in vertex and
frontal regions in conjunction with bursts of REM. Alpha waves are prominent and
the frequency is generally 1- 2 Hz slower than during wakefulness. There is an
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absolute absence of sleep spindles and K complexes. REM should not be scored in
the presence of relatively elevated tonic mental-submental EMG activity although
phasic twitches do occur. In epochs where there are no rapid eye movements but the
remainder of the record has the appearance of REM sleep, REM sleep should be
scored provided 3 minutes has not passed since the last rapid eye movement. REM
sleep always follows stage 2 or 4 sleep.
Rechtschaffen and Kales (1968) discuss more complex aspects of scoring REM
sleep.
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Movement time is a term used when more than 50% of a sleep epoch consists of
movement artefact and the underlying stage cannot be determined from any EEG or
EOG channel.
Normal young adults with good sleep hygiene will generally have a sleep
architecture comprising less than 5% of awake time; 2-5% of stage 1, 45-50% stage
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2, 3 - 8% stage 3, 10-20% stage 4 and 20 - 25% stage REM sleep (Carskadon and
Dement 1989).
Patients with severe sleep disordered breathing often have disrupted sleep alternating
between Stage 2 and awake. This presents a potential scoring difficulty according to
the Rechtschaffen and Kales (1968) criteria that suggest Stage 1 always precedes
Stage 2 after an awake period. In such cases, I followed this laboratory's policy,
which is to score these epochs as stage 2 if they meet criteria.
Respiratory Events
These events are classified as central, mixed and obstructive apnoeas and
hypopnoeas.
Central events are defined as the complete cessation of respiratory movement and
flow for 15 seconds (some authors use 10 seconds)
Obstructive apnoea is defined as the complete cessation of flow for a minimum of
10 seconds but with continued respiratory effort throughout the apnoea.
Mixed apnoea is defined as the complete cessation of flow for a minimum of 10
seconds with respiratory effort initially absent at the beginning, but returning
midway through the apnoea.
Hypopnoea (Fig 15) is defined as a minimum 50% reduction in thoracoabdominal
movement for a minimum of 10 seconds.
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Definitions of hypopnoea differ between laboratories. Some use a 50% reduction in
flow as the guideline and others require an additional minimum 4% oxygen
desaturation. The above definition has been validated in a series of patients with
clinical features of sleep apnoea but who do not have apnoeas (Gould et al 1988) and
is accepted as the current definition by the American Academy of Sleep Medicine
(1999). The total number of apnoeas and hypopnoeas is calculated and divided by
total sleep time to give the apnoea and hypopnoea index per hour of sleep (AHI).
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The frequency of oxygen saturation dips during sleep (Sp02) of 2, 3 and 4 % from
the running peak, along with minimum overnight saturation were analysed using an
automatic desaturation detection algorithm (Compumedics S, Australia).
Oxygen saturation whilst awake (Sa02) was measured manually from the oximetry
channel prior to sleep onset on the overnight polysomnography where relevant.
Arousals were not scored as part of this work.
3.3.3 Reproducibility
All studies were scored blind to index and control status.
A research assistant (MV) not involved in the study performed the blinding.
Three different operators scored studies over the period 1997 - 2002 (PB, NMcA,
RR). Although sleep stages and variability in breathing is scored according to strict
criteria as outlined above, there is a subjective element in marking such events. This
is due to variability in the quality of overnight recordings, unpredictability in the
occurrence of respiratory events, arousals and sleep patterns found in the study
population compared with a textbook pattern as well as in the experience of the
scorer.
Therefore, inter-rater and intra-rater reliability was evaluated by reanalysing a
randomly selected number of studies as follows:
9 studies originally scored by Operator 1 (PB) rescored by Operator 3 (RR)
9 studies originally scored by Operator 2 (NMcA) rescored by Operator 3 (RR)
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12 studies originally scored by Operator 3 (RR) re-scored by RR (blinded to previous
outcome) after a period of 3 months.
Results for inter-and intra-rater reproducibility for four criteria: AHI, REM-time,
TST and sleep efficiency is shown in Table 24. The correlation coefficient (using
Spearman's rank correlation) for both inter- and intra-rater scores was high.
Additionally, the mean differences between the initial (score 1) and subsequent score
(score 2) for operator 3 (RR) demonstrate high reproducibility.
Table 24: Scoring reproducibility for AHI, REM-sleep time, TST and Sleep
Efficiency









Inter-rater Reliability (n = 18)
AHI (per hour slept) 18 (24) 18 (24) ±2 0.91 < 0.0001
REM-sleep (mins) 69 (24) 76 (29) ±11 0.92 <0.0001
TST (mins) 336 (50) 339 (60) ±25 0.79 <0.0001
Sleep Efficiency (%) 75 (10) 75 (13) ±4 0.808 < 0.0001
Intra-rater Reliability (n = 12)
AHI (per hour slept) 21 (17) 21 (18) ±2 0.91 <0.0001
REM-sleep (mins) 86(15) 86(15) ±6 0.83 0.001
TST (mins) 391 (53) 390 (55) ±4 0.94 < 0.0001
Sleep Efficiency (%) 84(11) 84(11) ±0.9 0.97 < 0.0001
Finally, one index case had OSAHS diagnosed initially on overnight oximetry and
two index cases were diagnosed on the basis of an AHI detected by a nocturnal trial
of Autoset T®. These patients were not initially studied at the Scottish Sleep Centre
in Edinburgh, but the diagnosis was considered sufficiently reliable to allow for
inclusion in the study as both patients had all the hallmarks of OSAHS, had been
commenced on CPAP therapy and were continuing on treatment.
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3.4 DNA Extraction
3.4.1 Blood collection and storage
Venesection was performed on all subjects in the study at the initial interview.
20 mis of blood was collected after venepuncture at the cubital fossa using a 23gauge
needle and vacuum collection system directly into 2 x 10ml (or 4x 5ml) EDTA
(ethylenediamine t etraacetic a cid) t ubes. B lood t ubes w ere 1 abelled w ith t he n ame
and date of birth of each subject, or alternatively they were labelled with the
subject's study number.
Blood collected on subjects between 1997 and 2000 was subsequently packaged and
sent directly by first class post to Oxford where it was stored and DNA extraction
was performed (see section 3.4.2 below and Appendix 6).
Blood collected in 2001 - 2002 was stored in a -80°C freezer within hours of
venesection in the Edinburgh Wilkie Laboratory, from which it was taken for
processing.
Blood collected from subjects involved in the SIDS study was centrifuged and the
red cells and plasma decanted and stored separately in Eppendorf™ tubes in a -80°C
freezer. For DNA extraction purposes, the red cell and plasma portions were
reconstituted at room temperature.
Prior to DNA extraction and archiving at the Wellcome Trust Research Facility,
Edinburgh, all samples were labelled by code only so that no personal identification
was possible at the laboratory during processing.
3.4.2 Method of DNA extraction
Two methods of DNA extraction were employed using two different commercially
available kits.
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Blood samples collected between 1997 and 2000 (n=138) were processed at the
DNA Extraction Core Laboratory in the Wellcome Trust Centre for Human Genetics,
Oxford using the Wizard ® R Genomic DNA Purification Kit (Part # TM050;
Promega ™; http://www.promega.com). DNA was extracted from frozen 10ml
sample volumes of blood. The procedure was based on cell lysis, isolation of white
blood cells, nucleic lysis, protein precipitation and DNA extraction followed by an
ethanol wash. DNA was rehydrated using a rehydration solution and incubated at
65°C for one hour (see Appendix for protocol). DNA was then stored frozen at -
20°C until required.
The DNA samples were transported to the Wellcome Trust Clinical Research Facility
Genetics Core Laboratory in May 2002 and subsequently stored in a -80°C freezer
until analysed.
Working stocks of DNA were prepared at 50ng/ul. Measurement of mean purity
using a spectrophotometer (at 260/280 A) gave a result of 1.6 - 1.7 for all samples.
Blood samples collected in 2001 - 2002 (n= 73) and blood samples from the SIDS
study (n = 17) were processed directly at the Edinburgh Wellcome Trust Clinical
Research Facility Genetics Core laboratory using the Nucleon Extraction and
Purification Protocol (Product Code: Nucleon BACC3 RPN 8512 for extraction of
DNA from 10 ml ofwhole blood; © Amersham International pic).
The procedure involved cell lysis, deproteinisation, DNA extraction; DNA
precipitation; DNA washing and DNA resuspension (see Appendix 6 for protocol).
Blood was taken out of storage and allowed to defrost at room temperature. Before
the extraction procedure was commenced, lOOpl of blood of each sample was spotted
onto a Whatman FTA card, numbered and dated. The cards were stored at room
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temperature in sealed bags containing silica desiccant. This procedure is part of the
quality control protocol of the laboratory to enable a check DNA at the start and end
of the extraction process, but was not required in this study.
Once extracted, the DNA in solution was placed on a rotary wheel and allowed to re-
dissolve (one week) prior to storage at -2° to -8°C in the refrigerator (working stock)
or - 40°C (master stocks).
Working stock was prepared as described above and the concentration of DNA was
measured using the spectrophotometer as above.
Blood Donor Panels
The DNA in the two 96-DNA array panels was received extracted and purified by
ECACC. Their process yields high molecular weight material as verified by agarose
gel electrophoresis. The composition of each 96-sample array is completely defined
and standardised by ECACC so that each product lot will be identical. The identity of
each product lot is checked using STR (short tandem repeat) DNA profiling.
3.5 Genotyping
Two different techniques were used to obtain data on genotype. For Apolipoprotein
E, Polymerase Chain Reaction - Restriction Fragment Length Polymorphism (PCR-
RFLP) was used and the remainder of the gene polymorphisms in the study
(ADRB2; TNF-a; GHR; 5HT2A) were determined using the TaqMan-based allelic
discrimination assay (see 3.5.2 below). At present, an assay is not available for
Apolipoprotein E using the latter technique.
Except where noted, staff of the Genetics Core did all following procedures. Twenty-
five percent of DNA extractions as above were performed by me (RR) as well as the
PCR-RFLP under the supervision ofAC.
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3.5.1 Polymerase Chain Reaction - Restriction Fragment Length
Polymorphism Analysis (PCR-RFLP)
A genotyping procedure developed by Ossendorf and Prellwitz (2000) was used to
examine the APOE alleles in the study sample. The technique represents a substantial
improvement on previous PCR-RFLP techniques for APOE, which used only the
Hhal restriction endonuclease site resulting in small fragments (19-91 base pairs)
with subsequent poor resolution on agarose gel and other technical difficulties. This
has in the past led to a high rate ofmisclassification (Lahoz et al 1996).
The new technique uses the primers E2mut and E3 to amplify a 318 bp region of the
APOE gene t hat c ontains a v ariable n umbers o f r estriction s ites d epending o n t he
allele (E2, E3 or E4) and uses two enzymes for the digestion process: Haell and
4/7/77.
The two primers used in the amplification process were:
1. Upstream primer E2mut (forward primer):
5' ACT GAC CCC GGT GGC GGA GGA GAC GCG TCC
(the underlined sequence differs from the genomic sequence, which creates the AflHI
recognition site in the amplified fragment)
2. Downstream primer E3 (reverse primer):
5' TGT TCC ACC AGG GGC CCC AGG CGC TCG CGG
The actual sequence of the PCR product is shown in Fig 16.
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* The two variable positions are highlighted - the first is the cleavage site for Afllll
and the secondforHaell
Digestion of the PCR product by Haell and Afllll results in fragments of variable
size depending on the allele. Table 25 shows the RFLP pattern allowing for allele
and genotype identification.
Table 25: PCR-RFLP pattern for APOE using Haell and Afllll
RFLP (base pairs) according to enzyme
Genotype Afllll Haell
E2 E2 231 267
E3 E3 231 232
E4 E4 295 232
E2 E3 231 232 AND 267
E2 E4 231 AND 295 232 AND 267
E3 E4 231 AND 295 232
Preparation of the PCR Reaction Mixture
96 well plates were used for the PCR. Each well contained 50 pi of mixture
comprising 5 pi of lr|g/ul ofDNA/H20 added to 45 pi ofmaster mix.
The recipe for the master mix was as follows:
5 pi of lOx PCR buffer (15mM MgC12)
10 pi of 5 x Qiagen™ solution (Q)
1.25 pi of lOpM E2 mut f primer (Genosys™; 41.1nmol+41.1 nmol TE (Tris-EDTA)
= lpM solution)
1.25 pi of lOpM E3 r primer (Genosys™; 30.2 nmol+30.2 pmolTE = lpM solution)
1 ja,l lOmM dNTPs (deoxynucleotide mix; Sigma™ D-7295 0.2mls Lot 60K7029;
1 OmM solution)
0.3 jj.1 Taq polymerase (Qiagen™)
26.2 pi H20
Each 96 well plate was prepared with at least two wells of 50pl H20 to act as
negative controls. Reaction mixtures were incubated at 94°C for 3 minutes and
subjected to 40 cycles of amplification on the Peltier Thermal Cycler (PTC-225
DNA tetrad PCR machine®; MJ Research™) as follows: 94°C 30 seconds; 67°C 30
seconds; 72°C 30 seconds; 72°C for 10 minutes and then were left to hold at 15°C
overnight.
Restriction digests were prepared using lOpl of PCR product in each well to which
was added 0.5 ml of Haell (10U) and 1.2 pi of lOxBSA (Biolabs New England
B900IS) for stabilisation of the enzyme or 2 pi of AflHI (10U). This mixture was
then incubated at 37°C overnight on the Tetrad 37°C Programme. The products of
digestion were prepared for gel electrophoresis as follows: 1 pi Blue juice (loading
dye) added to 5 pi of digest mixture were placed in each well. Controls used were
ELO with Master Mix that had undergone PCR and one well with uncut PCR
product. A 100 bp ladder (Invitrogen™ Cat.No. 15628-019; lug/ml) was included in
each row on the 4% low melting point agarose gel to facilitate the sizing of the RFLP
patterns. The gel was prepared in advance using 15g agarose mixed with 375 ml of
0.5 x TBE (Tris-borate EDTA) and 7 drops of ethidium bromide. Four combs with
26 wells each were set in the horizontal electrophoresis unit (HU-25; SCIE-PLAS™
Ltd) and the gel was poured at room temperature and stored overnight in a cold room
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covered with 0.5 x TBE. The digest products were run at 250V for a maximum of 3
hours.
RFLP patterns on the gel were read under UV light using a Syngene™ camera (Gene
genius bioimaging system®). An example of the results obtained is shown in Fig. 18
in Chapter 4. The allele and genotype were read and scored by two independent
investigators (AC and RR). Data were entered onto a spreadsheet manually and then
transferred to an electronic spreadsheet.
3.5.2. Allelic Discrimination Analysis using TaqMan®
The TaqMan system is a method of following PCR in real time, which can be
adapted for the analysis of DNA sequence polymorphisms (Livak 1995). In this
study single nucleotide polymorphisms in the genes TNF-a, GHR, ADRB2 and 5-
HT2A receptor were determined using this technique. The basic chemistry of the
technique is illustrated below in Fig. 17.
Fig 17: Chemistry of the TaqMan-based Allelic Discrimination Analysis (explained below)
B8V0I88
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DNA was arranged in several 96 well plates and transferred to 2 x 384 well plates for
the assay. DNA quantity in each well was 10r|g in lpl volume.
Two probes are used in this system to detect the bi-allelic SNP of interest. Each
probe is specific to an allelic variant and labelled with a different reporter
flourophore (6-carboxy-flourescein (FAM™) or (VIC™)). The probe consists of an
oligonucleotide, complementary to the sequence of interest, located directly over the
single nucleotide polymorphism. It is labelled at the 5' end with reporter and the 3'
end with the quencher dye tetramethylrhodamine. The proximity of the quencher to
the reporter dye reduces the observed fluorescence signal if the probe is intact. This
also ensures that the 3' end of the probe is blocked and cannot act as a primer.
During PCR, as the forward primer extends, the target specific probe is degraded by
the 5'-3' exonuclease activity of the DNA Taq polymerase. With each round of
amplification, there is an increase in the intensity of fluorescence related to the
accumulation of PCR product.
The presence of two probes, each labelled with a different fluor allows for the
detection of both alleles in a single tube. Because the probes are included in the PCR,
genotypes are determined without any post-PCR processing - a feature unavailable
with most genotyping methods (Landegren et al 1998).
Fluorescence is then measured directly in the reaction well by the ABI PRISM 7900
HT Sequence Detector ™(Applied Biosystems®).
A series of controls are also added to the plates on which the samples are analysed
which contain no DNA template. Thus fluorescence levels are due solely to
uncleaved probe. At the endpoint of PCR, a laser collects a fluorescence spectrum (a
linear combination of the fluorescence emissions from the component dyes) and
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algorithms within the software extract the contribution of each component dye to the
observed spectrum to produce a scatter diagram. On this are plotted the allele-
specific components of each reaction (see Fig. 19 & 20 in Chapter 4).
The statistical analysis is performed automatically. Normalised fluorescence values
(Rn), defined as the amount of fluorescence from each reporter dye divided by that
from the reference dye, are imported into a statistical software package that is part of
the 7900HT® genotyping platform. An increase in signal of either FAM™ or VIC™
indicates homozygosity for that particular allele and an increase in both signals
indicates heterozygosity. Confidence limits of 99.7% must be met for a genotype to
be determined.
Alleles were read and classified on the plots by two readers independently who were
both blind to subject status (SB and AF).
Assay Design
Assay-on-Demand® and Assay-by-Design® (ABI™) were used to design probes
and primers. All are designed to work under standard conditions.
The precise sequences of the unlabelled amplification primers and labelled allele-
specific probes (published in part for Assay-on-Demand® only) used in this study
are copyrighted to the company. Table 26 below shows the SNPs for which primers
and probes were available.
Table 26: SNPs for which probes and primers were designed
Gene SNP position Type of SNP Base Change Type of Assay
ADBR2 + 79 Functional amino-acid substitution in
coding block
C:G Assay by Design
TNF-a -308 Functional promoter polymorphism G:A Assay by Design
5HTR2A 102 Silent mutation T:C Assay on Demand
GHR 561 Missense mutation in cytoplasmic
domain
C:T Assay on Demand
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Each 25(0,1 of PCR contained 10r)g of genomic DNA, 900r|M primers, 250r(M probes
and 12.5pL of TaqMan Universal PCR master mix (ABI), which contains buffer,
uracil-N-glycosylase, deoxyribonucleotides, uridine, passive reference dye (ROX)
and TaqGold DNA polymerase and MGB groove binders
The solution was pipetted into each well of a 96 or 384 well plate using an automated
liquid handling robot.
Amplification was performed using the Peltier Thermal Cycler (PTC-225 DNA
tetrad PCR machine®; MJ Research™). Fluorescence in each well was measured
before and after PCR using an ABI 7900 HT® machine (ABI™) as described above.
3.6 Data Collection and Statistical Analysis
All data collected in the course of this study was entered into a spreadsheet using the
statistical programme SPPS (release 10.0 for Windows, Chicago, Illinois).
For categorical variables, the chi-squared test was utilised to examine differences
between groups.
For continuous variables, comparisons between groups were made using the unpaired
and paired Student's t-test and ANOVA if data were parametric and the Mann-
Whitney U test and Kruskal-Wallis test for non-parametric distribution. The
Wilcoxon Rank sum test was used for paired data that were non-parametrically
distributed.
Tests of correlation were carried out using either Pearson or Spearman's rank tests
depending on whether the variables were parametrically or non-parametrically
distributed respectively. Typical error was calculated for the standard deviation for
the difference in score between two measures, divided by root 2.
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Binary logistic regression was used to assess the association of variables. This test
also allows for forward conditional regression analysis to be carried out examining
the significance of the interaction between covariates and their effect on the
dependent variable.
The significance of frequency differences of OSAHS between genotype discordant
sibling pairs was estimated using one sibling pair from each family by McNemar's
test of symmetry.
Power calculations were performed using the formulae and methods described by
Machin et al 1997 for case-control studies comparing two proportions and using the
odds ratio. The Stanford Power Calculator for case-control studies was also utilised
to check results (http://calculators.stat.ucla.edu/powercalc/). This programme is
based on Xlisp Stat by Jason Bond, based on FORTRAN examples of stplan by
Barry Brown et al. ("bwb@odin.mdacc.tmc.edu) using CGI forms (UCLA Dept. of
Statistics, California, USA). Power was checked at the a = 0.05 level.
2 2
Hardy-Weinberg (H-W) equilibrium was checked using the formula 1= p + 2pq + q
for allelic distribution in the population and the frequencies of minor and major
alleles were compared with published frequencies. Hardy-Weinberg equilibrium
indicates that the genotype frequencies can be determined directly from the allele
frequencies. Failure to demonstrate H-W equilibrium may result from genotyping
errors, inbreeding, g enetic drift, mutation or population substructure (Silverman &
Palmer 2000). H-W equilibrium can be assessed with a goodness-of-fit chi square
test for biallelic markers and for markers with multiple alleles, using a Markov Chain
Monte Carlo method (Guo & Thompson 1992). Significant deviations from the
expected proportions of homozygote and heterozygote classes in a population of case
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subjects may be caused by association with the disease allele. Lack of consistency
with H-W equilibrium among controls should prompt investigation for potential
confounders, including genotyping errors and population stratification.
P-values were corrected for multiple comparisons by the method of Holm (Holm
1979; Aickin and Gensler 1996). This method maintains the experiment-wise error
rate at a = 0.05 and does not assume independence among the multiple tests. The
advantage in this method lies in fixing the type 1 error at a and thereby decreasing
the type 2-error rate, unlike the Bonferroni method which is arguably too
conservative and may result in too many false negatives (see Perneger 1998 for
discussion). Furthermore, comparisons shown to be different by the Bonferroni test
will also be different using the Holm adjustment.
Significance was defined at an experiment-wise error of a < 0.05, two-sided. The
Holm's adjustment procedure for each set of comparisons involved first ordering the
p-values from smallest to largest and assigning a rank number (i) of 1 through to n.
Starting with the smallest p-value, each pi value was compared with its critical value
a/(n-i +1). If the p-value was less than or equal to its critical value, the paired
comparison was considered statistically significant at an experiment-wise a of 0.05.
In this thesis the p-value of each test looking at allelic/genotype distribution between
and within groups is presented with the critical a-value in brackets at which each p-
value is either accepted or rejected. All p-values in this thesis are for two-tailed tests.




4.0 Characteristics of the Study Population
The characteristics of the index cases and their siblings as well as subjects recruited
for the SIDS study are presented below. Results for the subjects recruited for the
SIDS study are not included in the sibling analyses.
The total number of subjects was 228. All subjects were Caucasian.
DNA samples for 17 (34%) of the SIDS subjects and 8 (3%) of the original sibling
study cohort were technically unsatisfactory or inadequate, and they were thus
excluded from the study. All values are expressed as mean +/- standard deviation (+
sd), except for gender, which is expressed in whole numbers as a ratio. The p-value
for the ESS and AHI are not represented as they were the defining values for the
groups.
Table 27: Characteristics of the Study Population (n=228





Sex ratio (M:F) 39:44 24:11 87:23 < 0.00011
Age (years) 48+11 51+9 52+9 0.017
BMI (kg/m2) 27+5 30+7 30+6 <0.00011
Neck circumference (cm) 37+4 40+4 41+4 <0.00011
SBP (mmHg) 129±17 135+17 137+18 0.0021
DBP (mmHg) 82+12 82+10 83+12 0.75
ESS (n/24) 8+5 6+3 15+4
AHI (events/hr) 9+5 37+18 42+23
Sleep efficiency** 78+12 73+13 72+15 0.023
REM time (mins) 72+27 68+27 65+30 0.1
NREM time (mins) 282+51 277+50 274+61 0.44
Sa02 (%) awake 97±2 96±2 96±2 0.01
Lowest Sp02 (%) 91±6 86+8 83+10 < 0.00011
* For comparison of no OSAHS vs definite OSAHS (x2-test for sex and Mann-Whitney test for
continuous variables)
** Sleep Efficiency as a percentage ofthe total time spent asleep divided by the time of the study
1 Significant using Holm correction for afor 24 comparisons (Table 27 and 28)
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Snoring was reported in 58 (70%) subjects without OSAHS, 33 (94%) in the
indeterminate category and all 110 (100%) subjects with definite OSAHS. This
reflects largely the selection criteria applied when recruiting the siblings of index
cases. Other data relevant to the population are presented in Table 28 below.
Table 28: Characteristics of the S tudy Population (n=228)





Snoring 58 33 110
Witnessed 13 20 71
apnoeas
Asthma 2 2 11 0.044
Bronchitis 5 3 11 0.432
Hayfever 9 9 16 0.45
Fractured nose 4 2 10 0.4
Current smoking 21 7 22 0.38
Alcohol (units) 9(IQR 5 - 22) 7(IQR 3 - 20) 10(IQR 5-15) 0.5
n= 49 n = 24 n=74
Diabetes mellitus 0 1 5 0.07
Myocardial
infarct
0 2 11 0.0031
Hypertension 3 6 30 <0.00011
* For comparison of no OSAHS vs. definite OSAHS (%2-test; Fisher's exact test; Mann-Whitney
testfor continuous variables)
If Significant using Holm correction for afor 24 comparisons (Table 27 and 28)
Subjects classified as indeterminate for OSAHS were not included in
subsequent genetic analyses or in cephalometric analyses.
4.1 Cephalometry
Cephalograms were available for 224 of 228 subjects: 148 men and 76 women.
All measurements are corrected for the magnification factor (1:1.1) and represent
actual dimensions in millimetres. The angles SNA, SNB and NSBA are recorded in
degrees.
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As stated above, all subjects indeterminate for OSAHS were excluded from the
analyses: 24 men and 26 women.
Of the remaining 148 men, 19 (13%) were edentulous and were discarded from
subsequent cephalometric analyses. Of the 76 women, 15 (20%) were edentulous and
were likewise not included in analyses presented below. Forward conditional
regression analysis comparing the dentate and edentulous populations including
BMI, age and sex in the analysis showed that the edentulous had a significantly more
backset maxilla (more acute SNA) (p=0.009) and shorter anterior maxillary height
(p< 0.0001). Furthermore, location of the occlusal plane is difficult to determine with
any degree of accuracy in those without teeth and affects other measurements that are
dependent on it such as posterior maxillary height, internal maxillary length and
anterior mandibular height.
Owing to the sexual dimorphism inherent in the skull, results for males and females
are presented separately.
In the male group, 8 subjects were non-snorers and in the female group, there were 3
non-snorers. These 11 subjects in total are represented in Table 29 but not included
in subsequent analyses or regression analyses. Table 29 below shows the bony
measurements and angles for male and female snorers with and without OSAHS as
well as the non-snorers.
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Table 29: Bony measurements and angles for dentate non-snoring and
snoring males and females with and without OSAHS.






75±5 (65 - 87)
77±5 (66 - 86)
78±5 (68 - 85)
Ranee
70+4 (64 - 77)
71±5 (63-84)




56+7 (44 - 73)
57+5 (47 - 65)
56+4 (48 - 62)
46±6 (35 - 58)
46+5 (34 - 60)




50±4 (42 - 61)
51+5 (44-60)
52.5±3 (48 - 56)
48+4 (40 - 54)
48+4 (40 - 54)




44+4 (36 - 55)
44+3 (37 - 49)
48+5 (42 - 57)
42+4 (34 - 50)
41+2 (36-45)




23±6 (6.4 - 36)
19+6(11-30)
19+5 (11-27)









36+6 (26 - 47)
33±4 (29 - 42)





40+4 (30 - 47)
40±4 (35.5-47)
40+7 (31 -54)
37+7 (26 - 52)





29+3 (24 - 34)
29+5 (21 -36)
29+3 (21 -34)





44+4 (26 - 54)








77+6 (64 - 89)
77+4 (69 - 84)
73+6 (66-81)
69±6 (60 - 83)
71+5 (57-79)







40+6 (26 - 52)
39+7 (32 - 52)
35+6 (18-45)
34+7 (23 - 53)




82+4 (72 - 95)
82+5 (72 - 88)
82+4(78-91)






79±4 (70 - 87)
80+4 (71 -87)
79±3 (76 - 85)
75+2 (72 - 80)
77±6 (66 - 86)




129±6 (116 - 144)
128±6(120- 142)
129+6(119- 136)
131±5 (121 - 138)
129+4(122 - 136)
132+4(130 - 136)
(Men: Yes n- 74; No n = 27; Non-snorers n = 8)
(Women: Yes n = 16; No n = 37; Non-snorers n = 3)
* Except for the angles SNA, SNB and NSBA, which are measured in degrees, all other
measurements are in millimetres.
Abbreviations: GoGn = gonion to gnathion distance; GoAr = gonion to articulare distance;
ANSPNS = anterior nasal to posterior nasal spine distance; PNSBA = posterior nasal spine to
basion distance; HMP = hyoid to mandibular plan distance; C3H = cervical vertebra 3 to hyoid
distance; HRGN = hyoid to retrogathion distance; ANSFOP = anterior nasal spine to occlusal plan
distance; GNFOP = gnathion to occlusal plane distance; IntMax = internal maxillary length;
PMAXHT = posterior maxillary height; SNA = sella-nasion-point A angle (maxillary angle); SNB =
sella-nasion-point B angle (mandibular angle); NSBA = nasion-sella-basion angle (cranial base
angle).
Since age and BMI can affect craniofacial growth and structure, these two variables
were included in all regression analyses.
Forward conditional logistic regression for all bony measurements and angles
showed t hat t he d istance o f t he h yoid b one t o t he mandibular p lane was t he o nly
significant factor associated with a diagnosis of OSAHS compared to snoring alone
in the male group (p = 0.01).
In the female group, the same analysis revealed that OSAHS was significantly
associated with a higher BMI (p = 0.002), a greater distance of the hyoid bone from
the mandibular plane (p = 0.038) and greater anterior mandibular length (p = 0.001)
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compared to snoring alone. When conditional logistic regression analysis was
undertaken looking at anterior lower facial height (anterior mandibular and anterior
maxillary height (GNFOP +ANSFOP)) in relation to OSAHS vs. snoring alone, the
association of a longer lower face with OSAHS was significant (p=0.016; OR 1.26;
CI95% 1 - 1.5) and explained 27.6% of the observed variance. When forward
logistic conditional regression analysis was performed using all variables as above,
but substituting GNFOP and ANSFOP with lower facial height alone, only higher
BMI and longer lower facial dimensions were significantly associated with OSAHS,
explaining 49.6% of the variance (p = 0.015 and p = 0.013) respectively.
A comparison by forward conditional regression analysis was m ade between m ale
and female craniofacial dimensions, controlling for age, BMI and a diagnosis of
OSAHS. Not surprisingly, all measurements were significantly shorter in the female
group. The females had significantly more backset mandibles as judged by SNB
compared to men (p < 0.0001). However, there was no difference in the SNA or
NSBA between the sexes.
When subjects with OSAHS alone were examined in relation to the effect of obesity
on craniofacial dimensions (Table 30), the male subjects with a BMI > 30kg/m2 had
significantly greater p osterior maxillary h eight, mandibular r amus h eight a nd h ard
palate length compared to the non-obese. In women the most significantly different
dimensions were the distance of the hyoid bone from C3 in snorers and the cranial
base angle in the group with OSAHS.
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Table 30: Significant Comparisons in Cephalometric Variables between
Obese and Non-0bese Men and Women with and without OSAHS
Variable** BMI < 30 kg/m2 BMI > 30 kg/m2 p-value
Male Non-apnoeic snorers
C3H2 38±4 (n=21) 46+6 (n=6) 0.002*
Male OSAHS
ANSPNS 49+4(n=52) 53+4 (n=22) <0.0001*
GoAr 54+6 60+6 <0.0001*
PmaxHt 39+7 45±7 0.003*
C3H2 40+4 43+5 0.005
NSBA 127+5 131±7 0.013
Female Non-apnoeic snorers
C3H2 32±3 (n=16) 38±4 (n=4) 0.007
Female OSAHS
NSBA 128+4 (n=7) 133+4 (n=8) 0.027
* Significant using Holm correction for afor 14 comparisons
**Except for the angles SNA, SNB and NSBA, which are measured in degrees, all other
measurements are in millimetres.
In order to explore determinants ofOSAHS in siblings, 22 pairs of dentate male sibs,
discordant for the diagnosis of OSAHS were analysed. Results showing a trend
towards association with OSAHS in the male sibs with smaller mandible and longer
distance of the hyoid from the mandibular plane are presented in Table 31 below.
Table 31: Significant Comparisons in Cephalometric Variables between Male
Sibs discordant for a Diagnosis of OSAHS
Variable** Sibs with OSAHS Sibs without OSAHS p-value*
(n = 22) (n = 22)
Age (years) 50+9 51+9 0.54
BMI (kg/m2) 28+4 28+4 0.39
GoGn 82+5 86+5 0.024
GoAr 59+6 63+6 0.031
HMP 26+6 21±6 0.013 (a=0.003)
* No significance using Holm correction for afor 15 comparisons ofbony measurements
**Except for the angles SNA, SNB and NSBA, which are measured in degrees, all other
measurements are in millimetres.
Forward conditional regression analysis controlling for age and BMI showed that
only a shorter mandibular corpus and lower hyoid in relation to the mandibular plane
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were significantly associated with a diagnosis of OSAHS in this group (p = 0.013
and p = 0.006 respectively).
The effect of ageing on the craniofacial complex was examined by dividing the
dentate men and women respectively into two groups: one group over 51 years and
the other group less than 51 years. (This age cut-off was chosen on the basis of
studies which have shown evident morphological changes in the craniofacial
complex occurring around the age of 50 years - see Doual 1997; Behrents 1985;
Macho 1986). Forward conditional logistic regression analysis in the male group
showed only GoAr (mandibular ramus height) to be significantly greater in those >
51 years (p = 0.01). There were no significant differences in any bony measurements
or angles in the female group.
Skeletal Class
Jaw profile is classified as orthognathic (skeletal Class I), retrognathic (skeletal Class
II) or prognathic (skeletal Class III). Classification is based on the difference
between the angles SNA and SNB which is the derived value ANB. Not surprisingly,
female subjects were significantly more likely to have skeletal class II profiles owing
to their backset mandibles compared to males (see Table 32).
Table 32: Distribution of Skeletal Classes between Male and Female Dentate
Subjects
CLASS I CLASS II CLASS III
FEMALES (n=61) 16 40 5
MALES (ii -129) 60 51 18
p=0.004; y2-test; 2x3 contingency table
A comparison of the female subjects with and without OSAHS showed no difference
in skeletal class distribution (%2-test; p = 0.8; 2x3 contingency table). Similarly, there
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was no difference in profile overall between obese and non-obese women (x2-test; p
= 0.3; 2x3 contingency table) regardless of OSAHS diagnosis, nor between women
aged 51 years and over compared to the younger age group (%2-test; p = 0.6; 2x3
contingency table). Results were similar for men. There was no significant difference
in profile distribution between men with and without a diagnosis of OSAHS (x2-test;
p = 0.95; 2x3 contingency table); the obese vs. the non-obese (x2-test; p = 0.3, 2x3
contingency table) and those aged 51 years and over compared to those who were
younger (x2-test; p = 0.23, 2x3 contingency table).
4.2 Blood Donor Controls
As stated previously, information on sex was provided for all anonymous blood
donors and age for half of them. Of the 192 donors whose DNA was utilised in this
study, 50% (n=96) were male (p = 1, x2 - test). Mean age and age range according to
sex is shown in Table 33 below.
Table 33: Mean Aqe and Aqe Ranqe of Anonymous Blood Donors
Males (n = 37) Females (n = 51) p-value*
Mean age + sd (years) 39 + 9 38 + 7 0.36
Age range (years) 24-61 24-54
* Student's t-test, equal variances assumed
The sex distribution between the blood donor controls and the 228 other study
subjects was significantly different (p=0.003, x -test) as was the mean age (p <
0.001).
4.3 APOLIPOPROTEIN E
As discussed in Chapter 3.5.1, the method used for examination ofAPO E carriage in
this population was PCR-RFLP. An example of the gels obtained in the process is
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presented in Fig 18 below. Seventy-eight samples ofDNA were analysed. However,
5 were discarded due to difficulty in reading the gel accurately by either investigator
independently.
Fig 18: Gel showing RFLP patterns for APOE using Haell and Aflll restriction
enzymes
Complete results for 73 subjects were available and the characteristics of the study
population including the Apolipoprotein E genotype and allelic frequencies are
presented in Table 34 below.
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Table 34: Characteristics of the Study Population for Apolipoprotein E










Sex ratio (M:F) 16:17 6:2 23:9 0.04
Age (years) 51+9 47+9 52+10 0.9




37+4 43±4 40+3 0.0031
SBP (mmHg) 133+16 140+20 136±15 0.24
DBP (mmHg) 86+9 78+8 80±12 0.94
ESS (n/24) 7+4 6±3 14±3 < 0.00011
AHI (events/hr) 16+11 43+22 42+19 < o.oooin
Sleep Efficiency 78+11 73+7 71±14 0.027
TST (mins) 367+61 339+30 332±65 0.009
REM time (mins) 68±23 59±16 64+27 0.45
NREM time (mins) 302+47 280+23 269+46 0.003H
Sa02 (%) awake 97+1.5 97±2 96±2 0.24
Lowest Sp02 (%) 90+6 89+2 85+8 0.0011
Genotype N = 33 00II£ N = 32
E3/E3 14 6 14 0.23
E2/E3 5 0 7
E3/E4 12 2 8
E2/E2 0 0 3
E2/E4 2 0 0
Allele VOvoII£ N= 16 II£
E2 7 0 13 0.13
E3 45 14 43
E4 14 2 8
* For comparison of subjects with no OSAHS vs those with definite OSAHS (^2-test for sex and
Mann-Whitney testfor continuous variables)
** Sleep Efficiency is calculated as a percentage of the total time spent asleep divided by the time of
the study
^Significant using Holm correction for afor 14 comparisons
There was no significant difference among groups in the distribution of either
genotype or alleles.
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In order to retest the hypotheses put forward by Kadotani et al (2001) (see Chapter
2.6) the group was divided into those with an AHI greater than or less than fifteen
(Table 35).
Table 35: Characteristics of the Study Population divided by AHI of greater
than or less than 15/hr
Variable AHI <15 AHI > 15 p-value*
ennII3 (n = 50)
Sex ratio (M:F) 8:15 37:13 o.ooi!
Age (years) 48+8 52+9 0.13
BMI (kg/m2) 28+4 27+3 0.56
Neck circumference (cm) 37+4 40±3 o.ooi!
SBP (mmHg) 132+17 136+16 0.337
DBP (mmHg) 87+10 81+10 0.024
ESS (n/24) 8+4 11±5 0.046
AHI (events/hr) 11+3 39+19
TST (mins) 378+56 334±60 0.005!
Sleep Efficiency** 79+11 72+13 0.03
REM time (mins) 72+20 62+25 0.071
NREM time (mins) 306±45 275±45 0.009
Sa02 (%) awake 97+1 96+2 0.017
Lowest Sp02 (%) 93+2 86+7 < 0.0001!
Genotype N = 23 Z II O






E2 2 18 0.080
E3 35 67
E4 9 15
* For comparison of subjects with no OSAHS vs. those with definite OSAHS (%2-test for sex and
Mann-Whitney testfor continuous variables)
** Sleep Efficiency is calculated as a percentage of the total time spent asleep divided by the time of
the study
^Significant using Holm correction for afor 14 comparisons
In order to examine whether those carrying the APOE4 allele differed in any way to
those without it, a further analysis was performed, the results of which are presented
in Table 36.
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able 36: Study Subjects according to Apolipoprotein E4 carriage
Variable ApoE4 -ve ApoE4 +ve p-value*
(n = 49) (n = 24)
Sex ratio (M:F) 33:16 12:12 0.15
Age (years) 51+9 51±8 0.98
BMI (kg/m2) 27+3 27+4 0.97
Neck circumference (cm) 39+4 38±4 0.54
SBP (mmHg) 135+16 133+16 0.73
DBP (mmHg) 83+10 85+12 0.52
ESS (n/24) 10+5 9+5 0.29
AHI (events/hr) 32+21 26±19 0.26
TST (mins) 345+56 357+73 0.45
Sleep Efficiency 74+12 76+14 0.6
REM time (mins) 64+24 68+25 0.53
NREM time (mins) 281±45 294+51 0.3
Sa02 (%) awake 97+2 97+1.5 0.07
Lowest Sp02 (%) 88±7 88±8 0.83
* For comparison of subjects with no OSAHS vs. those with definite OSAHS (x2-test for sex and
Student's t-testfor continuous variables)
Finally, the distribution of alleles in the study group was compared to published
frequencies for the UK population (Table 37). There was no statistically significant
difference between the two groups (p=0.3, x2-test, 2x3 contingency table).
'able 37: Allelic Frequencies in the Study Population vs. a UK population




* From: Corbo and Scacclii (1999)
No cephalometric comparisons were made in this group, as it was not considered
biologically relevant.
Based on odds ratios, the power for detecting a difference in the distribution of
alleles between the groups with or without OSAHS was greater than 80%. However,
the number needed to show a difference between E4 carriage alone based on AHI at
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a power of at least 80% (proportional differences) would have been 469 subjects in
each group.
4.4 RESULTS FOR TaqMan ANALYSES
The technique is described fully in Chapter 3.5.2 and was used for examination of
SNPs in the genes for TNF-a, GHR, ADRB and the 5HTR2A. The graphical analysis
of the alleles is shown in Fig 19 and 20 below. The plot for the serotonin receptor
gene- 2a polymorphism demonstrates the clarity of results for an ABI-designed
primer for commercial use whilst the plot for the ADRB polymorphism was custom-
designed for the study and showed a high rate of drop-out due to failure of the primer
as well as difficulty of delineating the polymorphism category by the plot reader.
The results for TNF-a and GHR are not shown, as the plots were similar to those for
the 5HTR2A.
Results for e ach gene w ill b e d iscussed i n t urn b elow. For all s ignificance 1 evels,
tables were constructed to establish rank and thereby the Holm-corrected a-level at
which the obtained p-value was either rejected or accepted.
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Fig19: Plot of the 5HTR2A promoter polymorphism C/T after TaqMan analysis
Marker: | ~3 Call: f ~3





jf X- ♦ » A*









Fig 20: Plot of the ADRB2 polymorphism C+79G after TaqMan analysis
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4.5 Tumour Necrosis Factor- Alpha
Genotyping results examining the -308 (A/G) SNP for TNF-a were available for 190
UK blood d onor c ontrols (99%) and 2 16 o f the 2 28 study subjects (95%). Of the
blood donor controls, 95 (50%) were male and the mean age was 38 + 8 years.
Population characteristics for the other 216 study subjects did not differ from those
presented in Table 27 above. The sex distribution between the blood donor controls
and the other study subjects was significantly different (p=0.003, x -test) as was the
mean age (p < 0.001).
The distribution of allelic frequencies and genotypes was significantly different
between subjects with a definite diagnosis of OSAHS and all subjects without a
diagnosis of OSAHS (Table 38). Allele distribution in the control group was in
Hardy-Weinberg equilibrium.
Binary logistic regression analysis showed a significant association for the TNF-a (-
308A) allele carriage with male sex (OR 1.6; CI95% 1.03 - 2.34; p=0.036), older age
(OR 1.04; CI95% 1.01 - 1.06; p =0.046) and a definite diagnosis of OSAHS (OR
1.82; CI95% 1.15 - 2.89; p = 0.01). These observations explained 1.5%, 4.6% and
2.4% o f t he v ariance i n t otal. Forward conditional 1 ogistic r egression sh owed t hat
when these three variables were entered into the equation, only age remained
significantly associated with the TNF-a (-308A) allele (OR 1.04; CI95% 1.014 -
1.06; p=0.001).
Logistic regression analysis showed no association of the (-308) A allele with AHI,
ESS, BMI, weight, height, neck circumference or blood pressure. Cephalometric
variable were not included in the analysis, as this was considered biologically
untenable as a hypothesis despite the implication ofTNF-a in bone growth.
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Table 38: Allelic and Genotype Frequencies for TNF-a (-308) A/G
Polymorphism in Subjects with de inite OSAHS vs. those without.
Genotype No OSAHS (n= 269) Definite OSAHS (n= 103) p-value*
G/G 175 (65%) 52 (50%) 0.034
A/G 83 (32%) 44 (43%) (0.025)
A/A 11 (4%) 7 (7%)
Alleles N = 538 N = 206
G 433 (81%) 148 (72%) 0.011
A 105 (19%) 58 (28%) (0.0125)
*X-test; Holmed a-value in brackets (multiple comparisons for data on polymorphisms in
ADRB, GHR, TNF-a and 5-HT-2a)
Twenty-one pairs of sibs discordant for carriage of the A allele (carriage of the A
allele vs. no carriage of the A allele) were discordant for the phenotype of OSAHS
(p = 0.001). All siblings who carried the A allele had OSAHS compared to none of
the non-carriers.
Power for detecting a difference in -308 A allele carriage in the entire group (n =
372) was 67% based on comparison of proportions. To achieve a power of 80% to
detect a difference in allele carriage would have required n = 322 in each group.
4.6 GROWTH HORMONE RECEPTOR
Genotyping results examining the +561 (T/G) SNP for the GHR were available for
192 UK blood donor controls (100%) and 218 of the 228 study subjects (96%).
Characteristics of the subjects did not differ significantly from those outlined above
(4.0).
The sex distribution between the blood donor controls and the other study subjects
was significantly different (p=0.003, x -test) as was the mean age (p < 0.001).
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The distribution of allelic frequencies and genotypes was significantly different
between subjects with a definite diagnosis of OSAHS and all subjects without a
diagnosis of OSAHS (Tables 39). Allele distribution in the control group was in
Hardy-Weinberg equilibrium.
Table 39: Allelic and Genotype Frequencies for +561 (T/G) GHR
Polymorphism in Subjects with de inite OSAHS vs. those without.
Genotype No OSAHS (n= 272) Definite OSAHS (n= 102) p-value*
T/T 84 (31%) 23 (23%) 0.016
T/G 139(51%) 47 (46%) (0.0125)
G/G 49(18%) 32 (31%)
Alleles N = 544 N = 204
T 307 (56%) 94 (46%) 0.011
G 237 (44%) 110(54%) (0.0167)
*£-test; Holmed a in brackets (multiple comparisons for data on polymorphisms in ADRB,
GHR, TNF-aand 5-HT-2a)
Binary logistic regression showed a significant association for carriage of the
genotype G/G with OSAHS (p = 0.008; OR 2.4; CI 95% 1.3 - 4.5). This explained
5% of the variance.
There was no significant association with any other variables except for BMI.
Those with a BMI greater than or equal to 30kg/m2 were significantly more likely to
have the G/G genotype (p = 0.004; OR 4 CI 9 5% 1.5- 8.5; 1 0% variance). The
association ofBMI and OSAHS with the G/G genotype was examined using forward
conditional logistic regression. Only a BMI greater than 30kg/m was found to be
significantly associated with G/G (p = 0.026), explaining 3% of the variance in the




Carriage of the G allele alone was significantly associated with BMI (p = 0.009, % -
test, 2x2 contingency table) as shown in Table 40 below.
None of the bony measurements or angles examined in the craniofacial complex was
associated with the G allele. Posterior maxillary height alone showed a trend towards
being larger in the group carrying the G allele (p = 0.057).
Table 40: Carriage of the +561 G GHR allele in subjects with a BMI greater
than or equal to 30 kg/m2
G-carriage BMI<30(n=151) BMI > 30 (n = 64) p-value*
ABSENT 50 (33%) 10(16%) 0.009
PRESENT 101 (67%) 54 (84%)
*yl - test, 2x2 contingency table
McNemar test for sibs discordant for the G/G genotype did not associate
significantly with a particular phenotype.
The power of detecting a difference in G and T allele carriage in the study group (n =
374) was 47% at a = 0.05. For power to be 80% would have required a total n = 768.
However, power was 93% to detect a difference between subjects with the G/G
genotype compared to those without it.
4.7 SEROTONIN RECEPTOR- 2A GENE
Genotyping results examining the promoter region polymorphism C/T for the
serotonin 2A receptor gene were available for 191 UK blood donor controls (99%)
and 2 18 o f t he 2 28 s tudy subjects ( 96%). P opulation characteristics d id not d iffer
from those presented in 4.0 above. The distribution of allelic frequencies and
genotypes was not significantly different between subjects with a definite diagnosis
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of OSAHS and all subjects without a diagnosis of OSAHS (Tables 41). Allele
distribution in the control group was in Hardy-Weinberg equilibrium.
Table 41: Allelic and Genotype Frequencies for 5FITR2A promoter
polymorphism C/T Subjects with d efinite OSAHS vs. those without.
Genotype No OSAHS (n= 272) Definite OSAHS (n= 103) p-value*
C/C 45 (17%) 12 (12%) 0.397
C/T 138(51%) 59 (57%) (0.05)
T/T 89 (33%) 32 (31%)
Alleles N = 544 N = 206
C 223 (41%) 83 (40%) 0.862
T 321 (59%) 123 (60%) (0.05)
-test; Holmed a in brackets (multiple comparisons for data on polymorphisms in ADRB,
GHR, TNF-cc and 5-HT-2a)
There were no significant associations with any other variables including BMI, age,
sex or blood pressure.
Sibs discordant for genotype were not significantly different in phenotype. Power to
detect a difference in the total population (n = 390) between C and T allele carriage
was 5% at the a = 0.05 level. To achieve a power of 80% would have required 1,377
subjects as cases and the same number for controls.
4.8 Beta- 2 Adrenoceptor
Genotyping results examining the C+79G (Gln27Glu) polymorphisms in the ADRB-
2 gene were available for 177 (92%) UK blood donor controls and 165 of the 228
study subjects (72%). Despite the smaller numbers overall, the population
characteristics (shown in Table 42 below) did not differ significantly from those
presented above in section 4.0. The p-value for the ESS and AHI are not represented,
as they were the defining values for the groups.
167
Table 42: Characteristics of the Study Population with and without definite
OSAHS (n=138)
Variable No OSAHS Definite OSAHS p-value*
(n =65) (n = 73)
Sex ratio (M:F) 30:35 57:16 <0.00011
Age (years) 48+11 52+9 0.04
BMI (kg/m2) 27+4 31+6 <0.00011
Neck circum. (cm) 37±6 41±7 <0.00011
SBP (mmHg) 128+17 139+19 0.003
DBP (mmHg) 81+12 83+12 0.3
ESS (n/24) 7+5 15+4
AHI (events/hr) 10±5 42+23
* For comparison of subjects with no OSAHS vs. those with definite OSAHS (x2-test for sex and
Mann-Whitney testfor continuous variables)
^Significant using Holm correction for afor 8 comparisons
The UK blood donor controls comprised 38 men and 57 women and had a mean age
of 38+8 years.
The distribution of genotypes but not allelic frequencies was significantly different
between subjects with a definite diagnosis of OSAHS and all subjects without a
diagnosis of OSAHS (Tables 43). Allelic distribution in the control group was in
Hardy-Weinberg equilibrium.
Table 43: Allelic and Genotype Frequencies for G+79C ADBR-2
Polymorphism in Subjects with de inite OSAHS vs. those without.
Genotype No OSAHS (n= 242) Definite OSAHS (n= 73) p-value*
G/G 80 (33%) 23 (32%) 0.023
G/C 123 (51%) 28 (38%) (0.0167)
C/C 39 (16%) 22 (30%)
Alleles N = 484 N= 146
G 283 (59%) 74 (51%) 0.096
C 201 (41%) 72 (49%) (0.05)
*X-test; Holmed a- value in brackets (multiple comparisons for data on polymorphisms i
ADRB, GHR, TNF-a and 5-HT-2a)
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There were no significant associations of the C allele with any other variables
including, BMI, blood pressure, age or sex. However, there was a significant
difference in the distribution of the CC genotype (Gln27Gln) between those with and
without OSAHS (Table 44). Binary logistic regression showed that the association of
the C/C genotype with OSAHS was significant (p = 0.009; OR 2.25; CI 95% 1.23 -
4.16). There was no association of the C/C genotype with any variables save for
height in men. Men with the C/C genotype were significantly taller than men without
it (1.79+6 m vs 1.76+6m; p= 0.009).
Table 44: Distribution of the C+79G ADBR-2 Polymorphism in Subjects
with definite OSAHS vs. those without.
C/C Genotype No OSAHS (n= 242) Definite OSAHS (n= 73) p-value*
Present 39 (16%) 22 (30%) 0.008
Absent 203 (84%) 51 (70%) (0.0167)
*%-test; Holmed a- value in brackets (multiple comparisons for data on polymorphisms in
ADRB, GHR, TNF-cc and 5-HT-2a)
Comparison of siblings discordant for the C/C genotype showed no association with
phenotype. Power to detect a difference between C/C genotype in the population
(total n = 315) was 81% at the a = 0.05 level.
4.9 Conclusion
In this chapter, the focus has been on a detailed presentation of results arising from
the study. The next chapter will be devoted to the discussion of the results; potential




This chapter comprises a detailed discussion of results presented in Chapter 4. The
main findings are summarised briefly below and discussed in turn. Not surprisingly,
study subjects with OSAHS differed significantly from those without it in all but a
few minor characteristics. There were significant differences in the cephalometric
measurements between apnoeics and snorers. In the genetic analyses, the APOE s4
allele was not associated significantly with a diagnosis of OSAHS nor was it
significantly more common in those with an AHI>15. The SNPs examined for each
of the 4 other candidate genes in this study (TNF-a, GHR, 5HTR2A, ADRB-2)
showed variable degrees of association with the OSAHS phenotype (Table 45).
Table 45: Summary of p-values (in bold when statistically significant) for
allelic distribution, minor allele carriage and genotype for subjects with and
without OSAHS for the genes TNF-a, GHR, 5HTR2A and ADRB-2.
Gene Allele/Genotype p-value Rank Holm - a
Allelic Distribution
TNF-a A/G 0.01080 1 0.0125
GHR G/T 0.0114 2 0.0167
ADRB-2 G/C 0.096 3 0.025
5-HT-2a C/T 0.862 4 0.05
Minor Allele Carriage
TNF-a A 0.010 1 0.0125
GHR G 0.112 2 0.0167
5-HT-2a C 0.239 3 0.025
ADRB-2 C 0.804 4 0.05
Minor Genotype
GHR G/G 0.006 1 0.0125
ADRB-2 c/c 0.008 2 0.0167
TNF-a A/A 0.276 3 0.025
5-HT-2a C/C 0.76 4 0.05
Genotype
GHR G/G; G/T; T/T 0.016 1 0.0125
ADRB-2 C/C; G/C; G/G 0.023 2 0.0167
TNF-a A/G; A/A; G/G 0.034 3 0.025
5-HT-2a C/T; C/C; T/T 0.397 4 0.05
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All allelic frequencies in the control group were in Hardy-Weinberg equilibrium
(p >0.05). The TNF-a (-308A) allele showed significant association with OSAHS
phenotype.
5.1 CHARACTERISTICS OF THE STUDY POPULATION
5.1.1. Subjects with and without OSAHS
The differences between subjects with and without sleep apnoea were marked and
not surprising. The most significant changes were for the sex ratio, with more men
than women in the OSAHS group. This is what would be expected from the
epidemiology with OSAHS twice as common in men (see Chapter 1, section 1.1). In
addition, those in the OSAHS group had a higher systolic blood pressure in keeping
with the association of OSAHS with raised blood pressure (see Chapter 1, section
1.5).
Examining for genetic associations in siblings reduced problems inherent to
population stratification in some of the analyses. The population studied was
Caucasian. Those who were recruited were largely drawn from Edinburgh and the
immediate environs, with one sibling pair from Glasgow, 2 sibling pairs from Fife
and 5 sibling pairs from Aberdeenshire. This population is generally representative
of t he C aucasian p opulation i n t he U K. According t o t he 2 001 Population R eport
Scotland based on Scotland's Census 2001 (General Register Office for Scotland
2002), of just over 5 million people living in Scotland, 98% were white, 1% were of
Indian origin, 0.3% were Chinese and 0.7% came from other ethnic groups. The vast
majority of people were also born in Scotland (87.1%) with 0.3% being born in
Wales, 1.1% in Ireland, 0.9% in other EU countries and 2.5% elsewhere. According
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to the latest figures from the census, there is significant mobility within the UK itself
with 11.6% of people moving into Scotland, 0.6% of whom move from outwith the
UK. There has been a 2% decline in the Scottish population from 1981 - 2001. Much
of this is attributable to large flows in migration. It is estimated that annually, there
are flows of about 50,000 people each way with the rest of the UK and 20, 000 each
way with the rest of the world. Within the age group of this study (majority in their
40's and 50's), migration and movement within and outwith the country is much
more limited as evidenced by the ageing of the population.
Thus, the study population is broadly comparable in ethnic terms to a random
assortment of UK Caucasian blood donors. This makes it unlikely that inter-ethnic
differences could have a major effect on allelic distribution. The fact that the SNPs
in the genes TNF-a; ADRB-2, 5-HTR2A and GHR were in Hardy-Weinberg
equilibrium in the control group (mixture of UK DNA and Scottish recruits)
mitigates against population stratification. The TNF-a alleles were also not
significantly differently distributed in this group compared to samples from South-
East England and Newcastle (Reynard et al 2000). Short tandem repeat (STR)
profiling, used in forensic work, has shown no practical differences in the Caucasian
population across regions of England and Scotland (Lee et al 1996; Evett et al 1996).
The majority of studies performed in Scotland using genetic association in SNPs
have used a West of Scotland population (e.g. Eskdale et al 2000, Kinane et al 1999,
McGarry et al 1999, Gallagher et al 1997 to name a few). This population is more
homogeneous than that found in the South-East (Lothian (Edinburgh)) and has less
fluctuation and migration to introduce genetic diversity (General Register Office for
Scotland 2001). In addition the fact that Edinburgh has had very significant
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immigration from other parts of the UK would minimise any potential differences
between our patient population and the UK Caucasian blood donors.
5.1.2. Phenotyping
One of the critical issues regarding the population under study is accurate
phenotyping. The factors used to determine phenotype were AHI and Epworth score.
The limitations of using AHI include whether it is the best index of OSAHS,
reproducibility, difficulty in extrapolating results between different centres due to
differing sensors and definitions used, and variation with age and gender (see
Chapter 1, section 1.0 and 1.8).
While there is not universal agreement on its precise definition, AHI remains the
more widely adopted measure for classifying the presence and severity of OSAHS.
Hypopnoea definitions remain disputable and may vary widely from centre to centre
(see for example Manser et al 2002). However the definition we have developed
(Gould et al 1988) and used is widely accepted including by the American Academy
of Sleep Medicine (1999).
In order to minimise the gender and age-related differences inherent in classifying
OSAHS, population-based studies documenting the range of AHI in specific age
categories according to sex were utilised to develop a classification scheme. The
populations used were Caucasian to reflect the race of the study population.
However, the AHI for an individual is also subject to the technique employed in
obtaining it and analysing it and may vary from night to night. The degree of
variation is not consistent. Most studies however, show there are no differences in
the mean AHI in a patient group on the first or subsequent nights (Bittencourt et al
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2001; Aber et al 1989; Bliwise et al 1991; Chediak et al 1996; Dealberto et al 1994;
Dean and Chaudhary 1992; Mosko et al 1988; Rebuffat et al 1994). However, a
proportion of subjects in all of these studies changed their classification of OSAHS
severity from the first to the second nights. This generally occurred in subjects with
milder forms ofOSAHS. This issue was addressed in a study by Le Bon et al (2000),
which showed that the gain in detection of OSAHS with an additional night of PSG
if the first one was negative was 15 - 25%. The value of performing a second night
when diagnosing OSAHS if it was suspected to be mild, was considered less efficient
but potentially helpful by Mendelson (1994).
We p erformed a single overnight study in all p atients (whether using home-based
monitoring or in-lab PSG). The virtue in classifying patients as having OSAHS by
combining both a score for the degree of sleep disordered breathing and a measure
of sleepiness is that those who may be slightly underestimated in the degree of SDB
on a one night study, will nevertheless be appropriately classified. Furthermore, the
existence of an indeterminate score further reduces misclassification by making a
wide distinction between those with definite sleep apnoea and those definitely
without it
All study participants were investigated in the same laboratory, using the same
standard techniques for setting up, recording and scoring events. There was a high
intra-and inter-rater reproducibility for analysing results which were performed blind
to subject status.
Further issues arise with the measurement of sleepiness. Although the ESS is one of
the most widely used and easily administered tests to ascertain a level of
somnolence, it always remains subjective. Olson et al (1997) addressed this issue by
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comparing scores on the ESS, Symptom Checklist 90 and MSLT in patients at a
sleep disorders clinic with diagnoses including OSAHS and narcolepsy. They found
that the ESS was a poor predictor of results on the most objective of the tests, the
MSLT and was influenced by psychological factors. However, Johns - the originator
of the ESS (1991; 1992; 1993; 1994) and Chervin et al (1997) found mild to
moderate negative correlations in ESS with reduced sleep latency on the MSLT. At
present, though neither an ideal nor complete measure of sleepiness, the ESS does
allow for a s lightly more r ealistic a ppraisal o f somnolence i n d aily 1 ife situations,
which other more objective tests may not. It is by far the simplest, most practical and
cheapest of the tools available for general clinical and research use and has been
validated in countless studies. Furthermore sleepiness is the major presenting
symptom of OSAHS (Whyte et al 1989) and the ESS is the best validated and most
widely used measure of subjective sleepiness (see Chapter 1, section 1.7). As long as
its limitations are home in mind, then it is also very useful in evaluating the
diagnosis ofOSAHS.
5.2 CEPHALOMETRY
The p resent s tudy i s t he first toe ompare b ony 1 andmarks and a ngles i n m ale and
female apnoeic and non-apnoeic snorers separately and to examine the differences
between male siblings discordant for a diagnosis of OSAHS. The findings are
discussed under separate headings below.
There are not many papers in the cephalometric literature dealing with OSAHS that
fulfil all the criteria for reproducible methods. The technique for performing
cephalometry is not described in detail in many papers (e.g. European methods for
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taking the radiograph differ from those in America, the UK and Australia), error
measurements are either omitted or inadequately described, and magnification of the
radiograph is generally omitted as is the method for identifying landmarks and
performing tracings. Furthermore, many papers are flawed in the selection criteria of
cases and controls, often fail to include correction for multiple comparisons and
show variation in cut-off points selected to distinguish controls from snorers from
subjects with OSAHS - all of which makes them difficult to compare to each other
(see Miles et al 1996 for discussion - over 30 papers can be identified). In addition,
despite the obvious differences between men and women anatomically, many papers
pool results for measurements without correction for sex, thereby invalidating their
data (e.g. Pracharktam et al 1992). For further discussion of these problems see Miles
et al (1996), who reviewed all papers published up to 1995. For these reasons, many
papers that are quoted frequently in the OSAHS and cephalometry literature are not
included in the subsequent discussion.
5.2.1 Cephalometric Findings in Apnoeic vs. Non-apnoeic Snorers
In t his s tudy, t here w ere few d ifferences b etween males with O SAHS and s imple
snorers with respect to bony landmarks or angles. Significantly, the hyoid bone was
lower in relation to the mandibular plane in those with OSAHS (p = 001).
This finding is comparable to that of Battagel et al (2000) who studied 115
Caucasian UK dentate male subjects, 45 of whom had OSAHS, 46 of whom were
snorers and 24 ofwhom were controls. There was no difference between the OSAHS
and snoring groups in terms of dentoskeletal measurements apart from the hyoid
bone which was significantly more inferiorly positioned in the OSAHS group.
176
These findings are in agreement with previous studies by Andersson and Brattstrom
(1991), Maltais et al (1991), Zucconi et al (1992) and Frohberg et al (1995).
Furthermore, an extrapolation of the work done on subjects originally recruited for
the Bolton-Brush longitudinal study in the USA on orthodontic and craniofacial
parameters by Nelson et al (2003) showed that male snorers, compared to non-
snorers had a more inferiorly positioned hyoid bone throughout life. The importance
of this observation derives from the observation that the tongue mass is more
concentrated in the hypopharyngeal region with a low-set hyoid. This hyoid position
may therefore be a poor prognostic indicator for successful use of mandibular
advancement splints [Lyberg et al (1989) and Mayer and Meier-Ewart (1995)].
There was no difference in bony angles between the OSAHS and snoring groups.
Neither mandible nor maxilla was more retroposed in one group compared to the
other, nor was there any difference in the cranial base angle.
These findings are supported by Battagel et al (2000), Jamieson et al (1986), Battagel
and TEstrange (1996), Steinberg and Fraser (1995) and Robertson (2002) who
looked specifically at the cranial base differences between snorers and OSAHS
patients. The implication of a wider NSBa is the placement of the craniofacial
complex closer to the cervical spine, thus contributing to the r eduction i n airway
space.
Studies addressing specifically the differences and similarities between female
apnoeics and simple snorers are not available and the small numbers reported in the
literature are either subsumed by the larger male group or not discussed separately.
In this study, women with OSAHS had a lower set hyoid bone in relation to the
mandibular plane than non-apnoeic female snorers (p = 0.038). These results and
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their implications mirror those for the male group. Furthermore, women with
OSAHS had a significantly greater lower facial height (mirrored in the greater
anterior mandibular length) compared to snorers. This was not present in the male
group. Reasons for this difference could be accounted for by small sample size (false
positive association), environmental/behavioural influences on the development of
the face (eg 1 ifelong mouth b reathing, n asal o bstruction) b eyond t he s cope o f t his
study and p ossible d ental i nfluences s uch asm issing m olar t eeth e tc (although a 11
subjects in this analysis were dentate). These findings have been reported previously
in male groups with OSAHS (Lowe et al 1986, 1996; Bacon et al 1990; Tsuchiya et
al 1992; Pae & Ferguson 1996). In a recent study, Kawashima et al (2002) found that
children with 25 - 75% of their tonsils visible and who had sleep disordered
breathing had a greater anterior lower facial height and a short nasal floor compared
to controls.
5.2.2 The Associations of Obesity and Cephalometric findings in
OSAHS
In the last decade, increasing attention has been focussed on the different
morphological characteristics of the obese and non-obese craniofacial skeleton.
Male subjects with OSAHS in this study who were obese (BMI > 30kg/m2) had
significantly longer mandibular rami, hard palate lengths and posterior maxillary
heights compared to the non-obese. There was also a trend toward a longer
mandibular corpus, greater distance of the hyoid from C3 anteriorly and a more
obtuse cranial base angle (but these were not significant when corrected for multiple
comparisons). In the female group, the only significant difference between the obese
178
and non-obese subjects with OSAHS was in a more obtuse cranial base angle.
However, the numbers ofwomen with OSAHS were small (n = 15).
In the male population studied, the findings for the posterior maxillary height and C3
to hyoid distance are similar to those in the Battagel et al (2000) study and
Tangugsorn et al (2000). A study by Paoli et al (2001) also showed differences
between 46 obese apnoeics (BMI> 30kg/m2) and 39 non-obese apnoeics which
comprised greater back-setting of the mandible (more acute SNB angle), longer
anterior cranial base measurement and greater mandibular ramus length in the obese
group. However, no corrections were made for multiple comparisons (31 in total),
which when I performed them using the Holm method, left only the hypopharyngeal
space and hyoid to chin distance significantly greater in the obese group.
The study by Ferguson et al (1995) which divided 161 men with OSAHS into 3
groups on the basis of neck circumference (correlated with BMI), showed that the
larger the neck circumference, the longer the maxilla and the mandible. Neck
circumference was also inversely proportional to the skeletal class (as measured by
ANB) and related to the SNB angle (thereby, retrognathia). The overall results of the
study suggested that bony abnormalities were of greater importance in the
pathogenesis of OSAHS in the less obese compared to the obese where soft tissue
parameters such as enlarged tongue and retropharyngeal tissue thickness played a
potentially more significant role. However, the division of the data set by neck
circumference rather than BMI and the use of Pearson's correlation rather than
statistical techniques incorporating correction for multiple comparisons make this
study difficult to compare directly with other reported findings.
179
Why should there be a difference in bony measurements between the obese and non-
obese subjects with OSAHS?
One recent study in obese adolescents (male and female) showed that they had
significantly larger craniofacial parameters and were more prognathic than their age
and sex-matched controls (Ohrn et al 2002). Interestingly, the authors postulated that
growth of the craniofacial complex in the obese population may be largely regulated
by increased levels of circulating IgF-1 acting directly at the level of the bone and
independently of GH. Growth hormone and IGF-1 normally increase during
adolescence. Fasting insulin levels are increased in obese adolescents (and adults)
compared to lean ones and this hyperinsulinaemia chronically suppresses levels of
IGF-binding protein - 1. Low levels of IGFBP-1 may thus lead to an increase in the
bioavailability of free IGF-1, resulting in low circulating GH and total IGF-1 (Attia
et al 1998).
This is in contrast to acromegaly, which may manifest similar changes in bony
structures to obesity, most notably prognathism, but is driven largely by excess GH
although elevated levels of IGF-1 can also exist (Dostalova et al 2001).
However, the changes in acromegaly are very gross (see for example Dostalova et al
2001) and more subtle differences are seen in the obese patient with OSAHS. The
number o f p atients i n t his study w ith p rognathism (Class III sk eletal c hange) w as
very small (18 men and 5 women). The vast majority of men were orthognathic.
These findings compare with those of Ferguson et al (1995) who reported neck
circumference to be inversely related to angle ANB (r2 = 0.03; p <0.05).
It is possible that there may be a small direct effect of GH and/or IGF-1 on bone
growth (and concurrently on soft tissue growth), which may be modulated by the
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patient's genotype for receptor or binding proteins. Alternatively, soft tissue growth
may be primary, and the alterations in the bony skeleton an adaptive compensatory
response, e.g. more obtuse cranial base angle, larger posterior maxillary height and
nasopharyngeal space to accommodate increased soft tissue bulk and allow for
adequate gas exchange.
5.2.3 The Effects of Age on Cephalometric findings in OSAHS
The e ffects o f a ge w ere 1 imited t o a n i ncrease i n t he m andibular c orpus h eight i n
male study subjects over the age of 51 years compared to those who were younger.
No differences were observed between the younger and older female age groups. It is
important when considering the craniofacial morphology in patients with OSAHS to
bear in mind changes that occur with age regardless of pathology and which may be
contributors to sleep disordered breathing as a result of this. Behrents (1985) was the
first to show systematically that the craniofacial complex continued to grow in adult
life using subjects from the Bolton-Brush study. Using subjects from the same
cohort, Nelson et al (2003) showed that the HMP distance increased significantly
with age regardless of snoring status (mandibular height was not measured). This
finding is consistent with two other studies by West et al (1999) and Maltais (1991).
A further study by Kawashima (2002) demonstrated that in male preschool children
with sleep-disordered breathing, the hyoid bone position was situated more
anteriorly, and they had a greater anterior lower facial height compared to girls. The
descending position of the hyoid with age is thought to be the result of the tongue's
enlargement i n r elation to t he i ntermaxillary s pace -at rend p ronounced i n m ales
(Cohen and Vig, 1976; Kollias and Krogstad 1999).
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In the Nelson et al study (2003) there was no significant change with age in the bony
angular measurements of NSBa, SNA and middle cranial fossa alignment from
puberty through to adulthood. A study by Doual et al (1997) investigating the
influence of ageing on craniofacial and cervical morphology in 84 men and 102
women (ages range 21 - 101 years) showed that morphological changes in the
craniofacial complex during adulthood became pronounced at around fifty years in
both sexes. They suggested that bone structures of membranous origin underwent
more significant modification compared with structures of endochondral origin.
Similar findings were shown by Macho (1986).
5.2.4 The Effects of Gender on Cephalometric findings in OSAHS
Differences in the craniofacial complex with gender are well recognised (Behrents
1985; Ursi et al 1993; Kollias and Krogstad 1999; Ingerslev and Solow 1975;
Buschang et al 1983) so it is difficult to understand why numerous studies looking at
OSAHS have lumped results for males and females together (e.g. Pracharktam et al
1992; Douglas et al 1995). Females are smaller at all ages, grow less and have
significantly shorter mandibles than males. Furthermore, mandibular plane rotations
in a forward direction are seen in males with posterior rotations in females
accompanied by compensatory changes in the dentition. At any age, therefore,
women have significantly more backset mandibles than men on average. This was
demonstrated in the c urrent study p opulation, e ven when allowance was made for
BMI, age and a diagnosis of OSAHS. Interestingly, there was no significant
difference overall between men and women in the SNA or NSBA angles.
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5.2.5 Genetic Factors affecting the Craniofacial Complex in OSAHS
In an attempt to examine whether there are certain heritable craniofacial features that
make sleep disordered breathing more likely, the bony measurements and angles for
male sibling pairs discordant and concordant for OSAHS were examined. (There
were insufficient female sibling pairs for adequate power for such an analysis).
There was no significant difference in any of the bony measurements or angles
between brothers concordant for the diagnosis of OSAHS. However, in the 22 pairs
of brothers discordant for OSAHS (equivalent in age, BMI and neck
circumference), those with the diagnosis had a trend towards a shorter mandibular
corpus and mandibular ramus and a lower-swung hyoid in relation to the mandibular
plane. Those without OSAHS, however, were still all snorers, thus limiting the
likelihood of finding cephalometric differences.
These results suggest that though siblings share the same characteristics that
predispose to snoring and sleep disordered breathing in relation to the rest of the
population, additional morphological characteristics are necessary to cause OSAHS
independently of obesity.
The observation that the hyoid is lower in sibs with OSAHS is especially interesting
in light of studies that have shown that children between 7 and 14 who snored had
significantly lower hyoid bones than did non-snoring children (Kulnis et al 2000).
Apnoeic children had also been found to have a longer HMP distances (Shintani et al
1992; Kawashima 2002). Nelson et al (2003) in their longitudinal study of snoring
vs. non-snoring subjects found that snorers had significantly lower-set hyoids
throughout life - from pre-puberty right through to adulthood although the H MP
distance increased throughout life in all subjects. This finding is confirmed for the
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age between 22 and 42 years especially in the male population by Kollias and
Krogstad (1999). It is possible that the low-slung hyoid, related to tongue bulk, is
present from childhood and may predispose toward snoring and apnoea in later life.
Numerous studies examining the adult OSAHS population have shown that the hyoid
is low-slung in this condition compared to either non-snorers or snoring controls
(Battagel et al 2000, Tangugsorn et al 2000; Andersson and Brattstrom 1991, Maltais
et al 1991, Zucconi et al 1992 and Frohberg et al 1995).
The regulation ofmandibular size, especially in postnatal growth, has been discussed
in Chapter 2. Sibs with smaller mandibles may have inherited the less functional
alleles of the GH, GHR, IGF-1 receptor and the various binding protein genes quite
apart from the other regulators of bone growth from sex hormones to Vitamin D.
In respect of whether genetic factors or environment are most important in the
development of the craniofacial complex, several studies have been published
looking at the heritability of the craniofacial complex (Ramsey et al 1992; Byard et
al 1984; Saunders et al 1980; Byard et al 1985; Byard et al 1988; Sorin et al 1991;
King et al 1993). All of these studies demonstrate that a proportion of facial
characteristics are the result of a polygenic mode of inheritance, with a certain
proportion subject to environmental influences or other disease conditions e.g.
perennial allergic rhinitis which may alter growth of the maxillo-mandibular
complex in those who are predisposed to its development (Trask et al 1987); nasal
blockage in early life (Yamada et al 1997).
There have been no extensive studies exploring craniofacial similarities or
differences between siblings with and without OSAHS to date.
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There h ave also b een no s tudies c omparing controls t o subjects with O SAHS and
their relatives. One study examined 51 non-obese relatives (25 males) of patients
with OSAHS and compared them to age, BMI and sex-matched controls recruited
from a GP register (Mathur and Douglas 1991). Unfortunately, only 36 pairs of study
subjects had available cephalograms. The major finding was of a backset mandible
and maxilla in the relatives compared to normal population controls. The authors
suggested that this could possibly indicate a heritable craniofacial structure
predisposing to OSAHS. Unfortunately no mention was made of whether the
population was dentate or not. The angles reported, especially for the SNA were high
in relation to other reported means in the literature for a Caucasian population (e.g.
Battagel et al 2000) which may be related to the small sample size. Regardless of
these points it was the first study to show that there are certain craniofacial features
that may divide the general population into those likely to develop snoring and
OSAHS and those that do not regardless of obesity.
5.2.6 Other considerations
An important consideration in all cephalometric studies is whether the subjects are
dentate or not. In the current study, the edentulous population had a significantly
more backset maxilla and a shorter maxillary height. Whether or not this may
independently contribute to a diagnosis of OSAHS has never been examined. A few
studies are available that have examined the effect of denture wearing over time.
Tallgren and Solow (1984) showed that over a period of 15 years, a change in hyoid
position occurred with denture wearing due to changes in the mandibular and
cervical inclination and craniocervical angulation. Karkazis et al (1997), in line with
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previous studies, demonstrated significant r eduction in anterior mandibular height,
which was especially dramatic in women within two years of starting dentures. There
are only three reports in the literature with respect to edentulism and sleep apnoea,
two concentrate on the production of prostheses for the edentulous (Meyer and
Knudson 1990; Robertson 1998) with the third being a case report on the worsening
of OSAHS with complete edentulism (Bucca et al 1999). Interestingly, in the latter
report, a striking decrease in the anteroposterior oropharyngeal wall distance on
supine cephalometry was shown when the patient had his dentures out. A study of a
further six men (Bucca et al 1999) showed that if they slept without dentures, there
was a marked decrease in the retropharyngeal space, an increase in the AHI and a
decrease in both mean and lowest arterial oxygen desaturation.
Another consideration in cephalometry is the role of ethnicity in the population under
study. In this population, all subjects were Caucasian and came from the Scottish
population which has been subject to genetic influx over the centuries (Picts, Celts,
Romans, Anglo-Saxons and others). A number of studies have explored racial
differences in cephalometric variables (Owens et al 2002;Moate and Darendeliler
2002; Liu et al 2000), some in relation to OSAHS (Will et al 1995). It is important
not to include those of different race in the same analyses. However, Richardson
(1980) in examining Caucasians of different ethnic groups (e.g., Swedish whites vs.
American whites) stated that quantifiable differences between such ethnic (rather
than racial) groups are small and there is an enormous degree of overlap. In such
instances, the greatest differences are to be found in the alveolar and dental areas of
the craniofacial skeleton.
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5.2.7 Limitations of the cephalometric Study
The major limitation of this study, as for all cephalometric studies, lies in the
examination of a three-dimensional structure using a two-dimensional technique.
However, the method is sufficiently powerful to allow for the recognition of trends
and changes in the craniofacial skeleton in a way that makes it comparable to other
studies in similar populations. Furthermore, its relative simplicity, ease of access,
low radiation exposure and low cost as well as its routine use in the practice of
prosthodontics and orthodontics makes it a more practical tool in the investigation of
the craniofacial complex than more sophisticated techniques.
The other limitation of the study comprised the lack of soft tissue measurements in
the study group. These were not performed owing to changes in soft tissue
parameters that are common in patients that use CPAP (Mortimore et al 1996;
Schwab et al 1996). Approximately 50% of the study group were already on CPAP,
which would invalidate the measurements and make comparison between groups
difficult.
Lastly, the study would have been further enhanced if there were age and sex-
matched controls from the normal population. However, this was not the original
study design and the population examined allowed for accurate assessment of
heritable factors in craniofacial structure and confirmed some of the previous





DNA extraction using both techniques documented i s standard. The only problem
arose with storage method of the bloods collected in the SIDS study making 50% of
them unusable. On initial collection, the bloods were spun and the plasma and cell
fractions were stored separately. Recombination of the two components did not yield
sufficient sample volume in 50% of the group. However, the DNA quality in the
samples that could be extracted was adequate to allow for analysis.
5.3.2 PCR-RFLP
There were no significant problems with the technique used for genotyping APOE
alleles. Small alterations were made from the published technique by Ossendorf and
Prellwitz (2000), which are documented in the Method section (Chapter 3, section
3.5.1). O f the 7 8 p atients genotyped, 5 results c ould not bee learly r ead b y either
scorer, independently and so were discarded.
5.3.3 TAQMAN- BASED ALLELIC DISCRIMINATION
The technique itself was not problematic. Primers designed by ABI systems that
were used in the study for GHR and 5HTR2a had minimal dropout on the plates.
Likewise, the primer designed for the TNF-a -308 (A/G) reacted consistently with
the DNA samples. The most problematic primer to construct was that for the C+79G
ADRB polymorphisms, which though passing quality control checks at ABI failed to
bind with the DNA in 38 % of the total sample. At present, the reason for this failure
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has not been fully elucidated but may have a connection to GC-rich regions within
ADRB2 which can also interfere with specificity in annealing in PCR-RFLP.
Approximately 15% of all SNPs that go through the assay-by-design (ABI systems
™) service will experience this problem. A slightly different technique has been
reported in the literature as posing problems with inaccuracies in base calling with
relation to ADRB2 (Humma et al 2000). Reassuringly, alleles in the control
population were in Hardy-Weinberg equilibrium and did not differ significantly from
published frequencies for a UK population mitigating against genotyping error in the
sample used.
TaqMan based allelic discrimination testing has an estimated error-rate of <1 in 2000
genotypes (Ranade et al 2001). This level of accuracy is achieved by ensuring
uniform buffer conditions by making up a large batch of master-mix and utilising a
robot i n t he p ipetting p rocedure t o e liminate sm all e rrors c aused b y h and. E ven a
small error can cause large differences in post-PCR fluorescence values. To correct
for pipetting errors, fluorescence values were measured prior to PCR. Theoretically,
all wells prior to P CR should have equal amounts of fluorescence from e ither the
reporter or reference dyes. However, the amounts tend to vary in practice and can
cause predictable variation in post-PCR fluorescence values. Mean fluorescence
values prior to PCR for each reporter dye are calculated for each plate. If the mean
value of a plate is significantly different from the others, as judged by a non-
parametric Wilcoxon signed-rank test, then post-PCR values for that particular plate
are adjusted accordingly.
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Although reading of the data is not automated in the system used in this study, visual
examination of the plots by two researchers blind to subject status ensured
independent verification of point allocation, and with a high degree of correlation.
The single greatest limitation of the technique is the fact that it is biallelic (ie can
only assay for one SNP at a time). (However, the whole technique of SNP
genotyping is biallelic, as opposed to microsatellite markers or short tandem repeats
that have multiple alleles). In Taqman based allelic discrimination analyses, there are
also problems with probe construction, especially if GC-rich areas in the g ene are
encountered in the area of the SNP, which is the case with APOE and also with
ADRB2. This may affect accuracy and reliability, and in such instances, PCR-RFLP
or DNA-sequencing are currently still the b est available methods. (They were not
conducted in our study due to time and budgetary constraints).
5.4 APOLIPOPROTEIN E
A third of the 73-strong population assayed for APOE was indeterminate for
OSAHS. Not surprisingly, there were significant differences between those with and
without a definite diagnosis of OSAHS in terms of the sex distribution (more men
had OSHAS), neck circumference and lowest nocturnal desaturation. However,
importantly, there were no significant differences between age, BMI and blood
pressure, both systolic and diastolic, at the time of the study. This is an important
consideration in view of the associations of ApoE with increased risk of vascular
disease and lipid metabolism.
Results for the genotype and allelic distributions of the APOE alleles, E2, E3 and E4
show no significant association with a diagnosis of OSAHS in the population
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studied. Reclassification of the group of 73 subjects according to an AHI of greater
than or equal to or less than 15 likewise failed to show a difference in genotype or
allelic frequency between the two groups.
A further hypothesis examined in this group was whether those carrying the APOE4
allele differed in any way compared to those who didn't. There was no difference in
any of the characteristics including AHI, sleep variables, nocturnal desaturation or
blood pressure. The same hypothesis tested previously by Mignot et al (2000)
suggested that those with the E4 allele had a greater AHI (see Chapter 2). The results
obtained in this study support the findings of Kadotani et al (2000) and Saaraleinen
et al (1998) that there are no differences in APOE alleles in OSAHS.
It is important to stress that the distribution of alleles in this study did not differ
significantly from that of a white UK random population (Corbo and Scacchi 1999).
Furthermore, the study was adequately powered to detect a true difference in allelic
frequency between the groups to 90% at the a = 0.05 level.
To detect the difference in APOE4 carriage alone in association with either OSAHS
or an AHI of 15 or greater would require 469 subjects in each group. To date no
study has presented genotyping results in this number with regard to ApoE in relation
to sleep.
Is there a link between sleep-disordered breathing or OSAHS and APOE4?
On the basis of previous results and the current study, it seems unlikely.
As previously discussed in Chapter 2, it appears biologically implausible that
carriage of the E4 allele should be associated with sleep disordered breathing
directly, and might only indirectly influence it. As a thrifty allele it may contribute to
obesity. However, even i f this were the case, differences in the allelic frequencies
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should be - and were not - detected between the obese and non-obese group in this
study and others. The presence of ApoE4 in various conditions ranging from
Alzheimer's disease to neuropathy is suggestive of association rather than of direct
causation. Its contribution to the pathobiology of these conditions is also disputed. It
is possible that it may act as a marker for another disease locus or gene as yet
unidentified and this may go some way toward explaining the variability of
associations from disease to disease and population to population.
Many attempts have been made to link sleep disordered breathing with cognitive
decline in aging (see Bliwise 2002 for discussion) but the link remains tenuous at
best. Of greater interest is the possible role for ApoE4 as a marker of vulnerability
for, or the presence o f, cerebrovascular disease. The role o f ApoE4 in the central
nervous system is complex, but some data suggest that ApoE expression is up-
regulated in response to cerebral ischaemia. Furthermore, a few studies have shown
ApoE4 subtype to be associated with poorer recovery from cardiac by-pass surgery,
haemorrhagic stroke and head injury.
Although one study has associated a significantly higher number of infarcts on brain
MRI in a group ofmen with OSAHS perfectly matched with normal controls (Davies
et al 2001), other studies that have been equally carefully conducted have shown no
increase in SDB in an older population with transient ischaemic attacks compared to
healthy age and sex-matched controls (McArdle et al. 2003). Other studies
examining the risk of stroke in association with sleep-disordered breathing, though
flawed in method, suggest a link (Bassetti and Aldrich 1999).
However, in the light of results presented in this study and previous studies, there is
currently n o e vidence for a d irect a ssociation o fA poE4 w ith O SAHS. Pursuing a
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possible link may not be a fruitful path forward at present and we may be better
served by focussing on genetic aspects of hypertension in OSAHS and the effects of
nocturnal hypoxaemia on vascular endothelial function at a molecular level.
5.5 Tumour Necrosis Factor Alpha
TNF-a is a potent inflammatory cytokine. The main source of TNF-a is activated
mononuclear leukocytes but it is widely secreted by a variety of other immune and
non-immune cell types including fibroblasts, smooth muscle cells, astrocytes and
neurones. Elevation ofTNF-a occurs in many infectious, inflammatory,
autoimmune and neoplastic diseases. An exhaustive list is documented and updated
at the following website:
http://www.bris.ac.uk/Depts/PathAndMicro/services/GAI/cvtokine4.htm
A functional TNF-a gene polymorphism consisting of a guanine (G) to adenine (A)
substitution exists at position -308 in the promoter region. Compared to the wildtype,
the -308A variant results in greater increase in TNF- a production in vitro and in vivo
(see e.g. Louis et al 1998; Bouma et al 1996; Huang et al 1999; Kroeger et al 2000;
Maurer et al 1999).
In this study, the TNF-a -308 A allele was significantly more common in subjects
with a d iagnosis o f O SAHS. C arriage o f t he A a llele w as s ignificantly a ssociated
with the OSAHS phenotype in allele discordant sib pairs, suggesting TNF-a may
have a disease-promoting role in OSAHS. The TNF-a -308 allele was also
significantly more common in the older age group (discussed below). The -308 A
allele was also associated with male sex. This last finding is most likely due to the
higher number of males in the OSAHS group and therefore to be spurious as there is
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no rationale for expecting such an association. Both differences disappear when age
and sex are controlled for in regression analysis.
OSAHS is an inflammatory condition
To date, four studies have demonstrated hypercytokinaemia in subjects with OSAHS.
Vgontzas et al (1997; 2000), Entzian et al (1996) and Liu et al (2000) the results of
which can be summarised as follows:
1. TNF-a and IL-6 are elevated in OSAHS independently of obesity
2. BMI positively correlates with TNF-a and IL-6 levels. This suggests that
these two cytokines may play a role in daytime sleepiness experienced by the
obese in the absence of OSAHS.
C-reactive protein (C-RP) levels have been found to be elevated in untreated sleep
apnoeics without any known comorbidities (Shamsuzzaman et al 2002). C-RP
production is enhanced in the liver by IL-6 and is a more stable marker of
inflammation over a 24-hour period than cytokines. An elevated C-RP level has been
shown to be a strong predictor of cardiovascular disease and is present secondary to
the hypoxaemia of high altitude together with elevated levels of IL-6. C-RP has also
been found to be elevated in obesity secondary t o increased expression of IL-6 in
adipose tissue (Crichton et al 1996; Mohamed-Ali et al 1997; Bastard et al 1999). A
higher BMI has been demonstrated in association with higher C-RP concentrations in
young adults aged 17-39 years, confirming a state of low-grade systemic
inflammation in overweight and obese persons (Visser et al 1999).
C-RP, IL-6 and TNF-a appear to produce their harmful effects by inducing
endothelial dysfunction (Das 2001). TNF-a damages endothelial cells, causes
apoptosis of endothelial cells and triggers procoagulant activity and fibrin deposition.
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TNF-a also enhances the production of reactive oxygen species including inducible
nitric oxide (NO) and decreases myocardial contractility in a dose-dependent fashion
(Das 1990, 1993, 1999).
In the overweight and obese, serum levels of TNF-a , serum-soluble TNF receptor
p55 and serum-soluble TNF receptor p75 have been found to be significantly higher
that in lean subjects (Tsukui et al 2000; Zahorska-Markiewicz et al 2000).
An increased association of the TNF-a -308 A allele with obesity in various ethnic
populations has also been shown, including Pima Indians (Norman et al 1995),
French and Northern Irish (Flermann et al 1998), French Canadians with differential
body fat deposition in line with gender differences (Pausova et al 2000) and Germans
(Brand et al 2001).
In the present study, although no association was found between obesity and the
higher TNF-a secreting genotype, the BMI overall was relatively increased - subjects
without OSAHS had a B MI of approximately 27 compared to those with OSAHS
who had a BMI of about 30. Our negative findings support those of Walston et al
(1999) who examined 424 non-diabetic patients of mixed race at the John Hopkins
Weight management centre in the USA and of Romeo et al (2001) who studied 194
Caucasian patients at an obesity clinic in Rome and found no association of obesity
with the TNF-a -308A allele.
The role of TNF- a in hypertension
Elevated TNF-a levels have been identified as a risk factor for recurrent myocardial
infarction and cardiovascular death and are associated with an increased risk of
stroke (Elkind et al 2002). TNF-a levels have also been correlated with ankle-
brachial index (Bruunsgaard et al 1999) and other measures of atherosclerosis
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(Elneihoum et al 1997) and most recently, atherosclerotic carotid plaques (Elkind et
al 2002). TNF-a levels are elevated in non-diabetic hypertensive subjects compared
to normal controls (Demirbas et al 2002). Samad et al (1999) showed that TNF-a is a
key factor in obesity-linked elevation of plasminogen activator inhibitor 1 in mice.
Because TNF-a is chronically elevated in adipose tissue in obesity and contributes to
insulin resistance and elevated TGF-P, there is a potential that this cascade of events
may lead to elevated plasminogen activator, tissue factor and possibly the activation
of other haemostatic genes that may promote cardiovascular risk (Samad et al 1999;
Das 2002).
Population studies searching for an association between TNF-a gene polymorphisms
and hypertension have been few and contradictory. Pausova et al (2000) in a French-
Canadian group of patients showed an association of the TNF-a -308 SNP with
higher blood pressure in relation to obesity, whilst results for over 641 patients and
710 controls in the Franco-Irish study by Hermann et al (1998) were negative.
There was no association of TNF-a genotype with raised systolic or diastolic blood
pressure within the study group in this thesis.
TNF- a is involved in the generation of sleepiness
TNF-a is known to induce Slow Wave Sleep (SWS) in several species (Kapas and
Krueger 1992; Shoham et al 1987) and TNF-a mRNA and protein expression in the
brain exhibits circadian activity (Floyd and Krueger 1997; Bredow et al 1997).
Takahashi et al (1995) showed that the use of TNF-a antibodies, binding proteins,
soluble receptors or receptor fragments reduce SWS in otherwise normal rats and
rabbits. Fang et al (1997) showed that mice lacking the 55kDa TNF receptor slept
less than normal control strains.
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Studies in human subjects have shown that plasma cytokine levels vary with the
sleep-wake cycle. Darko et al (1995) showed that plasma levels of TNF-a varied in
phase with EEG slow-wave amplitudes. Other studies have shown that TNF-a
levels p eak d uring s leep (Gudewill e t a 1 1 992; E ntzian e t a 1 1 996; V gontzas e t a 1
1999) in young adults. The peak occurs close to the offset of sleep - a rhythm not
present in the older adult.
The only studies to examine TNF-a polymorphisms in the field of sleep so far have
been in relation to narcolepsy (Kato et al 1999; Hohjoh et al 2001a & 2001b; Hojoh
2000). Flowever, the results have been contradictory and have also focussed on the
TNF-a (-857 T/C) promoter polymorphisms as well as the TNF receptor gene (-
196R). No correlation was made with the degree of sleepiness experienced by
subjects.
In this study, the TNF-a genotype in the population did not correlate with sleepiness
as measured by the ESS. However, this is a relatively crude measure influenced by
psychological factors which are absent on more objective tests of sleepiness such as
the MSLT or MWT (Olson et al 1998). The fact that the degree of sleep disordered
breathing did not independently associate with TNF-a A allele carriage, but a
diagnosis of definite OSAHS did (combination of SDB and ESS), suggests that there
may be a potential role for genotype influencing sleepiness.
TNF- a is associated with aging as a risk factor for OSAHS
There is a growing body of evidence that aging is an inflammatory condition.
Enhanced in vitro production of IL-6, TNF-a and IL-lb by mononuclear cells after
mitogen stimulation have been found in the older age group (Born et al 1995;
Fagiolo et al 1993; Grau et al 2001) and population studies have shown that the
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magnitude in increase in the concentration of IL-6 is a reliable marker for functional
disability and a predictor of disability and mortality in the elderly (Ferrucci et al
1999; Harris et al 1999).
Genotype may play a significant role in aging. One study (Bonafe et al 2001) of 700
individuals between 60 and 110 years of age showed a positive correlation of IL-6
levels with age. The IL-6 promoter polymorphism (-174 G/G) that predisposes
toward h igh 1 evels o f t his c ytokine's p roduction d ecreased i n frequency w ith age.
However, this effect was seen only in the male group - an observation that has been
made for other pro- and anti- inflammatory cytokine gene polymorphisms in various
disease conditions such as sepsis (Schroder et al 2000; Lio et al 2002a; 2002b).
The TNF-a -308 SNP has been investigated in only one group of elderly subjects to
date - 250 Finnish nonagenarians (198 women) who all came from the same town
with a population of 182,000 and were compared to 400 healthy blood donors (I8¬
60 years) from the town and the surrounding district. There was no statistically
significant difference between the two groups in genotype, but there was a likelihood
of significant consanguinity and controls were not stratified by decade or sex.
Furthermore, it is possible that by comparing healthy nonagenarians with healthy
young blood donors, that an element of bias was introduced whereby a proportion of
the population with comorbidity who were unable to donate blood or who had
deceased earlier than their same-aged counterparts may have had higher carriage of
TNF2 (speculative).
In this thesis, carriage of the -308 A allele was less common in the (younger) UK
blood donor population than in the older Scottish population studied. The rates of
this allele were 18% in the donors and 24% in the older Scottish controls (p = 0.1, y_2-
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test) (compared with 27%in the OSAHS patients (p = 0.5 vs Scottish controls)). Such
a small and non-significant difference in -308 A allele carriage between blood donors
and Scottish controls suggests that it is not age alone which is responsible for
increased TNF2 carriage in those with OSAHS. Furthermore, any such difference
would be unlikely to account for the difference in carriage of the -308 A allele by
OSAHS phenotype in allele discordant sib pairs. Thus, there appears to be a genuine
association of this allele with OSAHS, apart from its association with older age. This
is borne out by a significant association of the A allele with OSAHS even when age
and sex are controlled for.
This study has several limitations. As a case-control study, it can only demonstrate
an association of the -308 A allele with OSAHS and not causality. However, carriage
of the A allele was significantly associated with the OSAHS phenotype in allele
discordant sib pairs and this presents the strongest evidence that TNF-a may have a
disease-promoting role in OSAHS. There may also have been residual confounding
by other conditions affecting the prevalence of the -308 A allele in the OSAHS
population. All subjects were asked to report associated medical conditions by
questionnaire on enrolment into the study. The prevalence of conditions including
bronchitis, diabetes mellitus and known ischemic heart disease in the OSAHS
population, though higher than in the non-OSAHS population was low - 10%, 5%
and 10% respectively.
Furthermore, the distribution of the G and A alleles between the Scottish OSAHS
and Scottish non-apnoeic controls was non-significant (p = 0.5) as was the difference
between the latter group and the UK blood donors (p=0.1). All allelic and genotype
frequencies for the control group as a whole were in Hardy-Weinberg equilibrium
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according to published information (see e.g. Allen 1999; Reynard et al 2000),
mitigating against genotyping errors or problems with population stratification.
Allelic frequencies, when compared to published UK data for Caucasians for TNF-a
were also not significantly different excluding bias based on ethnicity (Reynard et al
2000). The power of the study was also adequate to determine a difference in allelic
frequency (two-group continuity corrected X2-test of equal proportions showed
power of 99% at a = 0.05 level). Although the sleep disordered breathing status of
the control group was unknown, this would tend to dilute the reported observation
rather than strengthen it.
Finally, it should be borne in mind that TNF-a -308 has been found to be in linkage
disequilibrium with HLA class I and 11 alleles, the class III region which encodes
several components of the complement system and the MHC class IV cluster which
includes lymphotoxin-a (one of five microsatellites within the TNF locus) and
lymphotoxin-p (Ruuls and Sedgwick 1999). The association of TNF-a -308 A with
OSAHS may therefore be due to the direct influence of the SNP in question and/or
due to linkage disequilibrium with other polymorphisms within the TNF-a gene or
other genes within the HLA system.
In conclusion, this is the first known study to examine the TNF-a -308 (A/G) SNP in
subjects with OSAHS, lending support to the argument that OSAHS is a disease
associated with inflammation.
5.6 GROWTH HORMONE RECEPTOR
The SNP +561 T/G for GHR has not been widely investigated. It is a variant of the
gene which lies close to the P561T SNP (within ~ lOkb) in the cytoplasmic domain
(exon 10) of the GHR, was identified by Chujo et al (1996) and Goddard et al in
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1997 and was the only one associated with increased mandibular height in a Japanese
population (Yamaguchi et al 2000). The +561G/T SNP in the GHR was chosen in
this study to act as a marker for possible disease associations as it may be in linkage
disequilibrium with more functional polymorphisms.
In this study, the GHR +561 G allele was more commonly found in the OSAHS
subjects, as was the G/G genotype. Of greater importance, was the independent
association of the G allele and G/G genotype with a BMI > 30kg/m2 in the study
population. There was no association with craniofacial bony measurements in the
whole population or when analysed separately in either men or women. Likewise,
there was no association with height within the study population. This latter finding
supports a previous report from Japan, which likewise did not find an association
with a GHR variant in the normal population (Chujo et al 1996) with height. Other
studies have been restricted to examining for GH and GHR variants in children and
adults with short stature (Goddard et al 1997; Goddard et al 1995 etc).
The absence of an association of the +561G/T GHR SNP with bony measurements in
the craniofacial complex is in contrast to the findings of Yamaguchi et al (2000).
However their study found a link with a slightly differently located SNP within the
cytoplasmic domain and with one bony measurement only. This finding in 100
members o f t he general p opulation m ay h ave b een b y chance a lone. Furthermore,
there is an ethnic difference between the populations studied and Yamaguchi et al
were not searching for an association with OSAHS.
The highly significant association of the G allele with obesity is of interest in view of
the major role of GH in the regulation of postnatal growth. Growth hormone
insensitivity which when complete is know as Laron dwarfism (Laron et al 1966) is
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characterised by small overall stature, classical craniofacial symmetrical reduction in
size, constriction of the upper airway, obesity, elevated GH levels and insulin
resistance. Recently the first report of a patient with Laron syndrome and OSAHS
was published (Dagan et al 2001). GH is important in the regulation of carbohydrate
and 1 ipid m etabolism (Nam and Marcus 2 000) a nd i s i ntegral t o t he regulation o f
insulin at both a pre and post receptor level (Dominici and Turyn 2002 for review).
In the obese adult and adolescent, GH levels are low (Attia et al) but growth
continues, largely due to the effects of IGF-1 and low IGFBP-1. Recently it has been
shown that the direct effects of leptin, sex hormones and insulin can directly activate
the IGF system in growth plates and at bone growth centres (Philip et al 2002)
independently ofGH.
With regard to sleep, it is known that GH levels influence the amount of SWS that an
individual has. There is a linear relationship between the amount of SWS and
increased GH secretion (Van Cauter and Copinschi 2000). During ageing, SW sleep
and GH secretion decrease exponentially and with the same chronology (Van Cauter
et al 2000; Murck et al 1999). There is also a sex-dependent effect on GH secretion
and its effects on sleep (Steiger 2002).
One study has examined GH secretion and peripheral sensitivity to its effects in the
obese and patients with OSAHS (Gianotti etal 2 002). A group of 13 adult males
with OSAHS, weight -matched patients with simple obesity without sleep-
disordered breathing and 10 normal lean males were studied with regard to their
response to: 1. GH response to GHRH and arginine and 2. IGF-1 and IGFBP-3
responses to a very low dose of recombinant human GH treatment for 4 days. The
GH response to the first intervention in OSAHS was lower than the response of the
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obese group, which was lower than the lean group. Further, the IGF-1 rise in
response to recombinant GH in OSAHS was significantly lower than in the obese
group. The findings suggested that OSAHS is characterised by a concomitant
impairment ofGH secretion and sensitivity. It would not be unreasonable to consider
that GH and GHR interactions may play some part in explaining these observations.
In fact Savage et al (2001) writing in the context of research into short stature, stated
that the effects ofmild growth hormone insensitivity due to an abnormal GHR which
may also affect metabolism, specifically insulin resistance, IGF-1 levels and IGFBP
levels and increase levels of obesity (Savage et al 2001) remained unknown and as
yet unresearched in the general population.
However, it is also possible that the hypoxaemia associated with OSAHS may
contribute to the reduction in circulating GH and peripheral sensitivity. It has been
shown that the reduction of the nocturnal secretion of GH in overweight OSAHS
patients is reversed by CPAP prior to a significant change in body weight (Grunstein
et al 1989; Saini et al 1993; Cooper et al 1995).
The degree to which an aberrant allele affects function depends on where the
polymorphism occurs in the gene. GH binding of the GHR induces dimerisation of
the GHR and activation of the tyrosine kinase JAK2 (Frank 2001). This leads to
tyrosine phosphorylation of the JAK2 itself and GHR and activation of a variety of
signalling molecules, including signal transducer and activator of transcription
(STAT) members, mitogen activated protein (MAP) kinase, phophatidylinositol 3 -
phosphate kinase etc (Carter et al 1996; Frank 2001).
Depending on which part of the receptor the SNP is situated and whether it results in
an amino acid substitution, which can affect configuration or not will determine its
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effect. If the latter occurs, then the somatogenic effects of GH will be curtailed or
blunted resulting in short stature or reduced growth (as demonstrated in STAT5b
knockout mice - Udy et al 1997), whereas if the receptor just shows reduced but not
entirely defective binding, then the effects may be more subtle and manifest as
abnormal lipid and carbohydrate metabolism.
In addition to the effects of the GHR polymorphisms on the somatogenic effects of
GH, there is new research in the area of GHR distribution in the CNS. In the last 10
years or so, evidence has accumulated that GH may exert profound effects on the
CNS. Replacement therapy in the GH deficient adults and children has revealed
beneficial effects on memory, mental alertness, motivation and working capacity as
well as ameliorating behavioural problems (Nyberg 2000).
Specific binding sites in the CNS have been identified including the choroid plexus,
hippocampus, hypothalamus and spinal cord. The density of GHR in the various
brain regions has been found to decline with age and the receptors differ somewhat
in size compared to their peripheral counterparts (Nyberg 2000).
Although many factors and pathways predispose to and are involved in the
psychological and mental dysfunction associated with OSAHS, it is also possible that
one o f t he p athways may involve growth h ormone w hich r educes i n amount w ith
age.
All allelic and genotype frequencies for the control group were in Hardy-Weinberg
equilibrium according to published information (Applied Biosystems™;
http://abassays.celera.com - minor allele frequency in Caucasians = 0.46), mitigating
against genotyping errors or problems with population stratification. Allelic
frequencies, when compared to published data for Caucasians were also not
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significantly different excluding bias based on ethnicity. Although the SDB status of
the control group was unknown, this would tend to dilute the reported observation
rather than strengthen it.
At present, the implications of a GHR SNP on CNS function and metabolic
derangement in the context of OSAHS are largely speculative. However, the
association of the +561 G/T GHR polymorphism with obesity should be investigated
further.
5.7 SEROTONIN RECEPTOR- 2A
The silent polymorphism T102C for the 5HT2A receptor (5HTR2A) showed no
differences in allelic association between subjects with definite OSAHS and controls
without it.
Inayama et al (1994) were the first to report an association with the silent mutation in
the coding region T102C in the 5HTR2A in association with schizophrenia. The
mutation does not alter the expression or structure of the protein and this suggests
that a functional receptor variant of 5HTR2A may be in linkage disequilibrium with
T102C. Spurlock et al (1998) and Nothen and Propping (1998) identified an A-G
polymorphism at -1438 in the promoter region of the 5HTR2A which was in
complete linkage disequilibrium with the silent T102C SNP, also confirmed by
Ohara etal (1999) andBasile et al(2001). Functional analysis of A-1438G using
luciferase assay demonstrated significant basal promoter activity in serotonin
expressing HeLa cells by both the A and G variants. Comparison of the A and G
variants however, showed no significant differences in basal activity or when
promoter activity was induced by cAMP and protein kinase C-dependent
mechanisms (Spurlock et al 1998). The size of the 5HTR2A gene (20kbp) which
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continues to be sequenced suggests that the silent SNP T102C studied is in linkage
disequilibrium not only with the A-1438G SNP but potentially with other, as yet
unidentified polymorphisms which may affect function of the gene.
The 5HT2A receptor has most recently been shown to be the predominant receptor
subtype in hypoglossal motor neurones (Zhan et al 2002), which are intimately
involved in the regulation of the major upper airway dilator during sleep, the
genioglossus muscle. Pharmacologic trials of 5-HT receptor agonists and antagonists
support this receptor subtype as well as 5-HT2c (found in much smaller quantities) as
the predominant post-synaptic facilitator of hypoglossal motor neurones (McAll &
Aghajanian 1980; Berger et al 1992; Kubin et al 1992; Al-Zubaidy et al 1996; Douse
and White 1996; Bayliss et al 1997; Inoue et al 1999). A further study on the
pharmacological activity of the serotonergic receptors in the hypoglossal nucleus
(Fenik and Veasey 2003) showed that the receptor 2A antagonist MDL - 100, 907
dropped intrinsic hypoglossal nerve respiratory activity by 61% and significantly
suppressed serotonin excitation of hypoglossal nerve activity in contrast to the 2C
receptor.
Whether the receptor subtype is modulated by and contributes exclusively to sleep
apnoea remains the subject of ongoing research at present. Certainly, the lack of a
distinct genotype in the OSAHS population for the 5-HT2a receptor would be
consistent with the observed variable responses to SSRIs that have been observed in
published trials (Jagadeeshan et al 2000; Berry et al 1999; Kraiczi et al 1999).
However, such a finding is not unexpected, as there has been much contradictory
literature in the psychiatric field. Genes encoding for the 5-HT transporter and
5HT2A receptor have long been proposed as candidates for possible involvement in
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mood disorders. The T102C polymorphism was identified (Erdmann et al 1996) and
investigated for a possible association with schizophrenia (Inayama et al 1996),
mood disorders (Zhang et al 1997) or response to treatment (Arranz et al 1995).
However, the results in favour of an association could not be replicated (Frisch et al
1999; Tsai et al 1999) in other populations. A study by Minov et al (2001) examined
2 polymorphisms of the 5HT-2A receptor (T102C and His452Tyr) in a German
population with unipolar depression (173 patients; 121 controls) as well as
polymorphisms in the promoter region of the serotonin transporter gene (5-
HTTLPR). His group found no significant association with depression in any of the
gene polymorphisms studied with depression. The most interesting finding was a
small but significant improvement in treatment response in patients (n=86) who
carried the C-allele of the 5-HT2A-receptor polymorphism (p = 0.023). However, the
patients were on various drug regimens (SSRI, TCA and ECT combinations) so the
results cannot be generalized. So far, this remains the only study reporting an effect
of the 5HT2A T102C receptor polymorphism on treatment outcomes in relation to
SSRIs.
SSRIs may not be the ideal pharmacological option in OSAHS as they are not
entirely selective for 5-HT in microdialysis experiments (Pozzi et al 1999) and may
inhibit dopamine function in the midbrain (Kapur and Remigton 1996). Furthermore,
SSRIs have been associated with a decreased response to serotonin-2 (Glennon and
Dukat 1995) so other more selective agents may be required.
Another very important consideration, which cannot be controlled for in rat and other
animal experiments or indeed human experiments in relation to treatment responses,
is the impact of genetic imprinting. With imprinted genes, despite biparental
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inheritance resulting in 2 copies of the same gene, only one is expressed - the second
copy is 'silent' or imprinted. The expressed copy is governed molecularly by a
gamete-specific tag resulting in exclusive or predominant expression from the
maternal or paternal copy (monoallelic expression). Functional imprinting can
behave as a polymorphic trait - some but not all individuals express only the allele
from a given parent. The 5-HT2a-receptor gene was found to be paternally imprinted
and transcribed from the maternal allele only by Kato et al 1996. However, a study
by Bunzel et al (1998) examined brain tissue in 18 patients to assess the imprinting
status of 5HT-2a receptor in the CNS. They found that 4 of 18 samples showed
monoallelic expression, whilst the remaining 14 were bi-allelic for 5HTR2a
expression with no difference between imprinting status according to brain area.
Thus, 5HTR2A demonstrates polymorphic functional imprinting. This has essential
consequences for the evaluation of genetic association studies and studies where
responses to medications are analysed. Taking genomic imprinting into consideration
in an extended family study (using trios) no association of bipolar disorder with
5HTR2A was shown in a recent study (Murphy et al 2001).
Other associations that have been investigated in relation to the 5HTR2A have been
obesity and hypertension. Weight loss has been more studied in the 5HTR2C
receptor in association with anorexia nervosa in girls (Westberg et al 2002) and Type
II diabetes in association with obesity (Yuan et al 2000). Studies for the 5HTR2A
receptor have yielded conflicting data (Collier et al 1997; Ziegler et al 1999) in this
area. Whether obese patients with OSAHS may have a greater propensity to lose
weight depending on genotype may become clinically relevant in the future and may
play a role in what constitutes good medical advice. Two studies examining the
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5HTR2A -1438G/A promoter polymorphism which is in absolute linkage
disequilibrium with the T102C polymorphism have shown an association with
increased food and alcohol intake in those with the G allele (Aubert et al 2000) and a
higher BMI, waist to hip ration and abdominal sagittal diameter in homozygotes for
the G allele compared to homozygotes for the A allele (Rosmond et al 2002).
There was no difference in distribution of alleles or genotypes in the 5HTR2A
T102C polymorphisms in relation to obesity in our study group. Neither was there an
association with systolic or diastolic blood pressure, which has been shown
specifically for the T102C polymorphism in a study by Liolitsa et al (2001) in elderly
females with essential hypertension.
All allelic and genotype frequencies for the control group were in Hardy-Weinberg
equilibrium according to published information (Applied Biosystems™;
http://abassavs.celera.com). mitigating against genotyping errors or problems with
population stratification. Allelic frequencies, when compared to published data for
Caucasians were also not significantly different excluding bias based on ethnicity
(e.g. Williams et al 1997). Although the SDB status of the control group was
unknown, this would tend to dilute the reported observation rather than strengthen it.
Power to detect a difference between carriage of the C and T alleles in association
with OSAHS was very low. However, this does not preclude the possibility of a
modest genetic effect of the C allele on development of OSAHS. Lohmueller et al
(2003) in reviewing a meta-analysis of HTR2A associations with schizophrenia
commented that with a relative risk of 1.07 for a positive association, a replication
study would require 6,900 case-control pairs to achieve 80% power at p<0.05. This is
much larger than a typical association study with only hundreds of individuals. With
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an OR of 1.03 for OSAHS in association with the C allele, replication of this study
would require over 3,000 individuals.
Bearing this in mind and in contrast to the potential problems of treatment response
studies with 5HTR2A, more promising results have been obtained with the serotonin
transporter (5-HTT). This molecule is the initial site of action of SSRIs. A number of
polymorphisms have been identified, but the two most important ones are located in
the promoter region and the second intron of the gene (VNTR) (see Serretti et al
2002 for detailed discussion). The promoter region polymorphism has shown the
most promising results in terms of reproducibility in a number of populations when
treatment has been instituted. Probably the best study to date by Rausch et al 2002,
examined SSRI dose-response relationship to 5-HTT kinetics with significant
associations of the long promoter allele with placebo and drug response in
comparison to the short allele carriers.
Bearing in mind the considerable problems inherent in association and treatment
studies that polymorphisms in the 5HTR2A gene pose as well as the lack of
replicated results to date, it might be more fruitful to concentrate on the serotonin
transporter gene if pharmacological treatments for OSAHS are to be developed and
implemented successfully.
5.8 BETA-2 ADRENERGIC RECEPTOR
The ADRB2 C+79G SNP results in a change in amino acid structure (Gln27Glu)
which significantly alters receptor function (Liggett 1997). This SNP has been
associated with obesity, changes in lipolysis, oxidative metabolism and energy
expenditure, growth and hypertension. The other functional polymorphisms within
the ADB2 receptor are in tight linkage disequilibrium. It should also be noted that the
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ADBR2 gene is localized to chromosome 5q32-34 very close to several cytokine
genes. It is thus possible that the individual SNPs of the ADBR2 may be markers for
the action of cytokines in various pathological processes.
In our population, we failed to show a significant difference in the distribution of
alleles for the C+79G ADRB2 gene polymorphism between subjects with OSAHS
and controls. Genotype did differ however, and this was largely attributable to the
significantly increased prevalence of the C/C genotype (Gln27Gln) in subjects with
OSAHS. This distribution was significant in both male and female subsets of the
population and was not related to obesity or hypertension. In fact the only difference
was found for height in men with those with the C/C genotype being significantly
taller than those without it (p = 0.009).
The potential importance of the ADRB2 C+79G SNP lies in its association with the
regulation of energy expenditure and growth and its link with obesity and
hypertension.
ADRB2 is the dominant lipolytic receptor in white human adipose tissue (Yang and
McElligot 1989) and treatment of obese animals with selective beta2-agonists
promotes a marked redistribution of body composition with a decrease in the fat
mass and increase in the muscle mass (Yang and McElligot 1989). A recent study
correlating these findings in 1152 French men and women showed no significant
difference in the distribution of genotype in the population (Meirhaeghe et al 1999).
However, they also assessed individuals on the basis of their BMI and the amount of
regular physical activity that they undertook. Men with the Gln27Gln polymorphism
were significantly more likely to be obese than those without it. However, the degree
of obesity was counteracted by regular physical exercise. The authors concluded that
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those individuals with the polymorphism were capable of modifying their BMI
through exercise and thus, genotyping could prove useful in targeting prevention
such as physical activity in those were most likely to benefit.
A study by Hellstrom et al (1999) also examined for the association of
polymorphisms in the ADRB2 in relation to gender. They found that in 138 Swedish
men, the Glu27 allele was significantly decreased when they were obese (BMI >
27kg/m2), whereas this allele frequency was increased in the obese group of 109
women. They concluded that different genetic factors contribute to obesity in males
and females. Previous work by this group (Large et al 1997) had shown that female
homozygotes for the Glu 27 allele (G/G) were significantly more obese and had 50%
larger fat cells than controls and a fivefold increase in ADRB2-agonist affinity (using
terbutaline). Studies attempting to replicate these findings in other populations have
shown no such clear associations in either men (Bengtsson et al 2001; Kortner et al
1999 - German population; Echwald et al 1998 - Danish population; Hayakawa et al
2000 - Japanese population) or women (Bengtsson et al 2001; Oberkofler et al 2000
- Austrian population; Kortner et al 1999 - German population). A more detailed
study looking at cardiovascular risk factors (including blood pressure, cholesterol
levels, t riglyceride 1 evels e tc) i n a group o f 2 84 S wedish men o ver t he age o f 5 1
years, showed the Glu27Glu genotype to be associated with elevated leptin and
triglyceride levels only (Rosmond et al 2000). Bengtsson et al (2001) showed a weak
association of Gln27 with hypertension, but more importantly, demonstrated this
allele to be in linkage disequilibrium with the Cysl9 allele of the 5'LC-Argl9Cys
polymorphism which has much stronger associations with hypertension, obesity and
insulin resistance.
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The lack of an association between ADRB2 receptor gene polymorphisms (including
Gln27Glu) with hypertension has been further demonstrated by Hermann et al (2002)
who examined 1885 subjects with and without systolic hypertension in France,
Scotland and Northern Ireland. This supports other similar findings by Xie et al
(2000) whose population comprised black and white Americans. An association of
the Gln27Glu genotype has also been found with diabetes. Carlsson et al (2001)
showed that Type II diabetics carried the Gln27 polymorphism more frequently and
that siblings of these subjects with the Gln27 allele had significantlymore insulin
resistance. They concluded that Glu27 was protective.
What does emerge from this body of contradictory evidence is that the ADBR2 gene
may be important in function and change rather than being directly associated with a
particular level of obesity or hypertension. Apart from the study by Meirhaghe et al
(1999) quoted above, 2 studies by Ukkola et al have shown that polymorphisms in
the ADRB2 gene associated with codon 27 have significant impact on d ifferential
energy expenditure ( Ukkola et al 2001) and gene-gene interaction with alpha-2 and
beta-3 adrenergic receptor genes (Ukkola et al 2000). A third study by Macho-
Azcarate et al (2002) demonstrated that obese women with the Gln27Gln genotype
were better exercise responders.
All allelic and genotype frequencies for the control group were in Hardy-Weinberg
equilibrium mitigating against genotyping errors or problems with population
stratification. Allelic frequencies, when compared to published UK data for
Caucasians for ADRB2 were also not significantly different excluding bias based on
ethnicity (see e.g. Liggett et al 1997). Although the SDB status of the control group
was unknown, this would tend to dilute the reported observation rather than
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strengthen it. Power to detect a difference in phenotype with the C/C genotype was
81% at the p<0.05 level.
The association of the C/C genotype of the ADRB2 with OSAHS may be significant
in terms of distribution of body fat particularly as it has been shown to be in strong
linkage disequilibrium with the Argl6Cys polymorphism (Oppert et al 1995), energy
expenditure and insulin resistance. These factors may play an important role in the
development of cardiovascular morbidity in OSAHS by affecting vascular response
to hypoxaemia (Garovic et al 2002). There does not appear to be a link with blood
pressure of the Gln27Glu SNP in the population studied. Future studies examining
the role of ADRB2 in OSAHS, obesity or hypertension may need to take functional
aspects into consideration in order to be meaningful.
5.9 Concluding Remarks
In this section the results for the study presented in Chapter 4 have been discussed in
detail. The next section will summarise the findings of this thesis, highlighting the




This thesis explores genetic aspects and associations with OSAHS.
From the results of the study the following conclusions can be drawn:
1. OSAHS is not just a sporadic, but also a familial condition. The degree of
environmental influence on its development is currently unknown but is
almost certainly considerable including effects on obesity and face structure.
2. The OSAHS phenotype must take age and gender related changes in AHI into
account to try and achieve greater accuracy. The OSAHS phenotype
identified in this study is the product of many different changes at a single
point in time. Whether a definite OSAHS phenotype exists and remains static
throughout life and in relation to the effects of BMI and craniofacial change
is unknown at present.
3. Cephalometry is a simple and well-validated technique for examining the
craniofacial complex. In males, a smaller mandible and a lower-set hyoid
bone are the most important characteristics distinguishing siblings with from
sibs without OSAHS, independently of BMI and age. The influence of
environment on this structural difference is unknown at present.
4. Male and female apnoeics have lower-set hyoid bones than non-apnoeic
snorers.
5. Age, gender and BMI play a small but significant role in the continued
growth of the craniofacial complex in adulthood and may affect changes
associated with OSAHS. The impact of BMI on craniofacial parameters
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raises questions as to whether it is the chicken or the egg in terms of
determining the development of OSAHS.
6. Edentulism is a confounder in cephalometric studies in OSAHS and can
significantly affect bony measurements and angles. This is an environmental
effect on the craniofacial structure, which may independently predispose to or
worsen OSAHS.
7. Apolipoprotein E alleles are not significantly differently distributed in a
population with OSAHS compared to a general population from the same
ethnic group. There is no evidence for an increased AHI in subjects with the
E4 allele.
8. There is a significant association of the TNF-a-308 A allele carriage with
OSAHS and it is likely to be a 'disease-associated gene'. Carriers of the allele
may have increased generalised inflammation associated with OSAHS. There
is also an association of the allele with ageing which may contribute to the
development or worsening of OSAHS.
9. The GHR +561 G allele carriage is significantly related to morbid obesity.
There is no association of this allele with bony measurements or height in the
OSAHS population.
10. There was no difference in frequencies of the 5HTR2A T/C SNP between the
cases and controls. A polymorphism in the 5HRT2A gene or one that is in
strong linkage disequilibrium with it may not be directly responsible for
mediating the observed differences in upper airway collapsibility in OSAHS.
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11. ADRB2 Gln27Gln homozygosity is significantly more common in OSAHS.
There is a potential association with changes in energy expenditure, obesity,
insulin resistance and hypertension.
OSAHS appears to be a polygenic disorder with a complex phenotype and this lends
it unsuitable to genome-wide scans at the present time. The most common (and
informative) study design in complex disease using genome scans to find areas of
linkage is in affected sib pairs. However, the number of sib pairs required to lend
sufficient power to the study would require an unrealistically large effort and would
be economically and logistically unfeasible for a single research centre to attain (see
e.g. Gu et al (1996) for discussion ofpower in sib pair studies for linkage analysis).
Despite these considerations, Palmer et al (2003b) have published the first study to
perform a 9cM genome scan for OSAHS and obesity in 66 European American
pedigrees comprising 349 subjects. OSAHS was phenotyped on the basis of AHI
alone. The pedigrees were chosen on the basis of either an affected individual with
overnight, in-home measurement of breathing using a portable monitor (Edentec®)
or a proband who was a neighbourhood control individual. DNA was pooled and
multipoint variance-component linkage analysis was performed for the OSAHS-
associated quantitative phenotypes of AHI and BMI. The analysis identified
candidate regions on chromosomes lp (LOD score 1.39), 2p (LOD score 1.64), 12p
(LOD score 1.43) and 19p (LOD score 1.40) for linkage with AHI. BMI was linked
to the following regions: chromosome 2p (LOD 3.08), 7p (LOD score 2.53) and 12p
(LOD score 3.41). Further statistical modelling indicated that evidence for linkage to
AHI was removed after adjustment for BMI, excepting regions on chromosomes 2p
(adjusted LOD score 1.33) and 19p (adjusted LOD score 1.45). When the inverse
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was done (i.e. when BMI linkages were adjusted for AHI) the LOD scores were
roughly halved. Palmer et al (2003b) concluded on the basis of these results that the
interrelationship between OSAHS and obesity in Caucasians might be partially
explained by a common causal pathway involving one or more genes regulating both
AHI and BMI. Interestingly, the strongest association in this study, the chromosome
2p region contains the ADBR2 receptor. Furthermore, the 12q region contains the
vitamin D receptor and IGF-1 and the 19q region contains APOE.
In spite of this, there are a number of potential limitations to this study. Firstly, as in
the study by Buxbaum et al (2002) (see Chapter 2.1), AHI alone cannot be used to
phenotype OSAHS. Secondly, the statistical method used is not classical for family
studies - when families are used to examine for a disease-specific association, the
simpler the statistical test the more real the result. Risch and Teng (1998) have
discussed at length the use of the Transmission Disequilibrium Test and the SDT as
the most informative statistic. A summary of statistical methods used in family-based
studies is discussed by Kruglyak & Lander (1995), Holmans (2001), Whittemore &
Tu (2000), Hassan et al (2002). Furthermore, in many respects, the above study by
Palmer et al (2003b) became a case control study comparing families positive for the
diagnosis of OSAHS with control families living in the same area without it.
Theoretically, this should enhance the study, but the size of the sample remained
modest and would have limited the power of the genome screen to detect linkage and
increased the possibility of Type I errors (Terwilliger and Goring 2000). Further, the
study should have pointed out how it had fulfilled the criteria of Lander and
Kruglyak (1995) for genome-wide scans and which Palmer as co-author on a
previous paper reviewing 101 genome-wide scans in humans (Altmiiller et al 2001)
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advocated. LOD scores of less than 2 are not considered to demonstrate significant
linkage under most circumstances, especially in the context of modest power of the
sample size, lack of a reported significance threshold for the sample and the use of
quantitative traits. The latter possibly demonstrate intra-individual fluctuations over
time. In addition, difficulties in the consideration of covariate adjustment for
quantitative intermediate phenotypes may bias the phenotypes, introducing noise into
the linkage analysis. Perhaps it is premature to utilise genome-wide scans in OSAHS
at present and it is less likely to be successful as the phenotype is complex, at present
difficult to define over more than a single point in time. Like all complex diseases,
OSAHS also appears to by polygenic.
As Silverman and Palmer (2000) have pointed out, a significant limitation of linkage
analysis is the difficulty of fine mapping the location of the gene influencing a
complex disorder. There are usually insufficient meioses within 1 to 2 megabases of
the disease gene to detect recombination events. With the effects of phenocopies and
genetic heterogeneity in complex disease, critical recombination events may not be
identified with certainty.
Choosing candidate genes for OSAHS in case-control studies remains difficult
because a large number of disparate co-aetiologies need to be considered. These
include obesity, craniofacial structure, upper airway control and sleepiness. Each of
these aetiologies in turn is regulated by a wide variety of genes and mechanisms that
are not necessarily related yet may interact and influence each other. Furthermore,
the role of epigenetics is becoming increasingly important consideration and
emphasizes the potential importance of influences that are difficult to measure with
accuracy. Above all, this study highlights that there is still much to be done in our
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search for the relevant genetic factors that will lead us to a greater understanding of
this complex disease.
6.2 FUTURE DIRECTIONS
This study has answered few questions, but raised many more. Each broad area will
be discussed in turn.
6.2.1 Phenotyping
Further investigation should be undertaken into whether the OSAHS phenotype
remains static throughout life, or whether is changes with time and under different
environmental conditions. At present, we are limited to studying the phenotype at a
single point in time - when it calls itself to clinical attention, generally in middle age.
Longitudinal studies should be undertaken, firstly identifying those who have
OSAHS in childhood and following them through and secondly, continuing to follow
those with sleep disordered breathing identified in adult life. There may be large
differences in underlying genotype, for instance, between those progressing into old
age with asymptomatic SDB, compared to those who develop symptoms and require
treatment. We may discover that we are dealing with a range of diseases that
manifest as a single phenotype at a particular point in time in the individual's life
rather than a single disorder. Further study is needed to determine the best variables
to be used to define phenotype and the age and gender related cut-offs to be used.
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6.2.2 Craniofacial Development
Cephalometry continues to be a cheap, effective and universally applicable tool for
identifying discrepancies in growth and craniofacial structure.
Further work should be undertaken in examining siblings in relation to age and sex-
matched controls who are unrelated and extending this to the use of technologies
such as MRI and CT scanning. Once again, longitudinal studies using unique data
sets like the Bolton-Brush and Fels studies would be greatly enhanced by improved
phenotyping of individuals with OSAFIS by conducting PSG and other studies.
Further studies should be conducted in looking at the differences in diagnosis and
treatment response in the dentate vs. the edentulous. This has been overlooked
completely in sleep apnoea research.
6.2.3 Obesity
Obesity is a highly complex disorder and the large number of redundant energy
pathways makes true candidate gene association studies difficult. On the basis of
current results, functional studies exploring the role of the ADRB2 polymorphisms
on weight loss and energy expenditure as well as the existence of insulin resistance
and body fat distribution in OSAHS (Mortimore et al 1998) may lead to clinically
meaningful and potentially useful results. The same applies to GHR SNP studies in
obesity, which should be combined with functional endocrinological investigations.
6.2.3 The Upper Airway
Further work needs to be done on defining the role of other transmitter-mediated
pathways in the regulation of upper airway tone during sleep.
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It is too simplistic by far to accept that the hypoglossal nerve alone is the only
significant regulator of this and by implication the serotonin receptor.
However, it remains without doubt the most important mechanism that we are aware
of at present. Of greater importance than the serotonin receptor in mediating different
pharmacological responses may be the serotonin transporter. In functional studies
looking at the treatment of depression, the serotonin transporter polymorphism has
had functional correlates with differing clinical response. One fruitful avenue in the
area of OSAHS would be to examine for differences in allele distribution in the
promoter polymorphism of 5HTT and its correlation to functional outcomes in a
double blind, placebo controlled treatment trial of SSRI.
6.2.4 Cytokines, Sleep and Aging
The role of cytokine g ene polymorphisms in the regulation of sleep appears to be
inextricably 1 inked t o a geing. Further s tudies n eed t o b e c onducted examining t he
role of IL-6 and IL-lgene polymorphisms in sleepiness, OSAHS and ageing. Work
on the TNF-a SNP identified to be of importance in this study should include more
objective testing of sleepiness in the human population coupled with measurement of
responses to treatment. Furthermore, changes in upper airway could be p otentially
different in the population with - 308A carriage. The study needs to be replicated in




OSAHS is a complex disorder and future work attempting to unravel its genetic basis
may be better served by utilising a combination of linkage analysis with association
studies on SNPs in the areas of interest. At present, much remains to be done in
elucidating the precise role of genes involved in the regulation of craniofacial growth
as well as upper airway control. Once the basic biochemical and physiological
processes have been completely understood, then the role of various SNPs and their
impact on the process will be rapidly resolved.
For the time being though, it seems that OSAHS, this common, polygenic disease
will continue to be a challenge and at many levels a mystery for a long time to come.
The origin ofall science is in the desire to know causes; and the origin ofall false
science and imposture is in the desire to accept false causes rather than none; or,
which is the same thing, in the unwillingness to acknowledge our own ignorance.
'Burke and the Edinburgh Phrenologists' - The Atlas, February 15, 1829
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The Epworth Sleepiness Scale
Sex (Male = M / Female = F)
Date:
Age (years)
How likely are you to doze off or fall asleep in the situations described in the box below,
in contrast to feeling just tired?
This refers to your usual way of life in recent times.
Even if you haven't done some of these things recently, try to work out how they would
have affected you.
Use the following scale to choose the most appropriate number for each situation:
0 = Would never doze
1 = Slight chance of dozing
2 = Moderate chance of dozing





Sitting, inactive in a public place (eg a theatre of a meeting)
As a passenger in a car for 1 hour without a break
Lying down to rest in the afternoon when circumstances permit
Sitting and talking to someone
Sitting quietly after a lunch without alcohol
In a car, while stopped for a few minutes in the traffic
















John ) Owens est. dms, mba
0131 536 2355 (Secretary) - 0131 536 2356 (Appointments) - 0131 536 2636 i Scarf Nurses;
0131 536 2362
ctor Professor N J Douglas Cons. Phvsic.an: Dr T W Macicay
NJD.MO.
is you may know, we have been doing some research which shows that sleep apnoea
ends to run in families. To allow us to understand the mechanism of this and, hopefully to
How us to develop drug treatments for sleep apnoea, we wish to try to identify the genes
vhich determine whether you develop sleep apnoea. I write to ask you whether you will
e able to help us with this research.
Ve require to get the help of 150 of our thinner patients with sleep apnoea - and you come
nto this category. For each patient, we also require the help of one brother or sister. I
vould, therefore, be grateful if you would do three things to help us. Firstly, would you
ilease fill in the enclosed form (1) indicating the number of brothers and sisters that you
Lave. Secondly, I would be grateful if you would send one copy of the enclosed
[uestionnaire to each of them and ask them to return the questionnaire to YOU. If you
Leed more copies of the questionnaire, please phone Maggie on the above number,
rhirdly, I would be grateful if you would then return all the completed questionnaires to
is, along with Form 1, as soon as possible - a stamped addressed envelope is enclosed.
rhe reason that we are sending out the questionnaires is so that we can select the most
tppropriate brother or sister to help with our studies and ask them if they would agree to
>articipate. For your information, your brother or sister would be asked to help us by
.pending a single night in the Sleep Laboratory and also by having one small blood test
aken and - where agreeable - a single x-ray of the head. We will also ask you to have the
;imple blood test at your next clinic visit or by arrangement.
. very much hope that you will be able to help us with this important research. Please do
tot hesitate to contact me ifyou require any further information.
Yours sincerely
Meil J Douglas MP FRCPE










Name: Date ofBirth: . Tel No:
Address:
Brother or Sister ofpatient named:
Weight: Height:
1. How likely are you to doze off or fall asleep, in the following situations, in contrast to feeling
just tired? This refers to your usual way of life in recent times. Even if you have not done
some of tjiese things recently, try to work out how they would have affected you. Use the
following scale to choose the most appropriate number for each situation.
0 = would never doze 1 = slight chance of dozing




Sitting, inactiv e in a public place (eg a theatre or a meeting)
As a passenger in a car for an hour without a break
Lying down to rest in the afternoon when circumstances permit
Sitting and talking to someone
Sitting quietly after a lunch without alcohol
In a car. while stopped for a few minutes in traffic
TOTAL
2. Do you snore during sleep? yes/no
If yes: Do you snore on your back only / on back and side / in all positions
3. Has your bed-partner/room-mate ever noticed that vou stop breathing when asleep ?
yes/no
4. In the morning do you feel that your nights sleep was refreshing/satisfactory0
always / 4-6 nights per week / 1-3 nights per week / never
31 536 1001







NJD/ED John J Owens bsc. dms, mba.
20th June 1997




Director: Professor N J Douglas
Consultant Physician: Dr T W Mackay
Dear
SLEEP APNOEA RESEARCH
I recently wrote to you asking for your help in a research project on the genetics of
sleep apnoea and I enclose a copy of that letter. As best I can tell, I have not yet
received a reply from you and write to ask if you would be kind enough to help us in
this project. I am sure you realise that advances in the management of the condition
from which you suffer are only achieved with a great deal of effort and co-operation
and I very much hope that you will be able to assist with this important area of
research.
Please do not hesitate to contact me if you wish any further information.
With kind regards.
Yours sincerely,
NE!L J DOUGLAS MP FRCPE
Professor ofRespiratory & Sleep Medicine
ENC.
INFORMATION SHEET FOR PATIENTS INVOLVED IN THE
STUDY OF GENETIC LINKAGE IN SLEEP APNOEA
1) Purpose of the study
Previous studies that we have carried out have shown that the sleep
apnoea/hypopnoea syndrome runs in families. We are now trying to identify
why it runs in familes and specifically whether there is a particular gene
involved. Identification of a gene might allow us to develop new therapies for
this condition from which you suffer. This is a very long term objective and it
is unlikely that'this study will benefit you in the short term.
2) What you will need to do:-
We will ask you to list your brothers and sisters and pass on to them the
enclosed Questionnaire and return the completed Questionnaires to the
Sleep Laboratory. This is in order to allow us to select the brother or sister
who is most likely also to have the sleep apnoea/hypopnoea syndrome.
Clearly, this study is also voluntary on their part as well and we will enclose
Information Sheets for them too.
a) We will require to take one blood sample from you at a mutually
convenient time. This sample will allow us to identify whether sleep
apnoea is associated with a particular gene. Excess blood will be
destroyed after the testing has been done.
b) We stress that you are under no obligation to participate in the study. If
you require further information, please do not hesitate to contact Dr
Brander at 0131-536-2355. If you wish to take independent advice about
the study, this can be obtained from Dr Tom Mackay, via the same
telephone number. He is not involved in the study and can provide
unbiased advice about your participation and the overall value of the
study. All data obtained in the study will be confidential. We are,
however, required to notify your general practitioner about your
involvement in this project.
On completion of the study, we will inform all participants about the results via

















John j Owens bsc, dms, mba
'el: 0131 536 2355 (Secretary) - 0131 536 2356 i Appointments) - 0131 536 2636 i Staff Nurses >
ax: 0131 536 2362
)irector: Professor N J Douglas Cons. Physician DrT \V Mackay
NJD.MO.
Dear
[hank you for completing the questionnaire that we sent you recently about sleep
ymptoms. We would very much like to include you in our study of the familial and
;enetic components of sleep apnoea. I would therefore invite you to come to the sleep
aboratorv at pm on for an overnight sleep study
Mease do not hesitate to contact us if the above date is not suitable to vou
fhe study will involve measurement of your breathing and sleep patterns overnight, the
aking of a single blood sample and a single x-rav of your head to assess facial bone
tructure. We would be very happy to provide any further information that you require
ibout this and will certainly provide a detailed explanation when you come up to the sleep
aboratory.
We will cover your travel costs to the sleep laboratory and would be very grateful it you
vould give us receipts for this where relev ant.
With many thanks
fours sincerelv
k J DOUGLAS \1D FRCPE




burgSieepr^Laboratory TH E ROYAL I NJ FIRK/IARY
p;;;M^36 2355 (Secretary^FEDINBURGH
Fax: 0131 536 2362
CHIEF EXECUTIVE
Director: Professor N J Douglas Consultant Physician: Dr T MacKa în J Owens bsc, dms, mba
Dear
A study of your breathing during sleep will be carried out in the Sleep Laboratory, Ward 48,
Royal Infirmary, Lauriston Place, Edinburgh. Enclosed is a map of the Royal Infirmary. If you
are coming by car there is earmarked parking available for overnight sleep study subjects and
this is shown on the map. Please display the enclosed permit in your car. Car entrance is by
Chalmers Street only. Pedestrian access is available from Lauriston Place as well.
You should report to the Sleep Laboratory at 9 pm. The Sleep Laboratory is part ofWard 48
and is on the top floor of the building indicated. There is a lift you may use. Once you get to
the top floor, please ring the bell at the Sleep Laboratory door when the night sister will come
to welcome you. I ( or Dr Nigel McArdle) will be there as well. Please note that there will be
no staff in the Sleep Laboratory between 5 pm and 8.30 pm ( or on Sundays before 8.30 pm).
You should bring with you to your sleep study your normal night attire and wash things. You
will be given a single room to sleep in. In the morning, you will be provided with breakfast.
After taking the single blood sample and the x-ray, you will be free to leave at about 10 am.
For local (Scottish) subjects the travel expenses will be paid later by the University of
Edinburgh. For that purpose, we would need your National Insurance Number. I will inform
you later about the results of your sleep study. If there is something to be concerned about, we
would like to inform your GP as well. For that purpose, I would need the name and address of
your GP.
With many thanks
Looking forward to seeing you
Yours sincerely
Dr Pirkko E. Brander, MD, postdoctoral fellow
Mr% BVV
INFORMATION SHEET FOR RELATIVES INVOLVED IN THE
STUDY OF GENETIC LINKAGE IN SLEEP APNOEA
1) Purpose of the study
Previous studies that we have carried out have shown that the sleep apnoea/
hypopnoea syndrome runs in families. We are new trying to identify why it runs in
families and specifically whether there is a particular gene involved. Identification of
a gene might allow us to develop new therapies for this condition.
2) What you will need to do
As you know, you have a brother/sister (delete as appropriate) with this condition
and they will have passed on to you this information and the enclosed
questionnaire. We would be grateful if you would complete the Questionnaire and
return it to your brother/sister who will send it back to the Sleep Laboratory. This is
in order to allow us to select the brother or sister who is most likely to have some
irregular breathing at night. This study is entirely voluntary on your part. The study
will involve you in>
a) Completing the Questionnaire: If selected, we wiil ask you to attend the Sleep
Laboratory for one night for a sleep study which will be similar to the study which
your brother or big sister had when sleep apnoea was diagnosed. During this
night, we will record your breathing pattern and sleep pattern by taping wires on
to your body. None of this is painful and there are no needles involved. You will
be required to attend the Sleep Laboratory about 9 p.m. at nignt and will be given
breakfast at about 7.30 a.m.
b) Either the next morning or at a mutually convenient time, you will be asked to
attend the X-Ray Department at the Royal Infirmary for a single head x-ray. This
is to allow us to assess the structure of your facial bones which are an important
factor in the development of sleep apnoea. The x-ray dose involved in this is lew
and about the equivalent of a chest x-ray. If you are female, the head x-ray wiil
only be performed if you are post-mencpausal, have previously had a
hysterectomy, have had a surgical sterilisation more than 2 years previously or
have a negative pregnancy test.
c) In the morning after the sleep study or at some other mutually convenient time,
we would take a single blood sample from you. This sample will allow us to
identify whether sleep apnoea is associated with a particular gene. Excess blood
wiil be destroyed after the testing has been done.
c) We stress that you are under no obligation to participate in the study. If you
require further information, piease do not hesitate to contact Dr Brander at 0131-
536-2355. If you wish to take independent advice aoout the study, this can be
obtained from Dr Tom Mackay, via the same telephone number. He is not
involved in the study and can provide unbiased advice aoout your participation
and the overall value of the study. All data obtained in the study will be
confidential. We are, however, required to notify your general practitioner about
your involvement in this project.
On completion of the study, we will inform ail participants about the results via a
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LOTHIAN RESEARCH ETHICS COMMITTEE
STANDARD CONSENT FORM
TITLE OF THE PROPOSED RESEARCH:




Respiratory Medicine Unit, Department ofMedicine, RIE.
TELEPHONE:
536-3252
FURTHER INFORMATION IS AVAILABLE FROM: (A person who is not
invo ved in the study)
Dr TW Mackay.
LIST ANY DRUGS TO BE GIVEN IN THE STUDY EXPLAINING THEIR
ACTION:
None.
LIST ANY PROCEDURES REQUIRED IN ADDITION TO THE STANDARD
PROCEDURES:
Sleep study; Head x-ray; Blood sample.
. I agree to participate in this study.
I have read this consent form and Patient/Subject Information Sheet
and had the opportunity to ask questions about them.
• I agree for notice to be sent to my General Practitioner about my
participation in this study.
11
• I agree to the provision of any clinically significant information to my
General Practitioner.
• I understand that I am under no obligation to take part in this study
and that a decision not to participate will not alter the treatment that I
would normally receive.
• I understand that I have the right to withdraw from this study at any
stage and that to do so will not affect my treatment.
• I understand that this is non-therapeutic research from which I





Four copies to be made
Top copy to be retained by Investigator
Second copy to be retained by patient/subject
Third copy to be sent to patient's/subject's General Practitioner
An additional copy to be filed in any relevant hospital case notes
12
PERSONAL INFORMATION:
Name: Date of Birth: Tel No:
Address:
1. How likely are you to doze off or fall asleep in the following situations, in contrast to
feeling just tired? This refers to your usual way of life in recent times. Even if you
have not done some of these things recently, try to work out how they would have
affected you. Use the following scale to choose the most appropriate number for
each situation:
Scale
0 = would never doze
1 = slight chance of dozing
2 = moderate chance of dozing
3 = high chance of dozing
Situation Chance of dozing (use scale)
Sitting and reading
Watching TV
Sitting inactive in a public place(e.g. a theatre or a meeting)
As a passenger in a car for an hour without a break
Lying down to rest in the afternoon
when circumstances permit
Sitting and talking to someone
Sitting quietly after a lunch without alcohol
In a car, when stopped for a few minutes in the traffic
TOTAL
2. Do you snore during sleep? Yes/No
If yes: Do you snore on your back only/on back and side/in all positions?
3. Has your bed partner ever noticed that you stop breathing when asleep?
Yes/No
4. In the morning do you feel that your nights sleep was refreshing /satisfactory?















REM sleep latency, minutes
Sleep period time, minutes
Time awake during sleep period, minutes











SLEEP QUESTIONNAIRE RESULTS SCORE
ESS
Current smoker (current=l; other 0)
Alcohol consumption (units/week)
Question 4(1—4; waking d night)
Question 6 (snoring; yes=l; no=0)
Question 6a (score 1-4; how long soring)
Question 6b (score 1-3; how often snoring)
Question 6c (score 1-3; postion)
Question 7 (score 1-4; toilet at night)
Question 8 (score 1-4; refreshing sleep)
Question 10 (score 1 -4; choking attacks)
Question 11 (witnessed apnoeas; 0=no, yes=l)
Question 12(1-4; sleeping against will)























H-PhW (parallel to B-Go)
PAS (on a line from B to Go)
UP-PhW (parallel to B-Go)
UT-PhW (parallel to B-Go)
PNS-PhW (parallel to B-Go)
UL (PNS-UT)
UW
Ant. Maxillary length (ANS-FOP)
Ant. Mandibular length (Gn-FOP)









Enrolment Questionnaire and Letter
le o hian Universi y
Dspi als NHS Trust
Dear
As you may know, the Sleep Centre at the Royal Infirmary of Edinburgh is doing
research that shows that sleep apnoea runs in families. We trying to identify the genes
that may determine whether or not you develop sleep apnoea.
We would greatly appreciate your help with our research and also that of any of
your brothers or sisters that might be willing to participate.
All we require of you is a simple blood test and to enquire with your brothers and
sisters whether they would like to help out with the research.
We would then send a questionnaire to each of your brothers and sisters to help us
determine which one would best be able to help out on the grounds of snoring and
tiredness.
Your brother or sister would then be asked to come in for an overnight study to check
their breathing just like your initial study, to have a small blood test and to have a
head X-ray.
I shall call you within a week of receipt of this letter to ask you whether you would be
able to help us with this very important research.
If you require any further information, please do not hesitate to contact either one of
us.
Thank you.
Dr Renata L Riha BMedSc FRACP Prof. Neil J Douglas MD FRCPE
Clinical Research Fellow Professor of Respirator}' and Sleep Medicine
Director Sleep Laboratory
Encl. Information sheet
hian University Hospitals NHS Trust provides o comprehensive range of first class ocute adult and paediatric care to the people of Edinburgh, Lothian and beyond from the
3 locations: Chalmers Hospital, City Hospital, Liberton Hospital, Princess Alexandra Eye Pavilion, Princess Margaret Rose Orthopaedic Hospital, Royol Hospital for Sick Children,
firmary of Edinburgh, Royal Victoria Hospital, Simpson Memorial Maternity Pavilion, Western General Hospital.
le o hian Universi y &.
>spi als NHS Trust - t >v'*'
INFORMATION SHEET FOR PATTENTS INVOLVED IN THE
STUDY OF GENETIC LINKAGE TN SLEEP APNOEA
1) Purpose of the studv
Previous studies that we have earned out have shown that the sleep
apnoea/hypopnoea syndrome runs in families. We are now trying to identity why it
runs in families and specifically whether there is a particular gene involved.
Identification of a gene might allow us to develop new therapies for this condition
from which you suffer. This is a very long term objective and it is unlikely that this
study will benefit you in the short term.
2) What you will need to do
We will ask you to list your brothers and sisters. We will then contact your brothers
and sisters by letter explaining the study and asking them to fill out a questionnaire.
We will provide a stamped, self-addressed envelope for your brothers and sisters to
return the questionnaire to the Sleep Laboratory. This is in order to allow us to select
the brother or sister who is most likely also to have the sleep apnoea/hypopnoea
syndrome. Clearly, this study is also voluntary on their part as well and we will
enclose Information Sheets for them too.
a) We will require to take one blood sample from you at a mutually convenient time.
This sample will allow us to identify whether sleep apnoea is associated with a
particular gene. Excess blood will be destroyed after the testing has been done.
b) We stress that you are under no obligation to participate in the study. If you
require further information, please do not hesitate to contact Dr Riha on 0131-
536-2360. If you wish to take independent advice about the study, this can be
obtained from Dr Tom Mackay via 0131-536-2355. He is not involved in the
study and can provide unbiased advice about your participation and the overall
value of the study. All data obtained in the study will be confidential. We are
however, required to notify your general practitioner about your involvement in
this project.
On completion of the study, we will inform all participants about the results via a
meeting of the Scottish .Association for Sleep Apnoea Meetings and Newsletter or a
letter to you.
iian University Hospitals NHS Trust provides a comprehensive range of first class acute adult and paediatric care to the people of Edinburgh, Lothian and beyond from the
locations: Chalmers Hospital, City Hospital, Liberton Hospital, Princess Alexandra Eye Pavilion, Princess Margaret Rose Orthopaedic Hospital, Royal Hospital for Sick Children,
irmary of Edinburgh, Royal Victoria Hospital, Simpson Memorial Maternity Pavilion, Western General Hospital.
The Lothian University
Hospitals NHS Trust NHS
Lothian
Dear
kindly provided your name as having potential interest in
helping us out with research at the Royal Infirmary of Edinburgh Sleep Centre.
We would very much like to include you in our study of the familial and genetic
components of sleep apnoea and are grateful for your interest.
We would greatly appreciate it if you could fill out the enclosed questionnaire and
return it in the self-addressed, prepaid envelope.
We will then contact you about participation in our study - we are looking for people
who snore and have daytime tiredness.
Ifwe contact you, the study will involve a single night in our laboratory where we
will measure your breathing and sleep patterns.
We will also take a single small blood sample in the morning and a single x-ray of
your head to assess facial bone structure.
We will also inform your general practitioner that you are participating in the study.
Please, do not hesitate to contact us should you have any queries.
Once again, thank you very much for your help. "
Dr Renata L Riha BMedSc FRACP Prof. Neil J Douglas MD FRCPE
Clinical Research Fellow Professor ofRespiratory and Sleep Medicine
Director Sleep Laboratory
Encl. Sleep questionnaire; information sheet; Epworth sleepiness score; envelope
The Lothian University
Hospitals NHS Trust N
Lothian
INFORMATION SHEET FOR RELATIVES INVOLVED IN THE
STUDY OF GENETIC LINKAGE IN SLEEP APNOEA
1) Purpose of the study
Previous stucies that we have earned cut have shewn that the sieeo acncea/
hypepneea syndrome runs in famiiies. We are new trying tc Icentify why it runs in
fsmiiies and specifically whether there is a particular gene involved. Identification cf
a gene might aiicw us to develop new therapies fcr this condition.
2) What vou will need to do
As ycu knew, you have a brother/sister (delete as acprccnate) with this condition
and they wiil have passed en to ycu this information and the encicssc
questionnaire. We would be grateful if ycu wcuid complete the Questionnaire anc
return it the Sieeo Laccratcny. This is
in orcer to ailcw us to select the brother or sister who is most likely to have seme
irreguiar breathing at nignL This stucy is entirely voluntary en your pan. The study
wiil involve ycu in:-
a) Completing the Questionnaire: If selected, we wiil ask ycu tc attend the Sieeo
Lacoratcry fcr one night fcr a sieeo study whicn wiii be simiiar to the stucy which
ycur brother cr big sister had when sieec apncea was ciagnosec. Curing this
night, we wiii record your breathing partem and sieeo partem by taping wires en
to ycur body. None of this is painful and there are no neeoles invcived. Ycu wiil
be recuired to attend the Sieep Laocratcny accut 3 p.m. at nignt anc wiii be given
breakfast at accut 7.20 a.m.
b) Either the next morning or at a mutually convenient time, ycu wiii ce askec tc
attend the X-Ray Department at the Rcval Infirmary fcr a single heac x-rav. This
is tc aiicw us to assess the structure cf ycur facial benes whicn are an Important
factor in the development of sieec apnoea. The x-'sy ccse invcived in this is lew
anc accui the equivalent of a chest x-ray. If you are female, the heac x-rav wiii
cniy be performed if ycu are post-mencpausai, have previously had a
hysterectomy, have had a surgical sterilisation mere than 2 years previously cr
have a negative pregnancy test.
c; in the mcming after the sieep stucy cr at seme ether mutually convenient time,
we wculc take a singie bleed sample from ycu. This sampie wiil silcw us tc
identify whether sieep aoncea is asscciatec with a particular gene. Excess biccc
wiii be destroyed after the testing has seen cone.
c) We stress that ycu are under no cciigaucn tc participate in the stucy. if ycu
recuire further inr'crmaticn. please cc net hesitate tc contact Cr Srancer a: 0121-
326-2255. If ycu wish to take incecencent advice accu: the stucy, this can be
cctainec r'rem Cr Tom Mackay, via the same teiepnene number. He is net
invcivec in the stucy ana can prcvice unoiasec acvice accut ycur participation
anc the overall value of the stucy. All cata ootair.ee in the study wiil be
confidential. We are, however, required to notify ycur general practitioner accut
ycur invcivemen: in this project.
Cr. completion cf the stucy, we wiil inform ail particicants accut the results via a




Name: , Date of Birth: Tel No:
Address:
Brother or Sister ofpatient named:
Weight: Height:
1. How likely are you to doze off or fall asleep, in the following situations, in
contrast to feeling just tired? This refers to your usual way of life in recent times.
Even if you have not done some of these things recently, try to work out how they
would have affected you. Use the following scale to choose the most appropriate
number for each situation.
0 = would never doze 1 = slight chance of dozing




Sitting inactive in a public place (e.g. a theatre or a meeting)
As a passenger in a car for an hour without a break
Lying down to rest in the afternoon when circumstances permit
Sitting and talking to someone
Sitting quietly after a lunch without alcohol
In a car, while stopped for a few minutes in traffic
TOTAL
2. Do you snore during sleep? Yes/no
If yes: Do you snore on your back only/on back and side/ in all positions
3. Has your bed-partner/ roommate ever noticed that you stop breathing when
asleep?
Yes/no
4. In the morning do you feel that your night's sleep was refreshing/satisfactory?
Always/ 4-6 nights per week/ 1-3 nights per week/ never
he Lothian Universi y
os| itals NHS Trust
Sleep Laboratory Tel: 0131 536 2355 (Secretary) Fax: 0131 536 2362
Director: Professor N J Douglas Consultant Physician: Dr T MacKav
Dear
A study of your breathing during sleep will be carried out in the Sleep Laboratory. Ward 48,
Royal Infirmary, Lauriston Place, Edinburgh. Enclosed is a map of the Royal Infirmary. If
you are coming by car there is earmarked parking available for overnight sleep study subjects
and this is shown on the map. Please display the enclosed permit in your car. Car entrance is
by Chalmers Street only. Pedestrian access is available from Lauriston Place as well.
You should report to the Sleep Laboratory at 9 pm on
The Sleep Laboratory is part of Ward 48 and is on the top floor of the building indicated.
There is a lift you may use. Once you get to the top floor, please ring the bell at the Sleep
Laboratory door when the night sister will come to welcome you. Please note that there will
be no staff in the Sleep Laboratory between 5 pm and 8.30 pm (or on Sundays before 8.30
pm).
You should bring with you to your sleep study your normal night attire and wash things. You
will be given a single room to sleep in. In the morning, you will be provided with breakfast.
After taking the single blood sample and the x-ray, you will be free to leave at about 10 am.
Travel expenses will be paid later by the University of Edinburgh. For that purpose, we
would need your National Insurance Number. I will inform you later about the results of your
sleep study. If there were something to be concerned about, we would like to inform your GP
as well. For that purpose. I would need the name and address of your GP.
With many thanks
Yours sincerely
Dr Renata Riha BMedSc MBBS FRACP
f 1
othian University Hospitals NHS Trust provides a comprehensive range of first class acute adult and paediatric care to the people of Edinburgh, Lothion and beyond from the
'ing locations: Chalmers Hospital, City Hospital, Liberton Hospital, Princess Alexandra Eye Pavilion, Princess Margaret Rose Orthopaedic Hospital, Royal Hospital for Sick Children,
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We wrote to you in the summer regarding participation in some sleep research.
Unfortunately, due to our miscalculation with your and our summer breaks, we failed
to reach you by telephone in a reasonable period of time.
I am therefore writing again in the hope that you may reconsider our study and am
enclosing the initial letter and information which were sent to you.
We hope that by doing so, we are not inconveniencing you and thank you for giving
us the time to consider participating.
I shall try to contact you within about a week ofmailing out this letter.
Thank you again!
Best regards,
Renata L Riha BMedSc MBBS FRACP
Clinical Research Fellow to Professor Neil J Douglas
Scottish National Sleep Laboratory
University Hospitals NHS Trust provides a comprehensive range of first class acute odult and paediatric care to the people of Edinburgh, Lothian and beyond from theitions: Chalmers Hospital, City Hospital, Liberton Hospital, Princess Alexandra Eye Pavilion, Princess Margaret Rose Orthopaedic Hospital, Royal Hospital for Sick Children,iry of Edinburgh, Royal Victoria Hospital, Simpson Memorial Maternity Pavilion, Western General Hospital.
he I o hian Universi y
ospitals NHS Trust
Dear
I would like to thank you very much for agreeing to participate in our study of sleep
and genetics.
I am enclosing a list of dates available for an overnight sleep study in the next little
while and would greatly appreciate it if you could circle the date that suits you best
and return it to me in the stamped self-addressed envelope.
When I receive your reply, I shall call to confirm that date and send you out an
information letter about where to come.
If you have any queries or concerns, please do not hesitate in contacting me on 0131
5362360.




Clinical Research Fellow to Prof. Neil J Douglas
Encl. Information sheet; dates for study; envelope
othian University Hospitals NHS Trust provides a comprehensive range of first class acute adult and paediatric care to the people of Edinburgh, Lothian and beyond from the
ing locations: Chalmers Hospital, City Hospital, Liberton Hospital, Princess Alexandra Eye Pavilion, Princess Margaret Rose Orthopaedic Hospital, Royol Hospital for Sick Children,





■' PREFERRED TIMES TO BE CONTACTED:
WOULD PREFER NOT TO BE CONTACTED
(please tick above if this is the case)
he o hian Universi y
i spitals NHS Trust
Sleep Laboratory Tel: 0131 536 2355 (Secretary) Fax: 0131 536 2362
Director: Professor N J Douglas Consultant Physician: Dr T Mackay
Dear
Thank you very much for completing and also returning our sleep questionnaire.
I have asked one of your other siblings to come to our laboratory in the next few
weeks - it just means that we feel that you do not have an appreciable problem with
snoring or undue sleepiness at present!!
Once again, thank you for your time and trouble.
With best wishes
Dr Renata L Riha
BMedSc MBBS FRACP
othian University Hospitals NHS Trust provides a comprehensive range of first doss acute adult and paediatric care to the people of Edinburgh, Lothian and beyond from the
ing locations: Chalmers Hospital, City Hospital, Liberton Hospital, Princess Alexandra Eye Pavilion, Princess Margaret Rose Orthopaedic Hospital, Royal Hospital for Sick Children,
Infirmary of Edinburgh, Royal Victoria Hospital, Simpson Memorial Maternity Pavilion, Western General Hospital.
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Ase: Date of Birth
Tel No:







.Are you a : smoker non-smoker ex-smoker (for vears)
What did do vou smoke: cigarettes yes/no
cigars yes/no






























drinks per week .
glasses per week.
What medication, including sleeping pills are you taking at present'1




b) Do you snore every night / most nights/ occasional nights
c) Do you snore on your back only / on back and side / in all positions
3. How many times have you woken choking or suffocating in the past month?
never / 1-2 times / 3-6 times / more than 6 times
4. Are you ever forced to have a nap during the day?
yes/no
If so, how many naps (5 minutes) do you have per day?
1 -2 / 2-4 / 4-6 / more than 6
5. How many times have you fallen asleep against your will (for example, while eating,
driving or in company) in the last year?
never /1 -2 / 2-4 / more than 4 (give details below)
6. Do you drive?
yes / no
7. Have you ever had, or nearly had an accident because of falling asleep while driving?
yes / no (give details below)
8. Has you weight changed in recent years?
yes / no down / up
If so, what is the change stones lbs
When did your weight change occur :
9. Have you any comments on the questions above?
Name and address of your GP:
National Insurance number
PAST MEDICAL HISTORY











Broken nose yes no
Nose operations yes/no
Throat operations yes/no
Nerve problems yes no
How often do y ou wake between going .0 bed and getting up in the morning?
never i -3 times 3-6 times more than 6 times per night
Do you snore during sleep0
Yes/No
If yes:
a) How long have you snored loudly0
Always since childhood / last 5 years - 3 years / 1 year
Appendix 6:
DNA Extraction Protocols
PROTOCOLS FOR DNA EXTRACTION
The following procedure was based on the Promega™ DNA extraction kit utilised in
Oxford.
DNA was extracted from frozen 10ml sample volumes of blood:
1. 30 ml of Cell Lysis Solution was added to a sterile 50ml centrifuge tube.
2. The tube of blood was then gently rocked until thoroughly mixed and then 10
ml of the blood were transferred to the tube containing the Cell Lysis
Solution. The tube was then inverted 5-6 times to mix.
3. The mixture was incubated for 10 minutes at room temperature (inverted
again 2-3 times during the incubation) to lyse the red blood cells. The
solution was then centrifuged at 2,000xg for 10 minutes at room temperature.
4. Supernatant was then removed and discarded with approximately 1.4 ml of
residual liquid remaining.
5. The tube was then vortexed until the white blood cells were resuspended (10-
15 seconds).
6. lOmls of Nucleic Lysis Solution was then added to the tube containing the
resuspended cells. The solution was pipetted 5-6 times to lyse the white blood
cells. The solution became viscous.
7. 3.3mls of Protein Precipitation Solution were added to the nuclear lysate and
vortexed vigorously for 10 - 20 seconds.
8. The solution was then centrifuged at 2,000xg for 10 minutes at room
temperature.
9. The supernatant (dark brown protein pellet and supernatant) was transferred
to a 50 ml centrifuge tube containing lOmls of room temperature
isopropranol.
10. The solution was then gently missed by inversion until strands of DNA
formed a visible mass.
11. The mixture was then centrifuged at 2,000xg for one minute at room
temperature and the DNA became visible as a small white pellet.
12. The supernatant was decanted and lOmls of room temperature 70% ethanol
was added to the DNA. The tube was gently inverted several times to wash
the DNA pellet and the sides of the centrifuge tube and the solution was
centrifuged again as in step 11 above.
13. The ethanol was then carefully aspirated and the DNA pellet allowed to air
dry for 10 - 15 minutes.
14. 800ul ofDNA Rehydration Solution was then added to the tube and the DNA
rehydrated by incubating at 65C for one hour. The solution was periodically
mixed by gently tapping the tube.
Blood samples collected in 2001 - 2002 were processed directly at the Edinburgh
Wellcome Trust Clinical Research Facility Genetics Core laboratory using the
Nucleon Extraction and Purification Protocol (Product C ode: Nucleon B ACC3
RPN 8512 for extraction of DNA from 10 ml of whole blood; © Amersham
International pic). The procedure involved cell lysis, deproteinisation, DNA
extraction; DNA precipitation; DNA washing and DNA resuspension.
1. Blood was taken out of storage and allowed to defrost at room temperature.
Before the extraction procedure was commenced, lOOul of blood of each
sample was spotted onto a Whatman FTA card, numbered and dated. The
cards were stored at room temperature in sealed bags containging silica
desiccant.
2. Using aseptic technique, 40 ml of dilute Reagent A was added to the 10 ml
blood sample in a labelled 50 ml Greiner tube and rotary mixed for 4 minutes
at room temperature.
3. The solution was then centrifuged for 5 minutes at 2,600 rpm (1300g) and the
supernatant discarded.
4. To the residual pellet, 2 ml ofReagent B was added and the solution vortexed
to resuspend the pellet. The suspension was then transferred to a 15 ml screw
capped propropylene centrifuge tube.
5. 500 pi of sodium perchlorate solution was added to the suspension, which
was then mixed by hand - the capped tube was inverted at least 12 times.
6. 2 ml of chloroform was then added and the solution mixed by had as above.
7. Without remixing the phases, 300 pi ofNucleon resin was then added to the
solution and it was centrifuged at 1300g (2,600 rpm) for 3 minutes.
8. Without disturbing the Nucleon resin layer, the upper phase (approximately
2.5 ml) was transferred to a clean tube of 10 ml volume.
9. 2 volumes of cold absolute ethanol were added to the solution and the tube
mixed b y i nversion u ntil DNA b egan t o p recipitate. T he p recipitated DNA
was hooked out using a Pasteur pipette and placed in 1 ml of 70% ethanol and
washed.
10. DNA was removed from the wash and allowed to air dry for a few minutes,
and then placed in 1 ml of TE buffer.
11. The above solution was then placed on a rotary wheel and allowed to
dissolve (one week) prior to storage at -2° - -8°C in the refrigerator.
Appendix 7:
Publications and Presentations arising from this Thesis
PRESENTATIONS AND PUBLICATIONS ARISING FROM THE THESIS
ABSTRACTS
Apolipoprotein E4 - A role in the Obstructive Sleep Apnoea/Hypopnoea
Syndrome?
Riha RL, Brander P, Vennelle M, Douglas NJ
Presented at:
British Thoracic Society Winter Meeting 2002 (poster)
American Thoracic Society Conference 2003 (poster)
TumourNecrosis FactorAlpha Gene Polymorphisms in OSAHS.
Riha RL, Brander P, Vennelle M, Mc Ardle N, Douglas NJ
Presented at:
Obstructive Sleep Apnoea Conference in Helsinki 2003 (poster)
European Respiratory Society Conference 2003 (oral presentation)
American Thoracic Society Conference 2004 (oral presentation)
Obstructive Sleep Apnoea/Hypopnoea Syndrome and Snoring: A Cephalometric
Comparsion
Riha RL, Brander P, Vennelle M, Douglas NJ
Presented at:
- Australasian Sleep Association Annual Meeting 2003 (poster)
- American Thoracic Society Conference 2004 (poster)
The Beta2-Adrenoceptor Gene Polymorphism (C+79G) is associated with Sleep
Apnoea
Riha RL, Brander P, Vennelle M, Douglas NJ
Presented at:
- American Thoracic Society Conference 2004 (poster)
No Association ofa Serotonin 2A Receptor Gene Polymorphism with Sleep
Apnoea
Riha RL, Brander P, Vennelle M, Douglas NJ
Presented at:
- American Thoracic Society Conference 2004 (poster)
- European Sleep Research Society Conference 2004 (poster)
Association ofthe Growth Hormone Receptor with Sleep Apnoea and ObesityRiha.
RL, Brander P, Vennelle M, Douglas NJ
Presented at:
- American Thoracic Society Conference 2004 (poster)
- European Respiratory Society Meeting 2004 (poster)
MANUSCRIPTS UNDER SUBMISSION
The -308 (A/G) Tumour Necrosis Factor Alpha Gene Polymorphism is associated
with OSAHS.
Obstructive Sleep Apnoea/Hypopnoea Syndrome and Snoring: A Cephalometric
Comparsion in Siblings (accepted for publication in Sleep)
